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Treatment of melanoma based on targeted therapy and immunotherapy has dramatically
advanced over the past decade. Advances in targeted therapy have been based on inhibition of
the MAPK pathway while for immunotherapy, advances have been based on blocking immune
checkpoint proteins such as the PD-1/PD-L1 axis. PD-L1 serves as a potent immune suppressor
of the immune response enabling cancer cells to escape the immune surveillance. Recently, it
was reported in several studies that resistance to MAPK pathway inhibitors can be accompanied
by increases in constitutive PD-L1 expression in melanoma, highlighting the importance of
understanding the underlying regulation of PD-L1 expression.
However, the mechanism regulating constitutive PD-L1 expression remains unclear in melanoma.
In this study, one of the aims was to investigate whether DNA methylation plays a role in PD-L1
expression. Firstly, it was found that melanoma cell lines with constitutive PD-L1 expression
have a marked loss of global DNA methylation (hypomethylation), particularly in the intergenic
regions and repeat elements, which suggested an altered epigenomic landscape. A number of
endogenous retrovirus (ERV) elements that reside in the intergenic region were increased in
expression in the constitutive PD-L1 cell lines. This was accompanied by activation of the innate
immune response and transcription factors that can upregulate PD-L1 levels. Intergenic lncRNAs
that are in close proximity to immune related genes were also upregulated in the constitutive
PD-L1 cell lines. Moreover, DNMTi (global demethylation) mediated PD-L1 upregulation was
revealed to increase many of the same innate immune response genes and transcription factors that
were upregulated in the constitutive PD-L1 samples supporting the role of DNA hypomethylation
in PD-L1 expression.
Furthermore, how PD-L1 expression is associated with resistance to MAPK targeted inhibitors
remains unclear. Here, it was found that constitutive PD-L1 expression is associated with a
transcriptomic state that is characteristic for dedifferentiation which is mediated by the loss of
SOX10 expression and upregulation of other transcription factors such as SOX9. Moreover,
constitutive PD-L1 samples were associated with a reduced expression of genes involved in
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oxidative phosphorylation demonstrating an altered metabolic program.
Overall, we found evidence that supports constitutive PD-L1 expression in melanoma is regulated
by the viral mimicry pathway via global hypomethylation. Furthermore, constitutive PD-L1
expression is closely associated with dedifferentiation mediated by loss of SOX10 which provides
insight as to why PD-L1 expression increases upon development of therapy resistance.
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1.1 Melanoma
Melanoma is a malignant cancer that arises from melanocytes, cells that generate melanin
pigments which provides protection from UV damage and gives skin colour (Tsao et al., 2012).
Melanoma can arise from melanocytes that reside within numerous tissue types. Given that
melanocytes primarily reside in the skin, melanoma predominantly arises from the cutaneous
tissue (Rabbie et al., 2019). To a lesser degree, melanoma can also arise from the eyes (uveal or
ocular melanoma), in the mucosal membrane (mucosal melanoma), or under the nails or palms
or soles of the feet (acral lentiginous melanoma) (Rabbie et al., 2019). Other types of cancer that
arises from the skin include basal cell carcinoma and squamous cell carcinoma. In this thesis,
skin cutaneous melanoma (SKCM) will be the main subtype of melanoma that will be discussed.
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Melanoma is notorious for being the deadliest skin cancer due to its aggressiveness and ability
to metastasize early throughout the body (AmericanCancerSociety, 2019; Cockerell, 2012).
Indeed, although melanoma accounts for only 1 to 10% of all skin cancer cases, it is responsible
for the majority of skin cancer related deaths (AmericanCancerSociety, 2019; Cockerell, 2012).
1.2 Primary Melanoma: histology
The four major subtypes of melanoma based on histological classifications are superficial
spreading melanoma (SSM) or nodular melanoma (NM), lentigo maligna melanoma (LMM)
and acral lentiginous melanoma (ALM) (Smoller, 2006). Superficial spreading melanoma
and nodular melanoma account for more than 80% of all melanomas (Greenwald et al., 2012).
SSM is characterised with radial growth phase (RGP) where melanoma cells grow laterally. In
contrast nodular melanoma is characterised with vertical growth phase (VGP) where melanoma
cells grows vertically (Greenwald et al., 2012). Lentigo maligna melanoma arises from lentigo
malgina, a benign precursor lesion and this melanoma subtype is closely associated with
sun-damaged skin of the head and neck in elderly patients (Smoller, 2006). Acral lentiginous
melanoma, as previously mentioned, arises from the acral skin surfaces.
1.3 Melanoma subtypes: oncogenic mutations
Comprehensive whole genome and exome sequencing studies have revealed that melanoma has
one of the highest mutational loads compared to all other cancer types. This high mutational
burden is primarily due to cytosine to thymine (C>T) somatic mutations which is a common
marker of UV damage (Alexandrov et al., 2013; Chalmers et al., 2017; Berger et al., 2012; Hodis
et al., 2012; Pleasance et al., 2010; Krauthammer et al., 2012). However most of the somatic
mutations do not contribute to the cancerous phenotype and are referred to as passenger mutations
(McFarland et al., 2014). In contrast, mutations in only a few genes elicit a selective fitness
advantage by conferring oncogenic properties and these are referred to as driver mutations. In
cutaneous melanoma, mutant BRAF and NRAS oncogenic proteins represent the majority. The
BRAF mutants represent around 50% of all melanomas and is caused by recurrent mutations at
the V600 amino acid position (Tsao et al., 2012). The NRAS mutants represent around 20% of all
cutaneous melanomas and is caused by recurrent mutations at Q61 or at the G12/13 position (Tsao
et al., 2012). BRAF and NRAS mutants are mutually exclusive with a possible explanation being
that both mutants constitutively hyperactivates the MAPK signalling pathway and therefore there
is no selective advantage to possess them together (Tsao et al., 2012). BRAF/NRAS wild-type
melanomas are commonly stratified into its own subgroup and are characterised with a higher
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mutational burden (Ranzani et al., 2015; Appenzeller et al., 2019; Verduzco et al., 2018). Whole
exome sequencing studies have found NF1 to be the third most significantly mutated gene (10 to
15% of melanomas)(Network, 2015). Given that NF1 mutations mostly occurred in melanomas
without hotspot BRAF/NRAS mutations, it has been suggested that this could be an additional
subgroup of melanomas (Network, 2015). These mutations in NF1 consist of loss-of-function
mutations that range from nonsense to frame-shifts indels and spice-site mutations. Given that
NF1 suppresses the MAPK signalling pathway, the loss of NF1 can increase the MAPK signalling
activity. Thus, the all three BRAF, NRAS and NF1 mutants activates the MAPK signalling
pathway highlighting the importance of this pathway in melanoma pathology.
1.4 Melanoma subtypes: transcriptome (phenotype switching)
Mutations have not been able to explain the increased invasive and metastatic potential of
melanomas. Indeed mutations that activate the MAPK pathway have been shown to occur
during the early stages of melanoma development (Shain et al., 2018). Studies have shown
melanomas can reside in distinct transcriptomic profiles that are characteristic of a proliferative
(differentiated) and invasive (dedifferentiated) phenotype (Hoek et al., 2006; Jeffs et al., 2009).
Intrinsic and extrinsic cues reprogram the transcriptome profile resulting in switching between
these two cellular phenotypes, a phenomenon dubbed as the “phenotype switching”. Central
to these distinct phenotypes is the MITF transcription factor and its expression level underpins
the phenotypic plasticity, as MITF tightly controls the transcriptional activity and repression
of a large array of genes (Jeffs et al., 2009; Hoek et al., 2006). MITF is well-established as
a critical regulator of development and differentiation of neural crest-derived melanocytes
(Hartman and Czyz, 2015). In order to explain the role of MITF in regulating distinct phenotypes
in melanoma, the rheostat model was proposed where the level of MITF acts as a rheostat
to control distinct cellular phenotypes (Carreira et al., 2006). Low levels of MITF induce a
dedifferentiated invasive phenotype, intermediate levels favour proliferation and higher levels
MITF results in a differentiation-mediated senescence (Carreira et al., 2006; Ahn et al., 2017;
Seberg et al., 2017). In addition to MITF, SOX10 has also been demonstrated to play critical
roles in regulating distinct melanoma phenotypes (Tsoi et al., 2018; Shaffer et al., 2017). Similar
to MITF, SOX10 is also a neural crest lineage-specific transcription factor that is crucial
for melanocyte development (Sauka-Spengler and Bronner-Fraser, 2008). SOX10 can also
tightly transcriptionally regulate a large range of genes which includes MITF (Sun et al., 2014;
Bondurand et al., 2000; Fufa et al., 2015; Laurette et al., 2015). Moreover SOX10 and MITF
co-regulate the expression of thousands of genes by co-binding to thousands of genomic regions
(Laurette et al., 2015; Seberg et al., 2017).
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1.5 Targeted therapy in melanoma
Metastatic melanoma is notorious for its aggressiveness and its ability to metastasize and resist
therapeutic drugs (Damsky et al., 2014; Domingues et al., 2018). For decades dacarbazine was
the only chemotherapeutic agent approved for clinical use. However it was primarily regarded
as a palliative drug given its highly modest response rate (Bhatia et al., 2009). This conventional
one-size-fits all therapeutic approach with chemotherapy has started to quickly shift to a treatment
strategy that is tailored or personalised to an individual’s disease in order to generate the most
effective clinical outcome. Approximately 40% of all melanomas harbor an oncogenic mutation
in the BRAF gene which constantly hyperactivates the MAPK signalling pathway and in turn
results in rapid cell division and enhanced survival (Flaherty et al., 2010; Chapman et al., 2011).
Drug inhibitors of this mutant BRAF protein induce rapid cancer cell death and tumor regression
which led to the FDA approval of BRAF inhibitors vemurafenib and dabrafenib in 2011 and
2013 respectively (Finn et al., 2012). However a major limitation to these targeted drugs is that
responses are short lived due to the rapid onset of acquired resistance that causes tumor relapse
(Flaherty et al., 2010; Chapman et al., 2011; Finn et al., 2012).
1.5.1 Resistance to MAPK pathway inhibitors via dedifferentiation in
melanoma
The dedifferentiation phenotype driven by low MITF and/or low SOX10 activity have
been shown to confer intrinsic and acquired resistance to MAPK pathway inhibitors in
BRAF-mutant melanoma cell lines and is associated with vemurafenib-resistance in patient
biopsies (Konieczkowski et al., 2014; Müller et al., 2014; Zipser et al., 2011; Verfaillie et al.,
2015; Sun et al., 2014; Shaffer et al., 2017). The therapeutic resistance associated with the
dedifferentiated state suggests that mechanisms promoting survival in response to MAPK
pathway inhibitors have been activated. Current clinical strategies involving targeted treatment
generally target melanoma cell populations that are “addicted” to the hyperactive MAPK
pathway for survival and rapid cell division. However, increasing evidence suggests that
melanomas in a low MITF or low SOX10 mediated dedifferentiated state have “rewired”
signaling cascades that redistribute oncogenic signaling toward multiple pathways, including
non-MAPK pathways, in addition to the MAPK pathway (Konieczkowski et al., 2014; Müller
et al., 2014; Ji et al., 2015; Verfaillie et al., 2015; Sun et al., 2014; Shaffer et al., 2017). In other
words, instead of total dependence on a single growth-regulatory pathway, dedifferentiation
allows usage of multiple pathways to confer drug resistance (Ravindran Menon et al., 2015).
This has strong clinical relevance given that upon MAPK pathway inhibition, subpopulations
with a dedifferentiated state within tumors can allow them to utilize alternative mechanisms
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for survival. This correlates with various signaling activators and confers treatment resistance,
and therefore permits time for treatment resistant cells to acquire additional mutations and/or
epigenetic aberrations that subsequently can allow tumor regrowth and tumor relapse (Chatterjee
et al., 2017b). In the following, we discuss several of the key signaling activators, including
EGFR and other receptor tyrosine kinases, which are associated with low MITF or SOX10
expression and resistance to MAPK pathway inhibitors in melanoma.
1.5.2 EGFR
Activation of various receptor tyrosine kinase (RTK) signaling pathways has been demonstrated
to confer resistance to MAPK pathway inhibitors (Sun et al., 2014; Müller et al., 2014; Ji et al.,
2015). However, EGFR signaling is reported as being crucial for the development of resistance
to MAPK pathway inhibitors in melanoma (Sun et al., 2014; Ji et al., 2015; Wang et al., 2015a).
When EGFR signaling was assessed in post-treatment patient biopsies compared with
pre-treatment tumors, 6 of 16 patients had increased EGFR activation as detected by IHC
(Sun et al., 2014). Treatment resistance attributed to EGFR signaling was also shown in
melanoma cell lines (Ji et al., 2015). EGFR signal transduction pathways have been shown to
be part of the same transcriptional program as WNT5A, promoting resistance to vemurafenib
in whole-transcriptome microarray analysis (Anastas et al., 2014). In colorectal cancer (CRC),
resistance to vemurafenib treatment of BRAF-mutant CRC is mediated by EGFR expression,
which is a consequence of the epithelial lineage of CRC. Intrinsically activated EGFR signaling
pathways are found to promote innate resistance to BRAF inhibitors in CRC (Salomon et al.,
1995; Prahallad et al., 2012). It has been demonstrated that upon BRAF inhibition, EGFR
signaling enables feedback re-activation of the MAPK pathway (Corcoran et al., 2012) and
activation of the PI3K–AKT pathway (Prahallad et al., 2012). Increased EGFR transcription
results following the demethylation of DNA enhancer elements in the EGFR promoter (Wang
et al., 2015a). While the EGFR signaling pathway is normally inactive in the melanocyte neural
crest lineage (Real et al., 1986), dedifferentiation in melanoma as a result of low MITF or/and
low SOX10 levels leads to increased activity of the EGFR signaling pathway (Ji et al., 2015).
Indeed, EGFR-mediated resistance in melanoma is associated with profound alterations in gene
expression patterns, which correlate with dedifferentiation, as defined by a reduction in MITF
levels together with reduction in downstream targets of MITF and other important melanocytic
regulators, such as SOX10, PAX3, and LEF1. Knockdown of MITF leads to the activation of an
autocrine drug resistance loop that consists of increased secretion of EGF ligand and increases
EGFR expression (Ji et al., 2015). Forced expression of MITF in melanoma inhibits EGFR
signaling and increases sensitivity to BRAF and MEK inhibitors (Ji et al., 2015). Interestingly,
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increased expression of MITF in colorectal cancer cells was also found to increase sensitivity to
BRAF inhibitors (Ji et al., 2015).
In one study, slow-cycling populations of melanoma cells with high EGFR expression were
associated with low levels of the transcription factor SOX10, which is known to both upregulate,
and interact with MITF to regulate melanocyte lineage development (Sun et al., 2014). Like low
MITF, low expression of SOX10 promotes TGFβ signaling, which in turn activates numerous
receptor tyrosine kinases, including EGFR, PDGFR-B, ERBB3, and AXL (Sun et al., 2014;
Müller et al., 2014). Cells expressing high EGFR and low SOX10 were resistant to BRAF and
MEK inhibitors and exhibited slow cycling. However, upon treatment with MAPK inhibitors,
cells with high EGFR and low SOX10 were selectively enriched, while cell division was
increased. Interestingly, upon discontinuation of treatment with MAPK inhibitors, there was
a depletion of cells with high EGFR and low SOX10. These data suggest that the high EGFR
and SOX10 axis is only beneficial in the presence of MAPK inhibitors and without MAPK
inhibitors, the cells return to a drug-sensitive state (Sun et al., 2014).
Combination treatment of melanoma cells with gefitinib, an EGFR inhibitor, and vemurafenib
was unable to inhibit proliferation of the drug-resistant cells, indicating that other routes of drug
resistance were also present (Sun et al., 2014). As receptpr tyrosine kinases, such as PDGFR-B
and ERBB3, are expressed in melanoma cells with low SOX10, and given that many RTKs
stimulate both MAPK and PI3K–AKT downstream pathways, the combined inhibition of MAPK
and PI3K–AKT pathways using BRAF and PI3K inhibitors was found to restore inhibition of
proliferation in the drug-resistant melanoma cells (Sun et al., 2014).
1.5.3 Other signaling activators
A range of other signal activators was found to be associated with a low MITF and/or low SOX10
dedifferentiated state and treatment resistance in melanoma. The expression of AXL tyrosine
receptor kinase expression was significantly increased by low MITF levels, and conferred both
intrinsic and acquired resistance in melanoma cell lines (Konieczkowski et al., 2014; Müller
et al., 2014). Expression and activation of AXL, as determined by phosphorylation, as well as
other RTKs was further increased upon exposure to vemurafenib. AXL was able to maintain
MAPK pathway activity and activate the PI3K–AKT pathway when exposed to BRAF or MEK
inhibition (Konieczkowski et al., 2014). The high AXL/low MITF expression profile was also
observed in TCGA data, which includes transcriptional profiles for 356 patients, as well as in
tumor samples obtained from patient-derived xenografts (Müller et al., 2014). Other RTKs that
increased with high AXL included EGFR and PDGFR. It is thought that MITF suppresses these
RTKs either indirectly or directly, and thus reduced MITF levels lead to the activation of these
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various RTKs (Müller et al., 2014). Loss of SOX10 has also been shown to results in activation
of AXL as well as other receptor tyrosine kinases such as WNT5A, AXL, EGFR, PDGFRB, and
the transcription factor JUN (Shaffer et al., 2017). Inhibiting AXL did not result in significant
tumor cell death in drug-resistant cell lines suggesting that, although AXL contributes to the
drug-resistant phenotype, other RTK activity may also need to be cotargeted (Konieczkowski
et al., 2014).
The activation of NFκB was shown to be an important player in promoting treatment resistance
in MITF-low cells (Konieczkowski et al., 2014). In treatment-naïve melanoma cell lines, cells
with high NFκB and low MITF expression were intrinsically resistant to both single-agent
inhibition at multiple points in the MAPK pathway, and to combination BRAF/MEK inhibition
(Konieczkowski et al., 2014). Furthermore, NFκB signaling was sufficient to promote a switch
to a low MITF state that enabled resistance to MAPK pathway inhibition (Konieczkowski et al.,
2014).
Figure 1.1: Upon development of acquired resistance to BRAF inhibitors (such as Vemurafinib), dedifferentiation can mediate
the activation of receptor tyrosine kinases resulting in treatment resistance. Resistance is driven by activation of altnerative
signaling pathways such as the PI3K/AKT pathway and the JAK/STAT pathway.
1.6 Immunotherapy - PD1/PDL1 axis
Concurrently with developments in targeted therapy, advances in immunotherapy have made
profound breakthroughs in cancer, particularly in melanoma (Havel et al., 2019). These advances
primarily come from better understanding of immune checkpoints and the therapeutic success
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of inhibitors of immune checkpoints (Park et al., 2018). Numerous immune checkpoint proteins
have been revealed to suppress the immune function and permit escape from the immune
surveillance. The immune checkpoints utilised by cancer cells include PD-L1, TIM-3, LAG-3,
CTLA-4 (Park et al., 2018). Of the many immune checkpoints that cancers exploit to suppress
the immune response, blocking the PD-1 (receptor)/PD-L1 (ligand) axis has accounted for the
most clinical success in recent years (Havel et al., 2019; Park et al., 2018).
The PD1 receptor is encoded by the PDCD1 gene which is located on chromosome 2q37.3
(Keir et al., 2008). PD1 is expressed on the surface of activated T-lymphocytes in the tumor
microenvironment as well as in a wide range of other immune cells including B-cells, natural
killer cells, monocytes and dendritic cells (Agata et al., 1996; Keir et al., 2008). The PD-L1
ligand is encoded by the CD274 gene on chromosome 9p24.1 (Keir et al., 2008). In addition
to PD-L1 expression on the surface of cancer cells, PD-L1 is also widely expressed in a range
of cell types including T and B lymphocytes, macrophages, and dendritic cells (Keir et al.,
2008; Yamazaki et al., 2002). PD-L1 can also be expressed on non-immune cells including
mesenchymal stem cells, fibroblasts, vascular endothelium, neuronal cells, and keratinocytes.
PD-L1 binding to PD-1 induces an intracellular signalling pathway in the immune cells which
consequently exhausts immune cell activity leading to inhibition of T-cell proliferation, survival
and cytokine production (Butte et al., 2007; Freeman et al., 2000).
In the normal physiological state, PD-L1 acts as a checkpoint or “brakes” to suppress the immune
system in the event of excessive inflammatory reactions and to prevent autoimmune disorders
(Topalian et al., 2015). Cancer cells, including melanoma, have been shown to frequently
overexpress PD-L1 to inhibit the immune system. PD-L1 binds to the PD-1 receptor on T cells
in the tumour microenvironment and in turn suppresses anti-cancer T-cell activity (Topalian
et al., 2015) (figure 1.1). Antibody-based drugs that block PD-L1 binding with the PD-1 receptor
reactivates the immune response to eliminate cancer cells and have showcased unprecedented
durable responses in metastatic melanoma (Topalian et al., 2015) (figure 1.1). In contrast to
BRAF inhibitors where drug resistance develops in approximately 6 months (Finn et al., 2012),
melanoma patients who initially respond to anti-PD1 therapy commonly live for more than
5 years (Topalian et al., 2015). Responses to anti-PD1 or anti-PDL1 therapy have also been
observed in many other cancer types and consequently drugs targeting them have been approved
for clinical usage for treatment. This includes non-small cell lung cancer (NSCLC)(Borghaei
et al., 2015; Herbst et al., 2016), microsatellite instability-high (MSI-H) (Overman et al., 2017)
and deficient mismatch Repair (dMMR) cancers (Le et al., 2015, 2017), Hodgkin’s lymphoma
(Ansell et al., 2015; Chen et al., 2017b), renal cell carcinoma (Motzer et al., 2015), squamous
cell carcinoma of the head and neck (Ferris et al., 2016; Seiwert et al., 2016), gastric cancer
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(Fuchs et al., 2018) and hepatocellular carcinoma (El-Khoueiry et al., 2017).
1.6.1 Limitations of antibody based anti-PD1 therapy
Currently the major issue with immune checkpoint blockade drugs is that in many other tumor
types there are only modest clinical responses such as in prostate cancer, breast cancer and ovarian
cancer and in non-MSI colorectal cancer. Furthermore, even in cancer types where anti-PD1 or
anti-PDL1 drugs have been clinically approved, only a minority of patients demonstrate objective
clinical responses. Indeed only a fraction of metastatic melanoma patients (approximately 30%)
present durable clinical benefits whereas others do not initially respond due to intrinsic resistance
or have short-lived responses due to acquired resistance (Sun et al., 2018). Like the patients who
respond favourably, these nonresponsive patients are at risk of potentially severe immune-related
adverse events which could be prevented using alternative therapy regimes (Martins et al., 2019).
The low response rates and the inability to reliably predict who will respond to anti-PD1 drugs
has strongly warranted identification of predictive biomarkers and further efforts to find new
treatment options that can be used in combination with anti-PD1 or anti-PDL1 drugs.
Figure 1.2: A) The PD-L1 ligand expressed on tumor cells binds to the PD-1 receptor on cytotoxic T-lymphocytes. This
stimulates intracellular signalling in the T-lymphocytes which inactivates the immune activity. B) Anti-PD1 drugs inhibit
PD-L1 to PD-1 binding, resulting in reactivation of the T-lymphocytes and the immune response.
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1.6.2 PD-L1 as a predictive biomarker
The most well-studied predictive biomarker for response has been PD-L1 protein expression in
the tumor microenvironment. Compared to patients with PD-L1 negative melanomas, PD-L1
positive patients had better progression free survival compared with anti-PD1 therapy alone
(Larkin et al., 2015; Long et al., 2016; Carlino et al., 2016). However the effectiveness of PD-L1
expression as a predictive biomarker has been widely controversial. Although PD-L1 positivity
enriches for positive responses, there are cases where PD-L1 positive tumors are nonresponsive
and vice versa where PD-L1 negative tumors respond to PD-1/PD-L1 axis blockade in high
enough numbers such that PD-L1 expression is suboptimal as a predictive biomarker.
One possible explanation for this mixed treatment response is attributed, in part, to intrinsic
or extrinsic mechanisms of PD-L1 regulation (Zerdes et al., 2018; Cottrell and Taube,
2018). For instance, “inducible” PD-L1 expression where PD-L1 is induced extrinsically via
cytokines secreted by tumor infiltrative immune cells (Garcia-Diaz et al., 2017) is associated
with a favourable treatment response given that immune activity pre-exists in the tumour
microenvironment. On the other hand, PD-L1 can be “constitutively” expressed via an intrinsic
mechanism that arises tumor intrinsically via genomic or epigenomic alterations. Currently,
whether constitutive PD-L1 expression is associated with treatment response is unclear (Cottrell
and Taube, 2018; Taube et al., 2018). Due to the fact that constitutive PD-L1 expression is not
dependent on a pre-existing immune activity, it has been speculated that constitutive PD-L1
expression is associated with poor treatment responses to anti-PD1 drugs (Cottrell and Taube,
2018).
The dramatic treatment effects of anti-PD1 and anti-PDL1 drugs in only a minority of
patients has strongly highlighted the need to gain a deeper understanding into the mechanisms
underlying PD-L1 regulation. Indeed in recent years, there has been a vast accumulation of both
extrinsic/induced and intrinsic/constitutive mechanisms identified to regulate PD-L1 expression.
The wide range of mechanisms that regulate PD-L1 expression along with associations with the
tumor microenvironment has strongly showcased the complexity underlying PD-L1 regulation.
1.7 Regulation of inducible PD-L1 expression
The tumor microenvironment is an intricate network of malignant cells and non-malignant
cells including immune cells, fibroblasts, fat cells, stromal cells and vascular endothelial cells
(Jiang et al., 2019; Taube et al., 2018; Duan et al., 2018). In addition, many of these cells
secrete signalling molecules such as cytokines, chemokines, exosomes and growth factors. This
complex interplay of cells and molecular signals either promote or inhibit cancerous properties.
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Numerous inflammatory signalling molecules that are secreted in the tumor microenvironment
have been demonstrated to induce PD-L1 expression. These signalling molecules includes IFN-α
(Garcia-Diaz et al., 2017), IFN-β (Garcia-Diaz et al., 2017), IFN-γ (Garcia-Diaz et al., 2017),
TNF-α (Wang et al., 2017; Quandt et al., 2014), TGF-β (Baas et al., 2016), IL-4 (@ Quandt
et al., 2014), IL-6 (Kil et al., 2017), IL-10 (Zhao et al., 2011), IL-12 (Xiong et al., 2014), IL-17
(Wang et al., 2017; Zhao et al., 2011), IL-27 (Carbotti et al., 2015), epidermal growth factor
(EGF) (Zhang et al., 2016) and hepatocyte growth factor (HGF) (Balan et al., 2015). Out of
these signalling molecules, IFN-γ secreted from cytotoxic CD8+ T-lymphocytes, macrophages
and natural killer cells is most efficient in inducing PD-L1 expression (Garcia-Diaz et al., 2017).
IFN-γ binds to the IFN gamma receptor, to stimulate the JAK1-JAK2/STAT1-STAT2-STAT3
pathway which increase IRF1 expression. IRF1 in turn binds to the PD-L1 gene promoter to
enhance expression (Garcia-Diaz et al., 2017).
An extrinsic induction of PD-L1 expression via signalling molecules has been associated with
a favourable response with anti-PD1 drugs (Tumeh et al., 2014). This is because an induced
PD-L1 expression indicates that there are pre-existing anti-cancer immune cells in the tumor
microenvironment but repressed via PD-L1 binding (figure 1.2). Thus “induced” PD-L1
tumors are often referred to as “hot” or “inflamed” with infiltrative immune cells. Inducible
PD-L1 is also referred to as adaptive PD-L1 expression given that the tumor cell adapts to
the immediately surrounding anti-cancer immune response by upregulating PD-L1 expression.
Therefore, in these tumors, PD-L1 expression is heterogeneous and dynamic with more focused
expression near immune cells. Once the immunosuppressive PD-L1/PD1 axis is blocked using
monoclonal antibodies, the immune cells are reactivated to eliminate the tumor. Indeed IFN-γ
response related transcription signature could predict treatment response supporting its efficacy
in indirectly measuring PD-L1 induction by cytotoxic T-lymphocytes (Ayers et al., 2017).
1.8 Regulation of constitutive PD-L1 expression
A wide range of mechanisms have been found to regulate intrinsic PD-L1 expression highlighting
the importance of the relationship between genomics and immunology in cancer therapy (Subbiah
and Kurzrock, 2019). These mechanisms span a wide range of regulatory levels including genetic,
epigenetic, transcription factors, signalling pathways and post-translational.
1.8.1 Genetic: Genomic amplification of PD-L1
Genomic copy number amplification of the PD-L1 gene (CD274) locus on chromosome 9p24.1
has been identified in numerous cancer types. This includes Hodgkin’s lymphoma (Green et al.,
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Figure 1.3: PD-L1 expression can be categorised into inducible (also known as adaptive PD-L1 expression) and constitutive
PD-L1 expression according to extrinsic or intrinsic regulatory mechanisms, respectively. A) Schematic drawing of inducible
PD-L1 expression. PD-L1 expression on the cell surfaces is represented by a thick black line. PD-L1 is expressed on tumor
cells (green cells in the figure) near lymphocytes (orange cells) or macrophages (purple cells). PD-L1 can also be expressed
on these immune cells. The immune cells secrete cytokines such as IFN-￿ which induce PD-L1 expression. Thus, the tumor
adapts to the surrounding immune response by upregulating PD-L1 to suppress the anti-cancer immune cells (adaptive immune
resistance). The microscope image shows a metastatic melanoma stained for PD-L1 expression using immunohistochemistry.
PD-L1 expression can be observed on the junction of tumor and immune cells. B) Schematic drawing of constitutive PD-L1
expression shows PD-L1 expression that is diffuse or homogeneous on tumor cells without association with immune cells.
This type of PD-L1 expression represents a genetic or epigenetic alteration that intrinsically regulates PD-L1 expression. The
microscope image shows PD-L1 expression is strongly stained throughout all the tumor that is independent of immune cells.
It is important to note that tumors commonly also display both adaptive and constitutive PD-L1 expression (not shown).
Permission was received to use this image (Taube et al., 2018).
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2010), squamous cell carcinoma (Straub et al., 2016), triple negative breast cancer (Barrett
et al., 2015), non-small cell lung cancer (Ikeda et al., 2016) and small cell lung cancer (George
et al., 2017). interestingly, this region also contains the PD-L2 gene (PDCD1LG2) which is
only 42 kilobases from CD274 (Sun et al., 2018). Moreover, the JAK2 gene (janus kinase 2)
which can upregulate PD-L1 expression via activation of STAT, is also located in the same
locus and therefore increased JAK2 expression further augments PD-L1 expression (Green
et al., 2010; Chen et al., 2018b; Goodman et al., 2018). The amplification generally correlates
well with PD-L1 protein levels however not in all cases (Green et al., 2010; Straub et al.,
2016). For instance, 11 out of 15 (73%) of primary oral cavity squamous cell carcinoma cases
showed correlation between CD274 genomic amplification and PD-L1 immunohistochemistry
protein expression (Straub et al., 2016). Currently, it is unclear whether CD274 amplification
is associated with treatment responses to anti-PD1 therapy although there is a correlation.
Additional prospective work is required to assess CD274 amplification as a potential biomarker
(Goodman et al., 2018).
1.8.2 Epigenetic regulation of PD-L1
An accumulation of studies have demonstrated that DNA methylation correlates with PD-L1
mRNA expression levels suggesting a regulatory role. DNA methylation in the gene promoter
is generally associated with suppressed mRNA expression. Reduced DNA methylation of the
CD274 promoter was reported to regulate increased expression of PD-L1 in various cancers
including non-small cell lung carcinoma (Asgarova et al., 2018), acute myeloid leukemia
(Goltz et al., 2017b), head and neck squamous cell carcinoma (Goltz et al., 2017a), prostate
cancer (Gevensleben et al., 2016), and melanoma (Micevic et al., 2019). Moreover DNMT
inhibitor (DNMTi) treatment which induces global demethylation and large-scale transcriptional
changes have demonstrated upregulation of PD-L1 expression in non-small cell lung cancer
cell lines (Wrangle et al., 2013). Whether DNMTi mediated global demethylation upregulates
PD-L1 expression only via reduced methylation of the PD-L1 promoter or in combination with
demethylation of other genomic regions is yet unclear.
Histone acetylation, a general marker of open chromatin and thereby active gene expression
(Zhou et al., 2016), has also been identified to upregulate PD-L1 levels. Histone deacetylase
(HDAC) functions to remove acetylation and suppress expression, and hence HDAC inhibitors
largely upregulates expression of many genes (Haberland et al., 2009). HDAC inhibitor treatment
led to increase of histone3 (H3) acetylation at the CD274 gene region as determined by anti-H3
western blot analysis (Woods et al., 2015). Furthermore this increase in H3 acetylation
was accompanied by increased PD-L1 expression in melanoma cells lines. Moreover, the
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bromodomain-containing protein 4 (BRD4) was found to promote PD-L1 expression (Zhu et al.,
2016). BRD4 is a BET protein which functions to read histone acetylation and promote gene
expression. Inhibition of BRD4 using the JQ1 inhibitor suppressed PD-L1 expression of both
constitutive and inducible levels (Zhu et al., 2016).
1.9 Signalling pathways activate PD-L1 expression via intrinsic
and extrinsic mechanisms
Signalling pathways that tightly controls crucial biological processes are commonly dysregulated
in cancer resulting in increased cell proliferation, survival, dedifferentiation, invasiveness and
treatment resistance (Sever and Brugge, 2015). Numerous signalling pathways have also
been demonstrated to modulate PD-L1 mRNA transcription and both intrinsic and extrinsic
mechanisms have been shown to employ these signalling pathways to regulate PD-L1 expression
levels.
The JAK/STAT/IRF1 pathway was revealed to be the primary axis for IFN-γ to induce PD-L1
expression levels in melanoma (Garcia-Diaz et al., 2017; Lee et al., 2006). Moreover, the
JAK/STAT/IRF1 pathway was shown to be involved in constitutive PD-L1 expression in
NSCLC cells (Lee et al., 2006). Overexpression of wild-type EGFR or oncogenic EGFR mutant
can also increase PD-L1 expression via the JAK2/STAT1 pathway in head and neck cancer
(HNC) (Concha-Benavente et al., 2016) and in NSCLC (Zhang et al., 2016).
The PI3K/AKT/mTOR pathway was shown to be a mediator between IFN-γ stimulation and
PD-L1 expression as demonstrated by increased phosphorylated AKT levels (Zhang et al., 2017).
In line this with, a P13K/AKT signalling pathway inhibitor prevented IFN-γ mediated PD-L1
upregulation (Zhang et al., 2017). Moreover a loss-of-function mutation in PTEN, a suppressor
of the PI3K/AKT pathway, was demonstrated to constitutively promote PD-L1 expression in
glioma cell lines (Parsa et al., 2007) and in lung squamous cell carcinoma (Xu et al., 2014).
Consistently, knockdown of PTEN resulted in increased PD-L1 expression via the PI3K/APK
pathway in colorectal cancer (Song et al., 2013) and in triple-negative breast cancer (Mittendorf
et al., 2014). Moreover, mutant EGFR (Azuma et al., 2014; Lastwika et al., 2016; Sumimoto
et al., 2016), mutant KRAS (Lastwika et al., 2016; Sumimoto et al., 2016) and the EML4-ALK
fusion oncoprotein (Ota et al., 2015) were revealed to increase PD-L1 expression via the
PI3K/AKT pathway in non-small cell carcinoma. Finally, the loss of ARID1A, a component of
the SWI/SNF chromatin remodelling complex, activated the PI3K/AKT pathway to upregulate
PD-L1 expression levels in gastric cancer (Kim et al., 2019).
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The MEK/ERK pathway was also shown to increase PD-L1 expression upon IFN-γ induction
whereas blocking the MEK/ERK pathway prevented the IFN-γ from activating PD-L1 (Liu et al.,
2007). Constitutive PD-L1 expression via the MEK/ERK pathway has also been demonstrated
in numerous cancer types. KRAS mutants (Chen et al., 2017a; Sumimoto et al., 2016) and an
EML4-ALK fusion oncoprotein (Ota et al., 2015) were demonstrated to activate the MEK/ERK
pathway to increase PD-L1 expression in non-small-cell lung cancer (NSCLC). In melanoma
samples that developed resistance to BRAF inhibitors, the MEK/ERK pathway was shown
to modulate PD-L1 expression rather than the PI3K/AKT signal pathway (Jiang et al., 2013).
However another study found that neither the MEK/ERK nor PI3K/AKT pathway were involved
in constitutive PD-L1 expression in melanoma (Gowrishankar et al., 2015). These discrepancies
between different pathways regulating PD-L1 expression strongly emphasise that the pathway
used for PD-L1 expression is highly dependent on the context such as tissue type or whether
there has been development of drug resistance.
The NF-κB pathway was shown to activate PD-L1 expression in natural killer/T-cell
lymphoma (NKTCL) (Bi et al., 2016) following transfection with latent membrane protein
1 (LMP1)-harboring lentiviral vectors. The NF-κB pathway also mediated IFN-γ mediated
PD-L1 expression in melanoma (Gowrishankar et al., 2015). Overexpression of MUC1 was
demonstrated to increase PD-L1 expression via the NFkB pathway in NSCLC (Bouillez et al.,
2017). Moreover, the NF-κB pathway was shown to increase PD-L1 expression via the PIPKIγ
enzyme in triple negative breast cancer. PIPKIγ was involved in both intrinsic and extrinsic
IFN-γ induction mediated PD-L1 expression via the NF-κB pathway (Xue et al., 2017).
1.10 Transcription factors activate PD-L1 expression
Numerous transcription factors have been identified to directly bind either to an enhancer or
the gene promoter of PD-L1 to intrinsically modulate its expression in various cancer cell types.
These transcription factors includes AP-1 (Green et al., 2012; Sumimoto et al., 2016), STAT1
(Concha-Benavente et al., 2016), MYC (Casey et al., 2016; Kim et al., 2017), IRF1 (Lee et al.,
2006), NF-κB (Bi et al., 2016), HIF-1α (Barsoum et al., 2014) and HIF-2α (Messai et al., 2016).
The AP-1 transcription factor binds to an enhancer in intron 1 of the PD-L1 gene to promote
PD-L1 expression in Hodgkins lymphoma (Green et al., 2012). MYC was found to bind to the
PD-L1 promoter to induce expression in cell lines of B lymphoma, acute lymphoblastic leukemia
and osteosarcoma (Casey et al., 2016). IRF1 has been found to be involved in constitutive (Lee
et al., 2006) and inducible expression of PD-L1 via IFN-γ stimulation (Garcia-Diaz et al., 2017).
NF-κB has been shown to bind to an enhancer that is located approximately 140 kilobases from
the PD-L1 gene to promote PD-L1 expression (Chen et al., 2018a). The deletion of this enhancer
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using single-guide CRISPR/Cas9 RNAs (sgRNAs) reduced PD-L1 expression by approximately
10 fold at both mRNA and protein level in a lung cancer cell line. NF-κB has been shown
upregulate PD-L1 expression following IFN-γ induction (Gowrishankar et al., 2015) and latent
membrane protein 1 (LMP1)-harboring lentiviral vector transfection (Bi et al., 2016). In hypoxic
conditions, HIF-1α was shown to bind to the Hypoxia response elements 2 (HRE2) which is
located in the intron between exon four and five of the PD-L1 gene in breast and prostate cancer
cell lines (Barsoum et al., 2014). HIF-2α was shown to bind to the HRE4 in the PD-L1 proximal
promoter in clear cell renal cell carcinomas (Messai et al., 2016).
1.11 MicroRNA regulation of PD-L1
MicroRNAs regulate protein levels by binding to the 3’UTR region of mRNA which then
can result in either mRNA degradation or inhibition of translation. A series of studies have
identified microRNAs to bind directly to the 3’UTR region of the PD-L1 mRNA. This includes
miR-17-5p in melanoma (Audrito et al., 2017), miR-200 in NSCLC (Chen et al., 2014), miR-34a
in NSCLC cells (Cortez et al., 2016) and acute myeloid leukemia (Wang et al., 2015b), miR-513
in cholangiocytes (Gong et al., 2009, 2010), miR-142-5p (Jia et al., 2017) and miR-93 and
miR-106b (Cioffi et al., 2017) in pancreatic cancer and miR-138-5p in colorectal cancer (Zhao
et al., 2016). In line with the regulatory role of the 3’UTR region for the PD-L1 mRNA,
structural disruption of this region results in increased PD-L1 protein levels (Kataoka et al.,
2016). Structural variation that disrupted the 3’UTR region of the PD-L1 gene was seen in 27%
of adult T-cell leukaemia (13 out of 49 cases), 8% of diffuse large B-cell lymphoma (4 out of 48
cases), and 2% of stomach adenocarcinoma (9 out of 415 cases) (Kataoka et al., 2016).
1.12 Post-translational regulation of PD-L1
Post-translational modifications such as ubiquitination, deubiquitination, glycosylation which
affects PD-L1 protein stability have been recently found. It was shown that the PD-L1 protein
can be indirectly destabilised by cyclin D–CDK4 protein complex in basal-like breast cancer
cell lines (Zhang et al., 2018a). Cyclin D/CDK4 phosphorylates speckle-type POZ protein
(SPOP), which in turn results in ubiquitination mediated destabilisation of the PD-L1 protein
(Zhang et al., 2018a). Given that cyclin-dependent kinases (CDK) proteins control the cell
cycle, it was revealed that PD-L1 protein levels fluctuate during cell division, peaking in the
mitosis (M) and gap1 (G1) phases followed by a reduction in the late gap1 (G1) and synthesis
(S) phase (Zhang et al., 2018a). CMTM6, a ubiquitously expressed transmembrane protein,
was found to interact with PD-L1 to increase its protein level without influencing the PD-L1
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mRNA expression in multiple cancer types (Mezzadra et al., 2017; Burr et al., 2017). CMTM6
reduced the ubiquitination of PD-L1 to inhibit lysosome-mediated degradation (Burr et al., 2017).
Knockdown of CMTM6 reduced the PD-L1 levels in cell lines of melanoma, colorectal cancer,
lung cancer, and chronic myeloid leukaemia (Mezzadra et al., 2017). Moreover, CMTM6
was shown to be a positive regulator in both IFN-γ induced and constitutive expression of
PD-L1 (Burr et al., 2017). TNF-α induction of PD-L1 expression was shown to stabilise the
PD-L1 protein (Lim et al., 2016). TNF-α induced NF-κB signalling resulted in increased COP9
signalosome 5 (CSN5) expression. CSN5 inhibited the ubiquitination mediated degradation
of PD-L1. Finally, glycosylation of PD-L1 was demonstrated to repress proteasome-mediated
protein degradation. Glycosylation of PD-L1 prevented binding with glycogen synthase kinase
3β (GSK3β) which abrogated PD-L1 ubiquitination and its proteasome-mediated degradation
(Li et al., 2016). Moreover, stimulating the EGFR pathway induced PD-L1 glycosylation
potentially by inactivating GSK3β (Li et al., 2016).
Figure 1.4: Constitutive and inducible regulation of PD-L1. Numerous extrinsic factors have been identified that stimulate
signalling pathways and downstream transcription factors to promote the transcription of PD-L1. PD-L1 can also be
constitutively expressed via intrinsic factors that alter the PD-L1 gene regulation including genomic amplification, promoter
demethylation, histone modifications and bromodomain regulation. Other genomic alterations that stimulates signalling
pathways and PD-L1 gene binding transcription factors can also drive constitutive PD-L1 expression. Posttranscriptional
mechanisms can regulate PD-L1 expression as demonstrated by various microRNAs that can bind to the 3’UTR region of the
PD-L1 mRNA to promote its degradation. Finally, PD-L1 protein stability can be influenced by glycosylation and ubiquitination,
which increases the PD-L1 protein pool by lengthening the protein half-life. Adapted from Shi et al., 2018.
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1.13 Concluding remarks
The unprecedented success of treatment that block the PD-1/PD-L1 axis has reignited research
into the field of using immunotherapy against cancer. Given that only a small subset of patients
benefit from antibody-based therapy, a major goal has been to identify biomarkers that can
predict treatment response. Although induced PD-L1 expression predicts a favourable response
it is as yet unknown whether constitutive PD-L1 expression is associated with response to
immunotherapeutic drugs. Because constitutive PD-L1 expression is independent of immune
infiltrates, it has been suggested that constitutive PD-L1 expression may confound the efficacy
of PD-L1 as a predictive biomarker (Cottrell and Taube, 2018). Interestingly, constitutive
PD-L1 expression has been associated with resistance to chemotherapy in acute myeloid
leukemia (Wang et al., 2015b) and MAPK pathway inhibitors in melanoma (Audrito et al., 2017;
Song et al., 2017). This suggests that upon acquired resistance to MAPK pathway inhibitors,
resistance to the immune response is also acquired through the overexpression of PD-L1.
Increased understanding of PD-L1 regulation may also help reveal new drug targets (Sun et al.,
2018; Zerdes et al., 2018; Shi, 2018; Wang et al., 2018). Indeed, it has been suggested that the
larger sized antibody-based drugs may not be able to fully penetrate the tumor microenvironment
to block the PD-1/PD-L1 axis, particularly the newly produced PD-L1 proteins on the cell
surface membrane, whereas smaller molecular drugs that binds to intracellular targets may have
a greater treatment efficacy (Lee and Tannock, 2010; Sun et al., 2018).
Overall, PD-L1 regulation has been revealed to be highly complex with multiple intrinsic and
extrinsic mechanisms that contribute in PD-L1 expression (Sun et al., 2018; Zerdes et al., 2018;
Shi, 2018; Wang et al., 2018). In many cases more than one type of mechanism simultaneously
acts to modulate PD-L1 expression (Ota et al., 2015; Sumimoto et al., 2016). For instance,
both the AKT/PI3K and MEK/ERK pathways have been found in some studies to concurrently
regulate PD-L1 expression (Ota et al., 2015; Jiang et al., 2013) and numerous studies do not
reveal a complete loss of PD-L1 expression upon knockdown of a single factor (Sumimoto et al.,
2016). Moreover, depending on the context such as the tissue type, different mechanisms can
predominantly drive of PD-L1 expression.
1.14 Aims and summary of the thesis
As outlined in this introduction chapter, many mechanisms are thought to potentially underlie
constitutive PD-L1 expression. However in melanoma, the mechanism underlying constitutive
PD-L1 expression is unclear. The MAPK pathway (RAS/RAF/MEK/ERK signalling pathway),
the PI3K pathway (PI3K/AKT signalling pathway) and the JAK/STAT pathway were found
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to contribute to constitutive PD-L1 expression in melanoma cells (Jiang et al., 2013; Audrito
et al., 2017). However in one study, neither the MAPK pathway, the PI3K pathway (PI3K/AKT
signalling pathway), the NF-κB pathway, the JAK/STAT pathway nor c-Jun were involved
in constitutive PD-L1 expression (Gowrishankar et al., 2015). Moreover, in another study,
reactivation of the MAPK pathway which developed following resistance to BRAF inhibitors
was not involved with constitutive PD-L1 (Song et al., 2017). In contrast, resistance mediated by
mechanisms independent of the MAPK pathway which involved transcriptome and methylome
reprogramming, PD-L2 and to a lesser extent PD-L1 expression were constitutively increased
(Song et al., 2017). One explanation for the discrepancy across these study is that the stability
of the PD-L1 expression levels varied due to the variation in length of time of MAPK pathway
inhibitor treatment. For instance, Jiang and colleagues who reported that the MAPK pathway
does increase PD-L1 levels, constitutive PD-L1 expression was assessed only after 72 hours
of BRAFi treatment which is not long enough to stabilise the PD-L1 overexpression (Jiang
et al., 2013). In contrast, the cell lines that were used by Gowrishankar and colleagues (where
the MAPK pathway was found not to play a role in PD-L1 expression) were stable for PD-L1
overexpression (Gowrishankar et al., 2015). In support of this, Song and colleagues treated their
cell lines for months to years with MAPK pathway inhibitors (Song et al., 2017), resulting in
a permanent resistant cell line. These resistant cell lines had increased PD-L1 expression and
were not dependent on the MAPK pathway. These discrepancies across studies highlights the
complexity of constitutive PD-L1 expression in melanoma. Moreover, it has been reported that
constitutive PD-L1 expression increases upon development of resistance to BRAF inhibitors and
chemotherapeutic drugs (Jiang et al., 2013; Audrito et al., 2017; Wang et al., 2015b). Currently
it remains unclear how constitutive PD-L1 expression is associated with treatment resistance
and melanoma aggressive features such as increased invasiveness and poor patient prognosis
(Audrito et al., 2017).
Therefore the overall aim of this PhD project is to gain a better understanding of the underlying
mechanism and aggressive phenotype of constitutive PD-L1 expressing cells in melanoma. To
do this, I have investigated the transcriptome and methylome of melanoma cells with constitutive
PD-L1 expression.
In chapter 3 of this thesis (the findings have been published in a journal), the aim was to get
a better understanding of whether DNA methylation plays a potential role in the regulation of
PD-L1 expression. Although the methylation status of the PD-L1 promoter has been shown to
correlate with PD-L1 expression, increasing evidence from other studies have suggested that
the methylation status in other genomic areas may regulate PD-L1 expression. This notion
comes from studies where global demethylation induced by DNMTi treatment have upregulated
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PD-L1 expression and other studies that have demonstrated DNMTi activates the innate immune
response via demethylation of intergenic regions. In chapter 3, we used RRBS and RNA-seq
to assess the methylome and transcriptome of constitutive PD-L1 cell lines. It was showcased
that constitutive PD-L1 melanoma cells, in comparison to inducible PD-L1 cells, have a marked
global hypomethylation that is particularly pronounced in the intergenic and intronic regions.
We also observed an increased expression of a group of endogenous retrovirus (ERV) elements
that reside in the intergenic region and an activation of genes in the innate immune response
pathway. This suggested that the hypomethylated state in the constitutive PD-L1 samples could
be resulting in the activation of the viral mimicry pathway where double-stranded ERV elements
activates the innate immune response, to increase the expression of transcription factors that
promote PD-L1 expression. Consistently, we found that DNMT inhibitor mediated reduction in
global methylation increased PD-L1 levels.
To further assess this altered epigenomic and transcriptomic phenotype of constitutive PD-L1
melanoma cells, in chapter 4 I aimed to strengthen our sample groups by increasing the size
and widen the PD-L1 expression margin between the inducible (low PD-L1 expression) and
constitutive (high PD-L1 expression) samples. Firstly, I searched five external gene expression
datasets (with a total of 200 melanoma cell lines) for melanoma cell lines that have a profoundly
higher CD274 expression. These cell lines with higher CD274 expression were acquired in our
lab and high PD-L1 protein levels were confirmed using flow cytometry.
In chapter 5, the aim was to get a better understanding of constitutive PD-L1 expression in
melanoma by thoroughly reassessing the transcriptome of the strengthened sample groups from
chapter 4. I found that constitutive PD-L1 samples have a distinct gene expression signature
that was associated with 1) an upregulated innate immune response, 2) dedifferentiation and
3) a downregulation of oxidative phosphorylation. A reprogrammed transcriptome was evident
with altered expression of transcription factors that play key roles in melanoma dedifferentiation
and treatment resistance. Transcription factors that can bind to the PD-L1 promoter was highly
expressed in the constitutive PD-L1 samples. Moreover, a large number of long non-coding
RNAs (lncRNAs), particularly intergenic lncRNAs, were upregulated in the constitutive PD-L1
samples.
In chapter 3, the upregulation of PD-L1 upon DNMT inhibitor mediated global demethylation
and the global DNA hypomethylated state of constitutive PD-L1 samples suggested that
DNA methylation is playing a role in PD-L1 expression. In chapter 6, to further explore
the role of DNA methylation in regulating PD-L1 expression, RNA-seq was used to assess
DNMTi mediated PD-L1 upregulation. I found that the innate immune gene expression profile
largely overlaps between genes upregulated in the constitutive PD-L1 cell lines and during
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DNMTi-mediated PD-L1 upregulation. This demonstrated that the DNA hypomethylated state
is playing a significant role in PD-L1 expression in the constitutive PD-L1 samples via activation





Parts of the bioinformatics workflow for the RNA-seq data analysis were published.
My contributions for this publication include writing the sections regarding generation
of count matrix from BAM files, how to perform differential expression analysis
using DESeq2, EdgeR and Limma Voom. Moreover, explanation of the differences
between these methods were made.
The RRBS library preparation and analysis were performed by Euan Rodger.
The RNA-seq analysis and the first draft was made by Aniruddha Chatterjee.
Mike Eccles edited the paper.
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Methods in molecular biology (Clifton, N.J.), 2018 , 1783 , 35-80
Parts of the experimental methods were published but were extended for this thesis.
This includes from section 2.1 to 2.8
Chatterjee, A.; Rodger, E. J.; Ahn, A.; Stockwell, P. A.; Parry, M.; Motwani, J.;
Gallagher, S. J.; Shklovskaya, E.; Tiffen, J.; Eccles, M. R. & Hersey, P.
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2.1 Cell culture of melanoma cell lines
CM138, CM145pre, CM145post, CM150post, CM143pre and CM143post were cultured
in DMEM medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin-streptomycin. WM2664 and WM115 were cultured in Minimum Essential Medium
(MEM-α) (Invitrogen) supplemented with 1% penicillin-streptomycin (Gibco, NY, USA)
and 10% FBS. NZM9, NZM40, NZM12, NZM15, NZM42 were cultured in MEM-α media
supplemented with 1% penicillin-streptomycin, 5% FBS and 0.1% Insulin-transferrin-selenium
(Roche)(Chatterjee et al., 2017b). MM127, MM595 and COLO239F were grown in RPMI 1640
(ThermoFisher Scientific) Medium supplemented with 10% FBS and 1% penicillin-streptomycin.
All cells were grown under standard conditions (5% CO2, 21% O2, 37°C, humidified
atmosphere), except WM115, which were cultured at 35°C. The company and catalog number
for all products are in the appendix (chapter 8).
2.2 Flow cytometry
2.2.1 Antibody panel design
Fixable viability stain 450 (FVS450, BD horizon, catalog#: 562247, clone: 29E.2A3) was used
to stain dead cells in order to selectively analyse live cells. The FVS450 stain has a fluorescence
emission maximum at 450 nm. The PE anti-human CD274/PD-L1 (Biolegend, catalog# 329706)
antibody and the isotype control antibody (PE Mouse IgG2b, Biolegend, catalog#:400314) has a
maximum excitation at 575 nm. No overlap in fluorescence emission was detected between the
FVS450 and the anti-PDL1 fluorophore or isotype control antibodies. The company and catalog
number for all products are in the appendix (chapter 8).
2.2.2 Antibody staining protocol
The follow steps were generally used for antibody staining in preparation for flow cytometric
analysis of cell surface PD-L1 protein expression. The example below is for analysing two cell
lines for PD-L1 expression. Approximately one million cells were used for each of the four
groups which consisted of three control groups (no stain control, live-dead stain control, isotype
control) and the PD-L1 antibody stain group.
To perform the PD-L1 antibody staining in preparation for flow cytometry analysis, cultures
melanoma cells were lifted off from the flask using trypsin and put into a 15 mL falcon tube
along with extra culture medium to deactivate the trypsin. Cells were spun down in a centrifuge
(350 G-Force/RCF for 5 mins, all spin steps remained the same for all steps) and the supernatent
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was removed supernatent. Approximately 3 mLs of PBS (or the amount needed to make it easier
for counting) was added to each sample in the 15 mL falcon tubes. The number of cells in each
sample were counted in order to acquire 4.5 million cells with 4.5 mL of PBS (1 mL contains 1
million cells). The remaining cells were put back into a culture flask with the appropriate medium
for regrowth. For each cell line, 1 million cells were put into four FACS tubes. For the live-dead
controls, heat was exposed using a heat incubator for 5 mins to kill a proportion of the cells. 0.5
μL of the FVS450 dye (live dead stain) was added into each of the FACS tubes and incubated for
15 minutes at room temperature. Cells were washed by adding 1 mL of FACS buffer (1 X PBS,
0.1% Bovine Serum Albumin, 0.01% Sodium Azide) followed by a spin down in the centrifuge
and removal of supernatent. A mastermix was made for the PD-L1 antibody stain with 2.5 μL
of PD-L1 antibody stain and 100 μL of FACS buffer multiplied by number of samples being
analysed plus 1 extra. For example, for 2 samples, a mastermix was made for 3 samples using
7.5 μL (2.5 μL times 3) of PD-L1 antibody and 300 μL (100 μL times 3) of FACS buffer. 100
μL of the PD-L1 antibody master mix was added into each FACS tube to be stained with PD-L1.
A mastermix was made for the isotype control stain with 2.5 μL of isotype control stain and 100
μL of FACS buffer multiplied by number of samples being analysed plus 1 extra. 100 μL of the
PD-L1 antibody master mix was added into each FACS tube to be stained with isotype control.
For the no stain control and the live dead stain control, 100 μL of the FACS buffer were added.
After mixing all samples using a vortex, cells were incubated for 15 min at room temperate in
the dark. 1 mL of FACS buffer was added and vortexed to mix. Cells were spun down at 350g
for 5 mins and 1 mL of FACS buffer was added as part of the first wash step. Supernatent was
removed and 1 mL of FACS buffer was added, spun and supernantent removes as part of the
second wash step. After the supernantent was removed following a spin step, 250 μL of FACS
buffer was added. Cells were then analysed on a flow cytometer on the same day. The company
and catalog number for all products are in the appendix (chapter 8).
2.2.3 Analysis
The PD-L1 expression levels of melanoma cell lines was determined using BD FACS CantoII.
All analyses were performed using the Kaluza (Beckman Coulter, version 2.0) software.
Approximately 10,000 events/cells were measured for each sample. The flow cytometry gating
was used to exclude dead cells and doublet cells. The median fluorescence intensity (MFI) for
the isotype control and anti-PDL1 was obtained. The MFI for PD-L1 staining was normalised for
background absorbance by subtracting out the isotype fluorescence value. The PD-L1 positive
percentage (in chapter 3) was determined by setting an expression threshold on the isotype
control. The gate on the isotype control was set to allow approximately 0.5% of the events to
be above the threshold. Subsequently, these gates were applied to the PD-L1 stained samples to
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determine the PD-L1 positive percentage. An expression level of at least five fold higher than
the isotype control was considered as “constitutive” expression of PD-L1. Changes of PD-L1
expression from vehicle control (DMSO) to decitabine treatment were calculated using medium
fluorescence intensities (MFI) and the formula:
𝑙𝑜𝑔2([(𝑀𝐹𝐼𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦,𝑡𝑟𝑒𝑎𝑡𝑒𝑑)−(𝑀𝐹𝐼𝑖𝑠𝑜𝑡𝑦𝑝𝑒,𝑡𝑟𝑒𝑎𝑡𝑒𝑑)]/[(𝑀𝐹𝐼𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦,𝑚𝑜𝑐𝑘)−(𝑀𝐹𝐼𝑖𝑠𝑜𝑡𝑦𝑝𝑒,𝑚𝑜𝑐𝑘)])
2.2.4 Interferon-gamma induction of PD-L1
Between 50,000 to 100,000 cells were seeded in a single well of a 24-well plate overnight with 1
mL of media. For each sample, around 10 wells were seeded in order to obtain a total amount of
between 500,000 to 1 million cells. The following day, the media was removed and fresh media
with IFN-γ (100 μg/mL, prospec, catalog#:CYT-206) was added to the cells. To do this, first
a master mix was prepared containing media and IFN-γ where for 1 mL of media, 1 μL of the
IFN-γ stock was added (to make a final concentration of 100 ng/mL). After removing the old
media from the cells, the 1 mL of the IFN-γ containing media was added to the cells. After 1 day
of IFN-γ induction, flow cytometry was used to assess PD-L1 expression as described in section
2.2.2.
2.2.5 Decitabine (DAC) and vitamin C treatment
First, stock concentrations of decitabine and vitamin C were made. The glass bottle of decitabine
(stock 1 mM, Sigma-Aldrich, cat#:A3656-5MG) contains 5 mg. To make a stock concentration
of 1 mM of decitabine, 21.91 mL of DMSO (Sigma Aldrich, catalog#: D8418, sterilised using a
filter after purchase) was added to the 5 mg of decitabine. The equation used was:
𝑀𝑎𝑠𝑠(𝑔) = 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛(𝑀) ⋅ 𝑉 𝑜𝑙𝑢𝑚𝑒(𝐿) ⋅ 𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟𝑊𝑒𝑖𝑔ℎ𝑡(𝑔/𝑚𝑜𝑙)
Therefore the calculation was 0.005(𝑔) = 1/1000(𝑚𝑀)⋅𝑉 𝑜𝑙𝑢𝑚𝑒(𝐿)⋅228.206(𝑔/𝑚𝑜𝑙) which
results in a volume of 21.91 mL to make a stock concentration of 1 mM. The chemical instability
of decitabine make it prone to degradation during repeated freeze and thaw (Rogstad et al., 2009).
Thus it is important to make numerous aliquots in order to prevent any freeze-thaw. Aliquots
of 0.5 ml were made and frozen at -80 Celsius. Melanoma cells were treated with a final DAC
concentration of 500 nM which was done, for example, mixing 7.0 fL of the stock DAC solution
(1 mM) for every 14 mLs of appropriate media. Approximately one million cells were used
for each treatment. For vitamin C (L-Ascorbic acid, catalog#:95209), 0.5 g was added to 5.678
mL (MilliQ water) to make a 500 mM of stock concentration. The calculation was 0.5(𝑔) =
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500/1000(𝑚𝑀) ⋅ 𝑉 𝑜𝑙𝑢𝑚𝑒(𝐿) ⋅ 176.12(𝑔/𝑚𝑜𝑙). Aliquots of 0.5 mL were made and frozen
at -80 Celsius. Melanoma cells were treated with a final vitamin C concentration of 57 μM
which was done by mixing 1.6 μL of the stock vitamin C solution (500 mM) for every 14 mLs
of appropriate media. 57 μM vitamin C was chosen as it is a low dosage that is suggested to be
at physiological levels (Liu et al., 2016a). Consistently, 57 μM of vitamin C did not alter cell
division of a colorectal carcinoma cell line (Liu et al., 2016a). The company and catalog number
for all products are in the appendix (chapter 8).
There were four treatment groups which included 1) DMSO (vehicle control), 2) DAC (500 nM)
or 3) vitamin C (57 μM) or 4) DAC with vitamin C (figure 2.1). For group 1 and 2, cell lines were
treated with DMSO or DAC for 3 consecutive days with daily replacement with fresh dosages,
respectively, and allowed to grow for another 3 days in fresh media. For group 3, cells were
treated with vitamin C for 6 consecutive days with vitamin C being replaced daily. For group 4,
cells were treated with vitamin C with DAC for 3 consecutive days, followed by only vitamin C
replacement for the subsequent 3 days.
Figure 2.1: Melanoma cell lines were treated with 1) DMSO (vehicle control), 2) DAC (500 nM) or 3) vitamin C (57 ￿M) or
4) DAC with vitamin C. The media was replaced with fresh DAC or/and vitamin C or DMSO daily for three consecutive days.




Total RNA was isolated from melanoma cell lines using the RNeasy Mini Kit (Qiagen,
catalog#:74106) following the protocol manual. This involved cell lysis, homogenisation of the
lysate using the QIAshredder (Qiagen, catalog#:79656), and using a spin column to selectively
purify RNA. DNase (RNase-Free DNase Set, Qiagen, catalog#:79254) was used to degrade
DNA during the extraction as outlined in the RNeasy Mini Handbook. Quality control was first
performed on the Nanodrop 2000 Spectrophotometer (Thermo Fisher Scientific) to assess the
RNA purity using the ratio of absorbance at 260 to 280 nm higher than 1.8. The RNA integrity
was assessed using the Agilent Bioanalyzer 2100 with the RNA integrity number (RIN) higher
than nine. The company and catalog number for all products are in the appendix (chapter 8).
2.4 Reverse transcription and qPCR for analysing endogenous
retroviral elements
Reverse transcription from RNA to complementary DNA (cDNA) was performed using the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, catalog#:4368814). For
each reverse transcription reaction, 20 ng of RNA per 1 μL was used. For example, 1600 ng
of RNA (diluted to make up 40 μL with MilliQ water) was used to make a total of 80 μL
complementary DNA (table 2.1).
Table 2.3: Reverse Transcription reaction
Reagents AmountPerReaction
10x RT buffer 8 μL
10X RT Random Primers 8 μL
25x dNTP Mix (100 mM) 3.2 μL
Nuclease-free water 16.8 μL
MultiScribe Reverse Transcriptase 4 μL
sample RNA 40 μL
total 80 μL
Real-time PCR (RT-PCR) reactions were made using the SYBR Premix Ex (TaKaRa,
catalog#:RR420W, SYBR® Premix Ex Taq). 10 μL reactions were made (table 2.2) into the
LightCycler 480 Multiwell Plate 96-well plate (Roche, catalog#:04729692001). Triple replicates
were used for every sample tested as a technical replicate for each experiment. Primer sequences
that were used are shown in table 2.4. Housekeeping genes were RPL27 and SRP14. Both
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housekeeping genes were validated with a amplification efficiencies between 90% to 100% and
obtaining a coefficient of determination value of higher than 0.97 between the Cycle Threshold
(CT) values and a series of sample dilutions. Real-time PCR reactions were performed on
the LightCycler 480 (Roche) machine using the protocol reactions outlined in table 2.3. The
CT values were obtained for each sample. Normalised relative quantification analysis were
performed using the qBasePLUS software (Biogazelle) which uses the geNorm algorithm
(Hellemans et al., 2007).
Table 2.4: qPCR reaction protocol for a single sample
Reagents AmountPerReaction
2X SYBR Green master mix 5 μL
forward primer (10uM) 0.4 μL
reverse primer (10uM) 0.4 μL
Milli-Q water 3.2 μL
cDNA or water 1 μL
total 10 μL
Table 2.5: qPCR LightCycler480 program
Conditions Temperature_Celsius Time_seconds Cycles AcquisitionMode RampRate_CelsiusPerSecond
Initial Denaturation 95 30 1 none 4.4
Denaturation 95 5 40 none 4.4
Annealing and Extension 60 30 40 single 2.2
MeltingCurve1 95 5 1 none 4.4
MeltingCurve2 60 60 1 none 2.2
MeltingCurve3 95 none 1 continuous 0.11
Cooling 50 30 1 none 2.2
2.5 Interferon blocking experiment for the PD-L1 constitutive
cell lines CM143-pre and CM143-post
The interferon blocking experiment (in section 3.2.1) was performed by Stuart Gallagher, Elena
Schklovskaya and Jessamy Tiffen from Peter Hersey’s group (The University of Sydney). Cells
with treated with blocking antibodies against interferon alpha receptor 2 (IFNAR2) (clone
MMHAR-2, PBL Assay Science, Piscataway, NJ, 10 mg/ml), IFNγR1 (clone GIR20s8, R&D
Systems, Minneapolis, MN, 5 mg/ml), or IFNγ (clone NIB42, Beckton Dickinson, Franklin
Lakes, NJ, 100 ng/ml) in the absence or presence of 104 U IFNα2A (Stemcell Technologies,
Vancouver, Canada) or 100ng/ml IFNγ (R&D Systems, Minneapolis, MN), as appropriate.
PD-L1 expression was measured by flow cytometry on day 3 (figure 3.2).
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2.6 Download and analysis of external melanoma cell line
datasets (200 melanoma cell lines)
The gene expression datasets that were analysed consisted of three microarrays which included
GSE16404 (Jeffs et al., 2009) that used the MWG human 20K platform and GSE7127 (Johansson
et al., 2007) and GSE4843 (Hoek et al., 2006), which both used the Affymetrix U133 Plus 2
platform (table 4.1). There were two RNA-seq datasets which consisted of GSE61544 (Müller
et al., 2014) and GSE80829 (Tsoi et al., 2018). Annotation files for affymetrix microarry platform
were downloaded from GEO using library(hgu133plus2.db). Probe details for GSE16404
were available in the downloaded datasets and was acquired in R using the fData function. Both
the RNAseq datasets (FPKM normalised) for GSE61544 (Müller et al., 2014) and GSE80829
(Tsoi et al., 2018) already came with gene names in the row. All datasets except for GSE7127,
the normalised data was downloaded. For GSE7127, the raw microarray dataset was downloaded
(CEL files) and normalised using Robust Multichip Average (RMA, from the affy package) and
trimmed mean of M-values normalization method (TMM, in the edgeR package), respectively.
All data was log2 transformed to investigate the PD-L1 expression levels.
library(hgu133plus2.db)
columns(hgu133plus2.db)








# Downloading data for GSE16404 [@Jeffs2009]
library(GEOquery)
gse <- getGEO("GSE16404", GSEMatrix = TRUE)
jeff.data <- gse[[1]]
# Downloading data for GSE7127 [@Johansson2007]
filePaths = getGEOSuppFiles("GSE7127")
# Downloading data for GSE4843 [@Hoek2006]
gse <- getGEO("GSE4843", GSEMatrix = TRUE)
ho.data <- gse[[1]]
# GSE61544 [@Mueller2014]
gse <- getGEO("GSE61544", GSEMatrix = TRUE)
muller.data <- gse[[1]]
# GSE80829 [@Tsoi2018]
gse <- getGEO("GSE80829", GSEMatrix = TRUE)
tsoi.data <- gse[[1]]
2.7 RRBS library preparation and sequencing
Reduced representation bisulfite sequencing (RRBS) library preparation was performed by Dr
Euan Rodgers (Otago University). RRBS was used to obtain a genome-wide methylation profile
(Chatterjee et al., 2012b,a, 2017a). Genomic DNA was first digested overnight using MspI
restriction endonuclease. The digested DNA was purified using the QIAquick PCR Purification
Kit (Qiagen, catalog#:28106). To remove the 3’ overhangs that was generated during DNA
digest, end-repair was performed to generate blunt ends using Nano End Repair Mix 2 (ERP,
Illumina, catalog#20015965). The DNA fragments were washed using the MinElute PCR
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Purification Kit (Qiagen, catalog#: 28006). To facilite adaptor binding, the 3’ end tails of
the DNA fragments are extended with a single adenine nucleotide. This “A-tailing” step was
performed with the A-Tailing Mix Mix (ATL, Illumina, catalog#20015965). Overall, the DNA
end-repair and A-tailing steps are needed to create binding sites for the adaptors which contains
Thymine (T) overhang. Next, adaptors were ligated to the DNA fragments using TruSeq DNA
Single Indexes Set A (Illumina, catalog#: 20015960) to allow for hybridisation in the flow cell
sequencer. The adaptor bound DNA fragments were washed using the MinElute MinElute PCR
Purification Kit. DNA fragments were size selected (40 to 220 basepairs) using a NuSieve
agarose gel and the size selected DNA fragments were extracted from the gel using the QIAquick
Gel Extraction Kit (Qiagen, catalog#:28706). Bisulfite conversion was performed using the
EZ DNA Methylation Kit (Zymo, catalog#:D5001). A PCR amplification was performed to
amplify the entire library using the TruSeq PCR Primer Cocktail (Illumina, catalog#20015965)
which anneals to the adaptor ends of all DNA fragments. Next, a second gel size selection
& gel extraction was performed to obtain DNA fragments with a length between 40 to 220
basepairs. The libraries were quantified using Qubit 2.0 Fluorometer (Life Technologies) and
the dsDNA HS Assay (Invitrogen, catalog#:Q32851). The quality and size distribution of the
libraries was determined using the Agilent Bioanalyzer 2100. The RRBS libraries were sent to
Otago Genomics Facility where four libraries were sequenced per flow cell lane on a Illumina
HiSeq2500 machine (100 bp reads, single-ended).
2.8 DNA methylation data analysis
Data analysis for RRBS libraries were performed by Dr Peter Stockwell and Dr Euan Rodgers.
The quality of the RRBS reads were checked using fastqc (version 0.11.5). Adaptor sequences
were removed from the reads using cleanadaptors available from an in-house tool called
Differential Methylation Analysis Pipeline (DMAP) (Stockwell et al., 2014). The Bismark tool
(Krueger and Andrews, 2011) was used to align the processed sequence reads to the reference
human genome (GRCh37). Mapping criteria allowed for only one mismatch (default = 2) in
the seed (i.e., in the first 28 bp of the sequenced reads). Low quality reads were filtered out
which obtained greater than 60% unique alignment for all the PD-L1 constitutive and inducible
RRBS libraries. The median non-CpG DNA methylation was 1.95% and 2.45% in the PD-L1
constitutive and inducible libraries, respectively (as measured by Bismark alignment), indicating
effective bisulfite conversion and low levels of true non-CpG methylation. The distribution and
level of CpG DNA methylation (on a scale of 0 to 1) was determined, using MspI fragments
(40–220 bp) as the unit of analysis rather than individual CpG sites or a tiled window approach
(Chatterjee et al., 2015, 2017b).
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Differential methylation analysis was performed using DMAP (functions of diffmeth and
identgenloc) (Stockwell et al., 2014). F statistic (ANOVA test) was applied on fragments that
had high quality methylation information. This high quality was defined by at least two CpG
sites covered by 10 or more sequenced reads (-F 2 -t 10 switch in the diffmeth program of the
DMAP tool) in at least 3 cell lines in each group, and identified regions showing the largest
methylation difference and significant P-values. False discovery rate of 5% was used on the
analysed fragments (at an alpha level = 0.05) to filter for significant fragments. Further filtering
of this list was done to obtain fragments with 0.25 (i.e., 25%) of higher methylation difference
(mean methylation on fragments) between the PD-L1 constitutive and inducible groups.
2.9 Analysis of transcriptomic data (refers to chapter three)
This section refers to chapter three where 12 melanoma cell lines were used for RNA-seq analysis.
The 12 samples include six inducible PD-L1 samples (CM145pre, CM145post, CM150post,
CM138, NZM22, NZM42) and six constitutive PD-L1 samples (CM142post, CM143post,
MelRMu, NZM9 and NZM40). For eight samples which excludes the NZM melanoma cell
lines, the RNA was extracted by Dr Euan Rodger. For four of the NZM melanoma cell lines, the
RNA was extracted by Dr Jyoti Motwani. For each sample, 1 μg of RNA was sent to the Otago
Genomics Facility where the RNA-seq library preparation was performed using poly-A-tailed
mRNA selection. This was followed by running the mRNA samples on an Illumina HiSeq 2500
sequencer (Illumina, USA) with 20 million paired-end reads and 2x 100 basepair read lengths
to generate raw FASTQ files. Data processing of the FASTQ files which included adaptor
trimming and read alignment were performed by Dr Peter Stockwell (University of Otago) and
all the downstream data analysis steps which included normalisation, differential expression
analysis and GSEA were performed by Dr Aniruddha Chatterjee (University of Otago).
The RNA-seq reads were adaptor trimmed using the cleanadaptors tool (Chatterjee et al.,
2012b) and mapped to the human genome (assembly GRCh37) using TopHat2 (Kim et al.,
2013). Transcripts were assembled and normalized gene expression levels were expressed in
FPKM (Fragments Per Kilo base per Million) values as generated by cuffquant and cuffnorm
programmes (Trapnell et al., 2012). Assembly of transcripts and generation of the FPKM
values was performed with the option “–fragbias- correct” and “–multi-read-correct” to improve
sensitivity of transcript detection (Roberts et al., 2011). 557 genes were found to be significantly
differentially expressed (DEG) between PD-L1 constitutive and inducible cell lines (P-value
<0.05, FDR corrected). This list was further filtered based on fold-expression change and
selected the genes that showed log2 fold change of mean FPKM (fragment per kilobase per
million read) ≥ 2, resulting in 508 DEGs (analysed with cuffdiff) (Trapnell et al., 2012).
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2.10 RNA sequencing and alignment information (refers to
chapter 5 and 6)
This section refers to chapter five where 17 melanoma cell lines were used for RNA-seq analysis
and chapter five where 20 melanoma cell lines were used for RNA-seq analysis. For 7 NZM cell
lines, the RNA was extracted by Dr Jyoti Motwani whereas for the rest, either Dr Euan Rodger
or I extracted the RNA. RNA quantity of 1 μg was sent to the Otago Genomics Facility where
the RNA-seq library preparation was performed using poly-A-tailed mRNA selection. This was
followed by running the mRNA samples on a Ilumina HiSeq2500 with paired-end reads, read
length of 2x 100 basepairs and 20 million reads. I performed all the analysis for chapter 5 and
6 which included adaptor trimming, read alignment and R data analysis. Reads were mapped to
the hg38 reference genome using Kallisto (version 0.44.0) (Bray et al., 2016). Each sample was
run with 100 bootstraps and with the --bias argument to correct for potential sequence based
bias. Annotations were acquired from GENECODE (Release 28 GRCh38.p12) which entailed
nucleotide sequences of all transcripts (protein-coding and lncRNA transcripts) on the reference
chromosomes. Tximport was used to import the kallisto gene-level counts data into R (Soneson
et al., 2015). The R codes used for this thesis are available in Zenodo (https://doi.org/10.5281/
zenodo.3375098).
2.11 R analysis
The R analysis section performed in this thesis was published as mentioned at the start of this
chapter (Chatterjee et al., 2018a). From this publication, my contribution included all R analysis
that was performed after the generation of BAM alignment files. This included obtaining the
count matrix into R from the BAM files, filtering out genes with low reads and duplicate genes,
exploratory data analysis (PCA plots and hierarchical clustering) and differential expression
analysis.
For filtering, genes with 5 or lower counts in at least seven samples (the lowest number of samples
in one of the comparison group which in this case was the constitutive PD-L1 group) were
removed before differential expression analysis. Genes with low counts make up a significant
proportion in RNA-seq datasets and can reduce power in the differential expression analysis (Van
De Wiel et al., 2013). Batch correction was performed using the removeBatchEffect function
in the edgeR package.
# An example of how the batch correction was done
# load tidyverse to be able use the pipe ( %>% ) function
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library(tidyerse)
# getting the cell line status (groups)
status <- c(rep("inducible", 10), rep("constitutive", 7)) %>% factor
# making the design matrix
design <- model.matrix(~0 + status)
# changing the colnames of the design matrix
colnames(design) <- gsub("status", "", colnames(design))





For unsupervised clustering (PCA, hierarchical clustering, k-means), raw counts was normalised
using the rlog (regularised log) function from the DESeq2 package (Love et al., 2014). rlog
is recommended for unsupervised clustering as it normalises for sequence depth as well as
controlling for genes with low expression having stronger weight after log2 transformation
during clustering (Love et al., 2014). For hierarchical clustering, elucidean distance and




For k-means, 20 random sets of starting positions were chosen and the default “total within-cluster
variation” method was used. The codes used is the following:
km.out <- kmeans(t(normalised_expression_matrix), centers = 2, nstar = 20)
km.out$cluster
For other analyses such as comparing gene expression between the inducible and constitutive
PD-L1 cell lines (ie. boxplots and heatmaps), the TMM method was used to normalise for
sequencing depth and RNA composition bias using the edgeR package (Robinson et al., 2010).
Differential expression analysis was performed using edgeR quasi-likelihood method (Robinson
et al., 2010). A False Discovery Rate (FDR) adjusted pvalue threshold of 0.05 and a zero threshold
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for the log 2 fold change was used to call significant genes.
Gene Set Enrichment Analysis (GSEA) was performed using gene sets available in the
Broad Institute Molecular Signatures Database (MsigDB) which included H1 (hallmarK),
C2 (curated) and C5 (gene ontology) (http://software.broadinstitute.org/gsea/msigdb).
Camera test was performed as available from the edgeR package. For generating a
gene-set score for each sample, single sample GSEA (ssGSEA) (Barbie et al., 2009) was
used from the GSVA package (https://bioconductor.org/packages/release/bioc/html/GSVA.
html)(Hänzelmann et al., 2013). The oxidation phosphorylation score and differentiation score
was obtained from MSigDB from the “KEGG_OXIDATIVE_PHOSPHORYLATION” and
“GO_MELANOCYTE_DIFFERENTIATION” gene sets, respectively. The viral mimicry score
was self-curated from published articles (Chiappinelli et al., 2015; Roulois et al., 2015) and
included DDX58, DDX41,IFIH1, OASL, IRF7, IRF1, ISG15, MAVS, IFI27, IFI44,IFI44L
and IFI16. To infer cytotoxic immune activity from gene expression data, the CYT-score was
calculated by finding the geometric mean from GZMA (granzyme A) and PRF1 (perforin)
(Rooney et al., 2015). The absolute abundance of eight immune and two stromal cell populations
were estimated using MCPcounter (Becht et al., 2016).
2.12 TCGA data analysis
The TCGAbiolinks package (Colaprico et al., 2016) in R was used to download SKCM
(Skin Cutaneous Melanoma) RNA-seq data from the NCI Genomic Data Commons portal
(https://gdc.nci.nih.gov/). The three main functions that were used were GDCquery (to search),
GDCdownload (to download) and GDCprepare (to load into R) (Silva et al., 2016).
2.12.1 RNA-sequencing data
Two types of RNA-seq data are available using the R package TCGAbiolinks which includes the
“legacy” data and the “harmonised” data (Silva et al., 2016). The “legacy” data is from the GDC
legacy archive are the originally processed data that was hosted by TCGA Data Coordinating
Center (DCC). For this legacy dataset, the genome reference (either GRCh37 or GRCh36) and the
data processing methods may have been different across the multiple cancer centres that analysed
the samples. Indeed there are various ways of performing sequence alignment and quantification
of mapped reads (Williams et al., 2017). In contrast the “harmonised” data were standardised by
reprocessing the raw data. This included realignment of sequence data against the same genome
(GRCh38) and used the same tool (HTSeq)(Anders et al., 2015) to quantify mapped reads to each
gene. Although the harmonised data is preferred, the SOX10 gene expression was not available
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in the harmonised dataset for an unknown reason [https://support.bioconductor.org/p/115312/].
Therefore the legacy RNA-seq dataset was used. Clinical details were also downloaded using
TCGAbiolinks. The code for downloading the data is in the following:
library(TCGAbiolinks)







The complete codes that were used to for download and downstream analysis is available on
Zenodo (https://doi.org/10.5281/zenodo.3375098)
2.12.2 DNA methylation (Infinium Human Methylation 450K BeadChip)
The TCGA Illumina Human Methylation 450 data (Beta values) was downloaded using
the R package RTCGAToolbox which accesses the Broad Institute’s GDAC Firehose. The
IlluminaHumanMethylation450kanno.ilmn12.hg19 package was used to obtain CpG
probe annotations including the CpG associated gene names and the associated regulatory
features (promoter, gene body and intergenic). The promoter region was identified using the
Regulatory_Feature_Group column and the intergenic and gene body region was identified




Complete codes for download and analysis are available in Zenodo (https://doi.org/10.5281/
zenodo.3375098).
2.12.3 Immune cell deconvolution
RNA-seq gene expression data was used to estimate the abundance of CD8 tumor infiltrative
lymphocytes (TILs) using three computational tools which were CiberSort (Newman et al., 2015),
MCPcounter (Becht et al., 2016) and xCell (Aran et al., 2017). Methylation 450k data were
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used to generate the meTIL (methylation TIL) score which was calculated with beta-values
from five CpG probes using the formula provided by Jeschke and colleagues (Jeschke et al.,
2017). To obtain the average TIL score from these four variables, first all zero CD8 values
produced from CiberSort, MCPcounter and xCell were converted to half of the smallest value
in that corresponding variable (as suggested by Matthew Parry, statistics department, Otago
University). This was done because zero values cannot be logarithmically transformed. All
values from the CiberSort, MCPcounter and xCell were logarithmically (log2) transformed. All
values were scaled to generate Z-scores by subtracting the mean and dividing by the standard
deviation. The average TIL score was then calculated for each sample using the arithmetic mean.
The average TIL-score and PD-L1 mRNA values were used to generate four groups from 469
samples according to high and low presence of TILs and PD-L1 expression (figure 2.2). First,
samples were split according to high and low TIL-score values using the median as a cut-off
threshold. Samples were then split again using the median PD-L1 mRNA expression levels as
the cut-off to generate 4 groups.
Figure 2.2: For 469 patients, both RNA-seq and 450k methylation data was available. CD8 Tcell abundance was estimated
for each sample using four computational tools where three uses RNA-seq data and one uses methylation 450k data. The
TIL-score was then calculated for each sample using the arithmetic mean. The TIL-score and PD-L1 mRNA values were used
to generate four groups from 469 samples according to high and low abundance of TILs and PD-L1 expression. First, samples
were split according to high and low TIL-score values using the median as a cut-off threshold. Samples were then split again
using the median PD-L1 mRNA expression levels as the cut-off to generate the final 4 groups. Groups 1 and 2 represents the
inducible and constitutive PD-L1 patient groups.
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2.13 MWG human 20K print-122 and HG-U133_Plus_2
platform probe investigation
To investigate which of the five CD274 transcripts was measured in the microarray
platforms, the genomic region where the CD274 probe binds were assessed. The CD274
probe binding sequence for MWG human 20K print-122 (https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GPL8640) was available via the Ocimum Biosolutions Human 40k
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL9365). The genomic region where
the CD274 probe binds was identified using BLAT (Kent, 2002) as available in UCSC website
(https://genome.ucsc.edu/cgi-bin/hgBlat). For the Affymetrix HG-U133_Plus_2 platform, the
genomic binding region for the CD274 probe was readily available in the Affymetrix website
(https://www.affymetrix.com/analysis/netaffx/showresμLts.affx).
2.14 Codes
All the R codes used for analysing raw fastq files in unix, data processing, generating figures,
and constructing this PhD dissertation is available on Zenodo (https://doi.org/10.5281/zenodo.





Marked Global DNA Hypomethylation Is
Associated with Constitutive PD-L1
Expression in Melanoma
This chapter (including figures and texts) was modified from our published paper.
Therefore this chapter is substantially based on this publication.
Chatterjee, A.; Rodger, E. J.; Ahn, A.; Stockwell, P. A.; Parry, M.; Motwani, J.;
Gallagher, S. J.; Shklovskaya, E.; Tiffen, J.; Eccles, M. R. & Hersey, P.
Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1
Expression in Melanoma. iScience, 2018, 4, 312-325.
The RNA-seq analysis, and the writing of the first draft was performed by Aniruddha
Chatterjee. The introduction contains work performed by other members in our lab whereas
the results section were all performed by me.
The RRBS library preparation and analysis were performed by Peter Stockwell and Euan
Rodger. Jyoti Motwani cultured the four NZM cell lines and extracted the RNA for
RNA-seq. The interferon blocking experiment was performed by Peter Hersey’s lab group
which included Stuart Gallagher, Elena Schklovskaya and Jessamy Tiffen
41
Work performed by Antonio Ahn included
- Characterisation of PD-L1 protein expression of the PD-L1CON and PD-L1IND samples
using flow cytometry
- TCGA SKCM data analysis (m450k data)
- DNMT inhibitor treatment and PD-L1 protein assessment
- RT-qPCR assessment of endogenous retroviral element mRNA expression
3.1 Introduction
Blocking the PD-1 to PD-L1 interaction using antibody based drugs has dramatically improved
melanoma therapy however only a small fraction of patients (approximately 30%) undergo
durable responses (Topalian et al., 2012). Thus there is a need for biomarkers that can predict
treatment outcome and new drug targets to improve response rates. PD-L1 expression has been
demonstrated to be predictive of response to anti-PD1 therapy (Abdel-Rahman, 2016). However
there have been mixed reports on the value of PD-L1 expression as a predictive biomarker.
Indeed PD-L1 as a single marker, has been of limited value as some patients with PD-L1
negative tumors respond to treatment, and vice versa some patients with PD-L1 positive tumors
do not respond to anti-PD1 drugs (Mahoney et al., 2015; Robert et al., 2015; Ribas et al., 2016).
One reason for these contradictory findings is that PD-L1 can be either inducibly or constitutively
expressed and these two mechanisms have been associated with opposing favourable or poor
response rates (Taube et al., 2018; Ribas and Hu-Lieskovan, 2016). Tumors with PD-L1
expression induced by cytokines (such as IFN-γ) secreted from tumor infiltrative immune
cells has been associated with being a favourable predictor of treatment given that there is a
pre-existing immune response inside the tumor before drug therapy (Cottrell and Taube, 2018).
In contrast, constitutive PD-L1 expression is regulated by an intrinsic molecular mechanism
and therefore does not depend on infiltrative immune cells. Constitutive PD-L1 expression is
therefore suggested to be associated with poor treatment responses (Cottrell and Taube, 2018).
In melanoma, constitutive PD-L1 expression is found in 1% to 20% (Taube et al., 2012; Teng
et al., 2015; Audrito et al., 2017; Emran et al., 2019) of cases. In these cases, PD-L1 expression
is homogeneously and strongly expressed throughout the whole tumor with or without tumor
infiltrative lymphocytes. It has been speculated that constitutive expression is driven by a
hyperactive signalling pathway arising from a genomic alteration (Jiang et al., 2013; Yamamoto
et al., 2009), but using our melanoma cell lines (Gowrishankar et al., 2015) and others (Atefi
et al., 2014; Spranger and Gajewski, 2016), have excluded a number of potential oncogenic
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pathways (MEK/ERK, PI3K/AKT, NF-kB, JAK/STAT pathways) that have been implicated in
other cancers.
DNA methylation have been suggested to play a potential role in the regulation of PD-L1
expression. Previous studies in non-small cell lung cancer cell lines demonstrated upregulation
of PD-L1 following DNMT inhibitor mediated global demethylation (Wrangle et al., 2013).
Similar findings were reported in studies on breast, colon, and ovarian carcinoma lines (Li
et al., 2014). Additionally, it was revealed that low or absent PD-L1 expression in 52 patients
with melanoma in The Cancer Genome Atlas (TCGA) was associated with high levels of DNA
methylation, as assessed using Illumina 450K arrays (Madore et al., 2016) supporting the idea
that DNA methylation may constitute an additional regulatory mechanism for PD-L1 expression.
In view of these findings, we went on to examine whether DNA methylation plays a potential
role in the regulation of PD-L1 expression.
We used melanoma cell lines with high levels of PD-L1 expression to compare levels of
DNA methylation and gene transcription to melanoma cell lines with low PD-L1 expression
levels. Eight melanoma cell lines were included in the study from Professor Peter Hersey’s lab
(University of Sydney) from their previous publication (Gowrishankar et al., 2015). These eight
cell lines included four PD-L1 constitutive cell lines where the PD-L1 protein was relatively
highly expressed as examined using flow cytometry (referred to as PD-L1CON). The other
four cell lines were inducible PD-L1 samples which had relatively low PD-L1 protein levels
but PD-L1 was inducible with IFN-γ treatment (referred to as PD-L1IND). Another two NZM
melanoma cell lines (Marshall et al., 1993) with high PD-L1 mRNA expression levels and two
further NZM cell lines with low PD-L1 expression levels were included in the study. These
additional cell lines had been identified based on a microarray dataset (GSE16404)(Jeffs et al.,
2009) and analysis number of RNA-seq data of NZM cell lines. As part of this analysis, PD-L1
expression in eight original melanoma cell lines and four newly identified NZM melanoma cell
lines was investigated using flow cytometry by me (for a full description of this analysis see
section 3.2.1). Overall this made a final sample number of 12 melanoma cell lines (6 PD-L1CON
and 6 PD-L1IND cell lines)(see figure 3.1). This study has been published (Chatterjee et al.,
2018b).
DNA methylation at the whole genome scale was analysed for the aforementioned six
PD-L1IND and six PD-L1CON lines samples using reduced representation bisulfite sequencing
(RRBS)(figure 3.1). The striking finding was that global DNA methylation levels in the
PD-L1CON cell lines were significantly lower than those in PD-L1IND cell lines (median
methylation = 0.47 and 0.63, respectively, Wilcoxon rank test p value <2.2 × 10−16, figure
3.2). The hypomethylation of PD-L1CON cell lines was particularly pronounced in the gene
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intronic and intergenic regions (figure 3.2A). The gene intronic region showed a 12% median
methylation reduction in the PD-L1CON group, whereas for the intergenic region, there was a
19% reduction in the median methylation. There were no significant DNA methylation changes
in gene promoters (defined as −5 kb to +1 kb) or exon regions in between the two groups
(figure 3.2A). PD-L1CON cells showed DNA hypomethylation in all the four classes of repeat
elements (LINES, Satellite elements, SINEs and LTRs) that were analysed (figures 3.2B–E).
The LTR family (consisting of endogenous retroviral elements or ERV) exhibited the highest
degree of hypomethylation in the PD-L1CON samples (figure 3.2E) with a median methylation
reduction that ranged from 13% to 19%. For L1 LINE elements, there was a 0.19 loss of median
methylation whereas in the L2 elements, there was a 0.11 reduction in median methylation in
the PD-L1CON group compared to PD-L1IND group. A total of 1,180 differentially methylated
fragments (DMFs) were identified in the PD-L1CON group compared to the PD-L1IND group
using 25% mean difference for a fragment as a minimum criteria. Consistent with the global
hypomethylation of PD-L1CON samples, 96.4% of the DMFs were hypomethylated. There
was a higher than 50% difference in methylation levels in three-quarters of the DMFs, and
105 regions were identified that showed higher than 75% methylation differences between the
PD-L1IND and PD-L1CON groups (Figure 3.2F). The significantly reduced methylation pattern
in the constitutive PD-L1 samples compared to the inducible samples suggested there may be
a common methylation-associated regulatory mechanism that may play a role in upregulating
PD-L1 expression.
RNA-sequencing (RNA-seq) was used to assess the transcriptome of the six PD-L1CON and six
PD-L1IND cell lines. RNA-seq analysis identified 508 genes that were significantly differentially
expressed (DEG) in the PD-L1CON samples compared to the PD-L1IND samples (FDR-adjusted
pvalue <0.05 and log2 fold change of mean FPKM ≥2). Out of these 508 DEGS, 222 were
downregulated (figure 3.3A) and 286 were upregulated (figure 3.3B) in the PD-L1CON samples.
Upregulated genes in PD-L1CON cell lines were strongly negatively correlated with global
methylation levels, whereas downregulated genes were positively correlated (figure 3.3A). 58
genes were found to have very high upregulation in PD-L1CON cell lines (log2 fold change >10,
figure 3.4C, right side of the distribution) compared with 19 genes that showed very strong
downregulation in the PD-L1CON cell lines (figure 3.4C, left distribution). Gene set enrichment
analysis (GSEA) showed that the downregulated genes in PD-L1CON lines were enriched for
development, cell differentiation and the melanin biosynthesis pathway (figure 3.4A). In contrast,
the upregulated genes were enriched for several cancer hallmark-related biological processes,
including epithelial-mesenchymal transition (EMT), interferon gamma response, upregulation
of the KRAS signalling pathway, hypoxia, and TNF-α signalling mediated by NF-κB (figure
3.4B).
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Figure 3.1: Summary of experimental design and the analysis pipeline for PD-L1 IND and PD-L1 CON cell lines to identify
epigenetic regulation of PD-L1 in melanoma. The upper panel shows representative FACS figures from PD-L1 CON and
PD-L1 IND cells
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Figure 3.2: Whole-genome-scale and element-wise methylation profiles in PD-L1 inducible and PD-L1 constitutive Cell Lines
(A) Boxplots showing genome-wide and genomic element RRBS methylation profiles for PD-L1 inducible (blue) and PD-L1
constitutive (red) cell lines; black bars indicate the median methylation. (B–E) Violin plots of PD-L1 constitutive and
PD-L1IND DNA methylation levels for different classes of repeat elements. (B) LINE elements (L1 and L2), (C) Satellite
elements (satellite, telomeric, and centromeric repeats), (D) SINE elements (Alu and MIR), and (E) LTRs (ERV1, ERVK,
ERVL, and ERVL-MaLR). In all cases the y axis represents the methylation level on a 0–1 scale. Annotations for repeat
elements were downloaded from the UCSC repeat masker database. (F) Methylation levels for the 105 differentially methylated
fragments (DMFs) showing >70percent methylation difference between the PD-L1 inducible and PD-L1 constitutive cell lines
(blue = unmethylated, red = fully methylated).
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Figure 3.3: Differential expression patterns in PD-L1 IND and PD-L1 CON cell lines (A) Mean-centered heatmap of the
expression level (log2 FPKMs) of 222 significantly downregulated genes in PD-L1 CON . (B) Mean-centered heatmap of the
expression level (log2 FPKMs) of 286 significantly upregulated genes in PD-L1 CON . The correlations of these genes with
CD274 (PD-L1) expression and global methylation status in the analysed cell lines are shown in the colored sidebars (left) in
both figures.
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Figure 3.4: (A) Enriched gene ontology terms relative to the 222 genes downregulated in PD-L1 CON cell lines. (B) Enriched
gene ontology terms relative to the 286 genes upregulated in PD-L1 CON cell lines. In figure (A) and (B), the x axis represents
–log10 of the p value. (C) Density histogram of the log2 fold changes for the significantly upregulated (n = 286, right side of
the histogram) and downregulated (n = 222, left side of the histogram) genes. Genes with log2 fold change >10 are indicated.
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3.2 Results
3.2.1 Characterising the inducible (PD-L1IND) and constitutive (PD-L1CON)
PD-L1 melanoma cell lines
This section is in reference to the flow cytometry characterisation of the PD-L1 expression
levels in the 12 melanoma cell lines (6 PD-L1CON and 6 PD-L1IND cell lines) as mentioned in the
introduction of this chapter. Six cell lines were selected as PD-L1IND where PD-L1 is relatively
lowly expressed but induced after IFN-γ treatment (Figure 3.5) and six cell lines were selected
as PD-L1CON expression (Figure 3.6).The proportion of PD-L1-positive cells in the PD-L1IND
cell lines ranged from 0.82%–6.79% (median = 1.7%) whereas in the PD-L1 positive cells,
the proportion of PD-L1 positive cell lines ranged from 41.6% to 99.07% (median = 93.57%).
The MAPK signalling pathway was shown to play a role in PD-L1 expression in lung cancers
(Stutvoet et al., 2019; Sumimoto et al., 2016), large cell lymphoma (Yamamoto et al., 2009),
Hodgkin lymphoma (Yamamoto et al., 2009) and melanoma (Jiang et al., 2013). However
the MAPK signalling pathway had previously been shown to be not playing a role in PD-L1
expression in our constitutive PD-L1 cell lines (Gowrishankar et al., 2015). Furthermore, the
number of different oncogenic driver mutations was the same in the inducible and constitutive
PD-L1 group. Both the inducible and constitutive PD-L1 group consisted of 4 BRAFV600E
mutant, one NRASQ61 mutant and one wild-type for NRAS and BRAF samples (Table 3.3).
Although I did not test whether PD-L1 expression can be further increased in the PD-L1CON
cell lines by IFN-γ induction, it was reported by our collaborators that PD-L1 expression
can be further enhanced upon induction in four of the samples that were tested (CM143.pre,
CM143.post, MelRMu and CM150.post)(Chatterjee et al., 2018b; Gowrishankar et al., 2015).
Altogether, these data suggested that factors other than IFN-γ or oncogenic signalling, are
involved in regulating constitutive PD-L1 expression.
A limitation from the previous results that showed a globally hypomethylated profile and distinct
transcriptome with PD-L1CON expression is that these were found in melanoma cell lines. Cell
lines do not always represent the genomic and phenotypic biology of in vivo patient tumors and
thus there is a strong need to validate our findings in patient tumors. A great source of patient
tumor RNA-seq and methylation data is the TCGA SKCM dataset which contains information
for 469 melanoma patients. In the following sections, to validate our findings of a reduced
global methylation in the PD-L1CON samples in comparison to the PD-L1IND group, the TCGA
SKCM patient samples were analysed. Moreover, in order to explain the link between a ERV
demethylation and an active innate immune response, the expression levels of a number of
ERVs were investigated. Furthermore, to support that PD-L1 expression is upregulated via DNA
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demethylation, DNMT inhibitors were used induce global demethylation and PD-L1 expression
levels were assessed in the PD-L1CON and PD-L1IND cell lines.
Table 3.3: Information on melanoma cell lines
cellline mutation group Percentage_of_PDL1positiveCells
CM138 BRAF(V600E) inducible 2.95
CM150.post BRAF(V600E) inducible 1.00
CM145.pre BRAF(V600E) inducible 2.22
CM145.post BRAF(V600E) inducible 1.18
NZM22 WT inducible 6.79
NZM42 NRAS(Q61K) inducible 0.82
CM142.post BRAF(V600E) constitutive 88.53
MelRMu BRAF(V600E) constitutive 41.60
CM143.pre BRAF(V600E) constitutive 83.55
CM143.post BRAF(V600E) constitutive 98.61
NZM9 WT constitutive 99.07
NZM40 NRAS(Q61H) constitutive 98.99
3.2.2 Investigation of whether constitutive PD-L1 expression (PD-L1CON) is
associated with global hypomethylation in the TCGA SKCM dataset.
The results presented in the introduction of this chapter (section 3.1, figures 3.3 and 3.4)
demonstrated that PD-L1CON expression is associated with a globally hypomethylated profile
and a distinct transcriptomic feature using melanoma cell lines. Given that cell lines are
not always representative of the genomic and phenotypic biology of patient tumor tissues,
validation was required using patient tumors. The TCGA SKCM dataset contains RNA-seq and
methylation data (Illumina Infinium 450k DNA methylation data) for 469 patients. Here, I asked
whether the reduction in global methylation in the PD-L1CON samples in comparison to the
PD-L1IND group could also be observed in melanoma tumors. In order to evaluate this question,
it is important to distinguish PD-L1 expression that arises from the presence of stimulatory
immune cell (particularly CD8 lymphocytes) from an intrinsic cancer cellular mechanism, given
that PD-L1CON expression is driven by the latter. Therefore, using the RNA-seq and 450k DNA
methylation data from the TCGA SKCM cohort (for 472 melanoma tumors), the abundance of
lymphocytes was estimated. Indeed computational tools are increasingly becoming more robust
for measuring compositions of non-cancer populations such as immune subtypes (Hackl et al.,
2016). These tools utilises the mRNA expression or DNA methylation profile that is specific to
the immune subpopulation of interest and use an algorithm to estimate their abundance in the
tumor (Hackl et al., 2016). Given that there are various computational tools for immune cell
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Figure 3.5: FACS analysis results of the inducible PD-L1 cell lines without IFN-gamma induction. Flow cytometry was used to
determine cell surface expression of PD-L1 in the PDL1 IND cell lines. The melanoma cell lines were stained with anti-PD-L1
(PE) and the isotype control antibody. Y-axis represents the number of cells analysed and x-axis represents the anti-PDL1 PE
fluorescence.
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Figure 3.6: FACS analysis results of the PD-L1 CON cell lines without IFN-gamma induction. Flow cytometry was used to
determine cell surface expression of PD-L1. The melanoma cell lines were stained with anti-PD-L1 (PE)(blue) and the isotype
control antibody (red). Y-axis represents the number of cells analysed and x-axis represents the anti-PDL1 PE fluorescence.
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deconvolution and it is unclear which tool is optimal, I selected four different computational
methods to estimate the abundance of CD8 lymphocytes and obtained an average value for
downstream analysis (described in method section of 2.11.3). The data consisted of 450K DNA
methylation and RNA-seq data in the TCGA-SKCM cohort from 472 melanoma tumors. Three
out of the four methods use RNA-seq data and includ CIBERSORT (Newman et al., 2015),
MCPcounter (Becht et al., 2016) and xCell (Aran et al., 2017)(figure 3.7). The fourth method
uses the 450k DNA methylation data to generate a methylation tumor infiltrative lymphocyte
score (meTIL score)(Jeschke et al., 2017)(figure 3.7).
CIBERSORT and xCELL gave an output of zero CD8 abundance for 109 and 247 tumors
respectively. Ninety six tumors were estimated to have zero abundance with both CIBERSORT
and xCELL (figure 3.8). For CD8 abundance estimates from CIBERSORT, xCell and
MCPcounter, the data were log2 transformed (figure 3.7). Given that the four CD8 values
are on different scales, all values were rescaled to have a mean of 0 and a standard deviation
of 1 (also known as a z-score). Subsequently a mean average CD8 value was obtained from
the four methods (referred to as CD8Final). Correlation between the five CD8 values (four
independent CD8 values and CD8Final) showed CD8Final to have the highest correlation (figure
3.9). The median of CD8Final and CD274 mRNA values were used as a threshold to obtain
four groups which included 1) TIL-/PDL1- (group1), 2) TIL-/PDL1+ (group2), 3) TIL+/PDL-
and 4) TIL+/PDL1+). This resulted in (out of the 469 TCGA SKCM samples) 38% that were
TIL-/PDL1- (group1), 12% that were TIL-/PDL1+ (group2), 12% that were TIL+/PDL- and
38% that were TIL+/PDL1+ (figure 3.10). The median average was selected as it would give a
similar proportion for each group according to what is recorded in the literature. This consists of
35% to 38% with TIL-/PDL1- (group1), 1 to 20% with TIL-/PDL1+ (group2), 5% to 20% with
TIL+/PDL1- and around 40% with TIL-/PDL1- (Taube et al., 2012; Teng et al., 2015; Audrito
et al., 2017; Emran et al., 2019). I considered group 1 (TIL-/PDL1-)(n = 180) as being most
representative of the PD-L1IND group and group2 (TIL-/PDL1+)(n = 55) most representative of
the PD-L1CON group. A caveat of the method used here for generating TIL-/PDL1- (group1)
and TIL-/PDL1+ (group2) groups is that group2 has a higher CD8 abundance level than group 1
(figure 3.11). This occurs because CD274 expression is highly correlated with CD8 abundance.
In contrast to the global hypomethylation found in the PD-L1CON melanoma cell lines compared
to the PD-L1IND samples, a global methylation difference between group 1 and group 2 in the
SKCM TCGA data was not detected (figure 3.12). One possible explanation for this discrepancy
is that HumanMethylation450 BeadChip probes are largely promoter-biased whereas RRBS has
better discrimination power to detect methylation differences in intergenic regions, introns, and
repeat elements. In addition, we specifically examined the five CpG island-associated probes
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in the promoter and 5′ untranslated region (5′UTR) of the PD-L1 gene (CD274) in the TCGA
data. CpG probes cg02823866 and cg14305799 were located within 200 bp of the transcription
start site (TSS) in the CD274 promoter, whereas cg15837913 was located within 1,500 bp
from the TSS (but still within the CD274 5′UTR). cg13474877 together with cg19724470 were
within the CD274 5′UTR. The two CpGs in the CD274 promoter were essentially unmethylated
(<5% mean methylation) in both group 1 and 2 (figures 3.13A-D), whereas the two CpGs in the
5′UTR showed a loss of methylation (13% for cg15837913 and 16% for cg19724470) in group 2
(representative of constitutive melanoma) compared with group 1 (inducible melanoma, figures
3.13E,F,I,J). Overall, there was an insignificant difference in methylation of the CD274 core
promoter between the two groups.
3.2.3 PD-L1CON samples exhibit an upregulated viral mimicry and
interferon expression signature, similar to that induced by DNMT
Inhibitors
DNMT inhibitor mediated demethylation of the cancer genome activates a host of immune
related gene signatures including the viral mimicry pathway (Roulois et al., 2015; Chiappinelli
et al., 2015), interferon stimulation, antigen processing and presentation, cancer testis antigens
and cytokine or chemokine (Li et al., 2014). Accordingly, the global hypomethylation of
the PD-L1CON cell lines was accompanied by a significant upregulation of several type I
interferon-stimulated, viral mimicry genes (IFI44, IFI27, OASL, IL29) and genes that are
upstream of the type I interferon pathway (IFNB1 and IRF7) compared with the PD-L1IND lines
(Chatterjee et al., 2018b). Moreover, DNMTi treatment was revealed to increase expression
of cytosolic double-stranded RNA (dsRNA) sensors that triggers the interferon response and
apoptosis (Chiappinelli et al., 2015). Consistent with these findings, a relatively high mRNA
expression of the dsRNA sensor RIG-I (DDX58) in the PD-L1CON cells (the mean log2 fold
change of 4.96) was found, as well as upstream transcriptional activators, including IRF1, in
PD-L1CON cell lines (Chatterjee et al., 2018b). These findings may be related to the innate
hypomethylation phenotype in PD-L1CON cells.
To examine if the gene expression patterns that was observed in PD-L1CON cell lines were also
observed in melanoma tumors, I analysed the RNA-seq data from TCGA-SKCM patients. The
same group 1 (TIL-/PDL1-, representative of inducible) and group 2 (TIL-/PDL1+, representative
of constitutive) melanoma cohorts were used as described in the previous section. Similar to
our findings in PD-L1IND and PD-L1CON cell lines, upregulation of viral mimicry and immune
response genes in group 2 patients compared with group 1 patients was observed, including 11
































































































































































Figure 3.7: Boxplot and density plot showing the CD8 abundance estimates from CIBERSORT, xCELL, MCPcounter and
meTILscore with 469 SKCM TCGA RNAseq data. The first 2 columns show the non-log transformed expression data whereas




















Figure 3.8: The correlation of CD8 abundance estimates between xCell and CIBERSORT. The colour (from blue to yellow)














































Figure 3.9: The correlation between the CD8 abundance estimates of CIBERSORT, xCELL, MCPcounter, meTILscore,
CD8Final (averaged value of the 4 methods) and CD274 mRNA (log2) expression levesl. The pearson correlation value are
displayed on the right sided boxes whereas the points of correlation are displayed on the left sided boxes. The left top to right




















TIL−/PDL1− (group1) TIL−/PDL1+ (group2) TIL+/PDL1− TIL+/PDL1+
Figure 3.10: Selection of four groups according to high (positive) and low (negative) TIL (tumor infiltrative CD8 lymphocyte)
and CD274 (PD-L1) levels. The x-axis (CD8Final) represents the averaged CD8 abundance level (from the 4 methods of
CIBERSORT, xCell, MCPcounter and meTILscore) and y-axis represent the CD274 mRNA (log2) expression levels. The
median value are shown by the dashed black line.
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a aTIL−/PDL1− (group1) TIL−/PDL1+ (group2)
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a aTIL−/PDL1− (group1) TIL−/PDL1+ (group2)
B
Figure 3.11: Group 1 and Group 2 patients represent the PD-L1 IND and PD-L1 CON groups, respectively.(A) The CD8
abundance estimates between group 1 and group 2 from 469 SKCM TCGA tumors. CD8 abundance was generated using an
average from four immune cell decomposition computational tool (MCPcounter, CIBERSORT, xCell and meTIL score)(see




















































































groups Group 1 (TIL−/PDL1−) Group 2 (TIL−/PDL1+)
Figure 3.12: Methylation levels based on 450K TCGA-SKCM data for Group 1 (TIL-/PDL1-) and Group 2 (TIL-/PDL1+)
patients (representative of PD-L1 IND and PD-L1 CON groups) according to gene body, intergenic and promoter regions.
Boxplots show the average beta values and interquartile range of all probes belonging to the feature.
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Figure 3.13: Methylation level difference between group 1 (representative of PD-L1 IND ) and group 2 (representative of
PD-L1 CON ) for the five probes that are located near the CD274 gene using the 450K TCGA-SKCM dataset. Two of the
probes are in the CD274 promoter (A-D) whereas three are in the 5’UTR region (E-J). The first column shows the boxplots
of the beta methylation value between group 1 (representative of PDL1 IND ) and group 2 (representative of PDL1 CON ).
The second column shows the correlation of CD274 mRNA expression (log2) with the methylation values for the five probes.
The pearson correlation value and p value are shown according to group 1, group 2 and combined (group 1 and group 2).
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1 (after FDR adjustment at 5% and log2 fold change of 0.5, indicated as * in figure 3.14).
These data suggested that global hypomethylation in PD-L1CON melanoma cells have an
activated viral mimicry pathway, which is induced by dsRNA molecules that are expressed from
endogenous retroviral elements in the human genome (Roulois et al., 2015; Chiappinelli et al.,
2015). Indeed DNMTi mediated demethylation of ERVs, which make up 8% of the genome,
can increase expression of dsRNA derived from these regions to stimulate the innate immune
response (Roulois et al., 2015; Chiappinelli et al., 2015). To explore this further RT-qPCR
was used to measure the expression of nine ERV genes that were previously identified to be
upregulated in a colorectal cancer cell line upon DNMTi treatment (Roulois et al., 2015). The
expression of only one of these nine ERV genes was higher in the PD-L1CON cell lines compared
with the PD-L1IND cell lines (figure 3.15). This included MLTA10 (mean-fold increase = 5.8,
FDR adjusted p value = 0.034). However for four other ERVs, there was a trend towards higher
expression in the PD-L1CON melanoma cells. This included MER21C (mean fold increase =
5.8, FDR adjusted p value = 0.12), MLT1C627 (mean-fold increase = 4.2, FDR adjusted p
value = 0.05), MER4D (mean-fold increase = 3.1, FDR adjusted p value = 0.12), and MER57B1
(mean-fold increase = 4.4, FDR adjusted p value = 0.12). The experiment was performed in
triplicate and was repeated twice. Standard error (SE) was chosen over standard deviation
to generate error bars as SE makes inferences about the population mean (measures how
precisely you have determined the population mean) whereas the standard deviation measures
the dispersion of the data without making inferences to the population mean (Curran-Everett,
2008; Lee et al., 2015). Therefore, these data suggest that ERV expression could be upregulated
in the PD-L1CON melanoma cells, however further testing is required.
3.2.4 DNMTi mediated global demethylation upregulates PD-L1 expression
more highly in the PD-L1IND samples compared to the PD-L1CON
samples
Finally, it was hypothesised that if global hypomethylation regulates PD-L1 expression, then
DNMT inhibitor (DNMTi) mediated demethylation will lead to a stronger enhancement of PD-L1
expression in the inducible lines, as they exhibit higher genomic methylation levels, compared
to the constitutive lines. DNMTi treatment results in degradation of DNMT proteins leading to
cellular replication dependent demethylation (Schermelleh et al., 2005). If the hypomethylated
state of PD-L1CON cell lines is playing a role in PD-L1 expression, PD-L1 expression may
increase in the PD-L1IND cell lines upon DNMTi treatment via the same pathway. 12 melanoma
cell lines were treated with a DNMTi called decitabine to induce for global demethylation (for










































Figure 3.14: Expression pattern of genes involved in the viral mimicry pathway according to TIL-/PD-L1+ (group 1,
representative of inducible in patient group) or TIL-/PD-L1+ (group 2, representative of constitutive in patient group)
from the melanoma tumors in the TCGA SKCM RNAseq data. Rows represent the gene expression level (Z-score with mean
of 0 and standard deviation of 1). Significantly differentially expressed genes are indicated with an asterisk (*)(t-test with


























































































































































































































































































































































































































































































































































































































































Figure 3.15: (A–I) Gene expression of the nine ERV genes as measured by RT-qPCR between the PD-L1 IND group (blue)
and PD-L1 CON group (red). There is a higher expression in 1 ERV gene (MLTA10) in the PD-L1 CON cell lines compared
with the PD-L1 IND group. P values were adjusted for multiple tests (t-test with FDR adjusted p values). Error bars represent
SE of two experimental repeats (each repeat was done in triplicate)
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exposure in normal media). This was followed by measurement of PD-L1 protein expression
using flow cytometry. As low dosage of DNMTi (0.5 μM) were used in these experiments, it
was assumed that without experimental validation, DNA demethylation was successful without
significant DNA damage. Initial studies that reported DNMTi mediated DNA damage, used up
to 10 μM of DNMTi (Palii et al., 2008) whereas studies that used low dosages (0.1 to 0.5 μM)
demonstrated minimal DNA damage and successful DNA demethylation (Wrangle et al., 2013; Li
et al., 2014). Nonetheless, a limitation of this study is that significant DNA damage is still feasible,
and demethylation was not confirmed. In all 12 cell lines, an upregulation of cell surface PD-L1
expression was observed upon DNMTi treatment. However the degree of PD-L1 upregulation
upon demethylation was higher in the PD-L1IND samples compared to the PD-L1CON samples
(figure 3.16). In five of the six inducible cell lines, cell surface PD-L1 levels were upregulated
>2 fold and particularly in CM145-pre, CM145-post, and NZM42, which showed an average
fold increase of 3.9, 10.0, and 4.7, respectively (figure 3.16). The PD-L1CON lines also generally
showed PD-L1 upregulation. However, as they were already expressing high levels of PD-L1, the
degree of change was relatively small compared with that of the inducible lines (figures 3.16C-D).
Among the PD-L1CON lines, only Mel-RMU showed >2-fold (2.44) upregulation of PD-L1 upon
demethylation (figure 3.16D).
In addition to DNMTi, vitamin C (ascorbic acid) has been shown to induce active demethylation
via enhacement of TET enzymatic activity. Vitamin C acts as a cofactor for the TET enzymes by
binding to its catalytic domain. TET enzymes catalyse the hydroxylation of 5-methylcytosine
(5mC) to promote demethylation (Tahiliani et al., 2009). The PD-L1CON and PD-L1IND cell
lines were treated with vitamin C, to induce active demethylation by enhancing TET enzyme
activity; however, this treatment did not result in any significant further increase of cell surface
PD-L1 expression in either the inducible or constitutive lines, except in the inducible cell line
CM145-post, which showed a 2.06 average fold increase in PD-L1 upon vitamin C treatment
(figure 3.17, the y-axis in this figure is a log2 fold change, therefore the 1.04 log2 fold change is
a 2.06 fold increase).
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Figure 3.16: Cell surface PD-L1 expression changes upon DNMTi (demethylation) treatment in (A) PD-L1 IND and (B)
PD-L1 CON cell lines with flow cytometry analysis. The FACS analysis performed at day 6 following 3 days treatment with
decitabine (DNMTi; 0.5mM) or mock treatment (DMSO). Changes in PD-L1 expression between DNMTi treated and the
control for PD-L1 IND (C) and PD-L1 CON (D) cell lines were calculated using medium fluorescence intensities (MFI) and
the formula log2 ([(MFIantibody, treated)-(MFIisotype, treated)]/[(MFIantibody, mock)-(MFIisotype, mock)]) (Wrangle et
al., 2013). Error bars represent SE of two independent experiments.
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Figure 3.17: Flow cytometry analysis of PD-L1 cell surface expression upon single and combination treatment of DNMTi
(demethylation) and vitamin C in PDL1IND and PD-L1CON cell lines. Flow cytometry analysis for PD-L1IND (A) and
PD-L1CON (B) cell lines were performed at day 6 for all 3 treatment groups of decitabine (DAC), vitamin C (VitC) and
decitabine with vitamin C (DAC + VitC). Decitabine (DNMTi; 0.5uM) and mock treatment (DMSO) were performed for




Antibody based therapy against the PD1 receptor or PDL1 ligand has revolutionalised cancer
therapy, particularly in melanoma. However given that only a subset of metastatic melanoma
patients respond durably, attention has focused on understanding the regulation of PD-L1 on
cancer cells in order to find new drug targets and identify predictive biomarkers (Zerdes et al.,
2018; Sun et al., 2018; Wang et al., 2018). Numerous studies have demonstrated the complexity
of PD-L1 regulation with mechanisms involved at the genetic, epigenetic, transcriptional,
post-transcriptional and protein levels (Zerdes et al., 2018; Sun et al., 2018; Wang et al., 2018).
In this chapter, the aim was to investigate whether DNA methylation plays a functional role in
the regulation of constitutive PD-L1 expression by using sequencing-based genome-wide DNA
methylation profiling combined with transcriptome profiling.
3.3.1 Constitutive PD-L1 expression in melanoma is associated with global
hypomethylation and transcriptomic upregulation
A striking global loss of methylation was observed in the constitutive PD-L1 cell lines compared
to the inducible PD-L1 cell lines using RRBS genome-wide methylation profiling (performed
by Euan Rodger, Peter Stockwell and Aniruddha Chatterjee). Interestingly, the large reduced
methylation were confined mainly to intergenic and intronic regions, rather than promoter regions.
In contrast, the same pattern of methylation differences could not be detected in the TCGA
450K melanoma methylation data, which one possible explanation is that the probes in the 450K
platform are designed mainly for the gene promoters and relatively few 450K probes are located
in the gene body or intergenic regions. Consistent with previously reported data, we found the
CD274 promoter was unmethylated (Chatterjee et al., 2016), with no evidence of differential
methylation occurring in the core promoter itself, which argues against methylation of the CD274
promoter being involved in constitutive PD-L1 expression.
Transcriptome profiles in these cell lines correlated with global methylome status, where the up
and downregulated genes in the PD-L1CON samples were negatively and positive correlated with
global methylation levels. Upregulated genes in the PD-L1CON lines were associated with EMT,
KRAS signalling, hypoxia, and NF-κB signalling, consistent with the known key pathways
that regulate PD-L1 transcription (Chen et al., 2016). The profound globally hypomethylated
state could be a contributing causative factor in the upregulation of these pathways in the
constitutive PD-L1 samples. Out of the 557 differentially expressed genes, only 39 showed
significant changes in methylation, with methylation differences mainly occurring in the gene
body or enhancer regions associated with these genes. This suggested that, rather than promoter
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methylation differences, large genomic methylation differences outside the promoter regions
could play a regulatory role in promoting the constitutive PD-L1 expression.
Interestingly, although global hypomethylation was correlated with mRNA upregulation in
PD-L1CON lines, for the majority of candidate genes that were differentially methylated and
differentially expressed, loss of gene body methylation was linked with their downregulation
in the PD-L1CON cell lines. Although DNA methylation in gene promoters is well established
to silence gene expression primarily by introducing binding site for the methyl-CpG-binding
domain (MBD) family proteins, causing a closed chromatin structure (Du et al., 2015; Baylin and
Jones, 2011), gene body methylation has been shown to increase transcriptional activity (Yang
et al., 2014; Jjingo et al., 2012). An explanation for this is that gene body methylation blocks
the expression of promoters or transposable elements that lie within the gene body (Maunakea
et al., 2010) or alternatively it results in nucleosome stabilization to enhance transcriptional
elongation (Yang et al., 2014). For example, IRF4 and DAPK1 showed notable downregulation
of expression and loss of gene body methylation in PD-L1CON cell lines. IRF4 is upstream
of the PD-L1 signalling pathway, and reduced levels of the IRF4 transcription factor lead to
upregulation of PD-L1 expression and promote T cell dysfunction (Wu et al., 2017). In addition,
reduced levels of DAPK1 were shown to be associated with reduced sensitivity to BRAF
inhibitor therapy, suggesting its possible role in targeted melanoma therapy (Xie et al., 2017).
These candidates and other genes containing multiple DMFs and deregulated gene expression
warrant future investigation in the context of PD-L1 to elucidate their mechanistic specific role.
3.3.2 Reduced expression ofDNMT3A correlateswith global hypomethylation
in PD-L1 constitutive melanomas
Global hypomethylation is perhaps the most accepted epigenetic paradigm in cancer (Baylin
and Jones, 2011), yet the mechanisms involved in this are not completely clear. Our study
offers fresh insights into the possible mechanisms for global hypomethylation in melanoma cell
lines. The de novo methylating enzyme DNMT3A mRNA expression was strongly negatively
correlated at mRNA and protein levels with PD-L1 expression and was positively associated with
globally elevated methylation levels (Chatterjee et al., 2018b), which is consistent with the notion
that hypomethylation in PD-L1CON cell lines may be the result of reduced levels of DNMT3A.
Additional investigations are required to determine whether DNMT3A indeed plays a central role
in the global hypomethylation and levels of PD-L1 expression in PD-L1CON cells.
Another known mechanisms that could potentially drive global hypomethylation in melanoma
is the active removal of methylation via TET enzymes (Guo et al., 2011; Ito et al., 2011).
Furthermore, active demethylation by TET enzymes did not appear to be involved in the
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PD-L1CON DNA methylation levels, as expression patterns of the TET family genes were not
correlated with global methylation levels or CD274 expression. This is also consistent with
our experimental data whereby treatment with vitamin C, a cofactor of TET enzymes, failed to
induce significant upregulation of cell surface PD-L1 expression, whereas DNMTi treatment
significantly increased cell surface PD-L1 levels. Taken together, our data provide evidence
that de novo regulation of global methylation levels in melanoma is potentially part of the
mechanisms regulating PD-L1 expression. One possible explanation for the association between
the global hypomethylation and constitutive PD-L1 expression is that global hypomethylation
results in changes in the signalling pathways involved in immune response and generation of a
constant “on” signal.
3.3.3 DNMTi treatment increases PD-L1 Expression, which like constitutive
PD-L1 expression in melanoma, is associated with a viral mimicry
phenotype
Studies in epithelial cancers and non-small cell lung cancer have shown that DNMT inhibitor
mediated DNA demethylation can induce an interferon gene signature response in the cells,
including PD-L1 (Li et al., 2014; Wrangle et al., 2013). The interferon gene signature was
activated as part of the viral mimicry pathway (Roulois et al., 2015) where upon demethylation,
endogenous retroviral sequences (ERVs) are expressed as dsRNA and in turn recognized by
dsRNA sensors (such as TLR3, MGA5, and RIGI) in the cells (Chiappinelli et al., 2015)
to activate an innate immune response. This is consistent with the findings here that repeat
elements, particularly the ERVs, were strongly hypomethylated in the PD-L1CON cells and that
ERV mRNA expression levels were more highly expressed in the PD-L1CON samples than in
PD-L1IND samples.
In addition, PD-L1CON cell lines have an upregulation of innate immune response genes that
are also upregulated from DNMTi mediated global demethylation (Chiappinelli et al., 2015,?).
This includes genes involved in the viral mimicry pathway such as IFI44, IFI27, OASL, IL29,
IFNB1 and IRF7. Analysis of TCGA melanoma patient transcriptome data revealed that these
viral mimicry genes were significantly differentially expressed between constitutive (group 2)
and inducible (group 1) patient groups. Taken together, these results support the notion that
upregulation of a viral mimicry phenotype is the result of global hypomethylation in PD-L1CON
cells. Further studies are needed to confirm whether constitutive upregulation of the type 1 IFN
pathway is a result of a hypomethylation-mediated viral mimicry phenotype.
In summary, based the results presented here, it is concluded that constitutive expression
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of PD-L1 is a consequence of global hypomethylation and that global DNA methylation
status is an important factor in the regulation of PD-L1. The exact mechanism of how the
hypomethylated state regulates pathways involved in PD-L1 expression in melanoma needs to
be further investigated, but constitutive expression of PD-L1 in melanoma cells may identify
melanomas that have endogenous activation of IFN signalling pathways, analogous to effects of
treatment with inhibitors of DNMT enzymes. We identified that downregulation of DNMT3A
was associated with global hypomethylation and PD-L1 expression. Further studies are needed
to examine whether this subset of melanomas have similar responses to PD1 checkpoint
inhibitor treatments or if they require combination therapies that target other consequences of




Identification of constitutively expressing
PD-L1 melanoma cell lines using external
datasets and flow cytometry
4.1 Background
Our previous analysis revealed that melanoma cells with PD-L1CON expression have an
upregulated gene expression program associated with epithelial-to-mesenchymal transition
(EMT), viral mimicry pathway, hypoxia and type 1 interferon response (chapter 3 of this
thesis)(Chatterjee et al., 2018b). In order to further investigate the distinct gene expression
profile of PD-L1CON samples compared to PD-L1IND samples, I aimed to first strengthen our
sample groups. Thus, here the aim included increasing the sample number in both constitutive
and PD-L1IND groups (from the previous number of 6 in each group). Moreover samples with
intermediate PD-L1 expression (identified using hierarchical clustering and k-means) were
removed in order to maximise the difference of PD-L1 expression between the 2 groups.
Melanoma cell lines were chosen instead of melanoma tissue as PD-L1CON expression is easier
to measure from cell lines. This is because for cell lines, there are no immune secreted cytokines
that can induce PD-L1 expression. In melanoma tumors, IFN-γ secreted from immune cells
can induce PD-L1 expression (Garcia-Diaz et al., 2017) in addition to PD-L1CON expression.
Therefore, for tissue, it is difficult to differentiate between PD-L1CON and PD-L1IND expression.
One major challenge was identifying additional melanoma cell lines with significantly high
expression of PD-L1 as this is infrequent in melanoma. Given gene expression is generally
correlated with protein expression (Vogel and Marcotte, 2012; Liu et al., 2016b), I searched for
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melanoma cell lines with high CD274 expression levels from publicly available gene expression
datasets and sought to acquire them in our lab and confirm high PD-L1 protein levels using
flow cytometry. The NCBI GEO database hosts a wealth of global gene expression data from a
large source of research publications, and through this database I identified 5 external databases
which encompassed 3 microarray datasets and 2 RNA-seq datasets with a total of 200 melanoma
cell lines. Subsequently samples with substantially higher expression of CD274 were identified
and acquired in our lab for PD-L1 protein analysis using flow cytometry. From the previous
six samples in the PD-L1CON group, two samples were removed from the constitutive group
(due to lower PD-L1 expression) and three new samples were added to make a total of seven.
From the previous six samples in the PD-L1IND group, four new samples were added to make a
total of ten. Therefore, overall here I obtained a total of seven samples in the PD-L1CON group
and ten samples in the PD-L1IND group with a substantial difference in PD-L1 protein (average
log2 fold-change of 3.82) and gene expression (average log2 fold-change of 7.16) in preparation
for downstream analysis in chapter 5 of this thesis. Moreover six samples were found in the
intermediate PD-L1 group however these were excluded from downstream analysis.
4.2 Results
4.2.1 Assessment of different CD274 probes within the Affymetrix (U133
Plus 2) and MWG human 20K microarray platforms.
Microarray platforms contain distinct probes that bind to different regions of the same gene which
may or may not correspond to the same transcript. This means that simply averaging the probe
values arising from the same gene may result in losing important information arising from distinct
transcripts. Thus to assess the expression of distinct transcripts that may arise from the same gene,
it is highly recommended to examine the probes separately.
The gene expression datasets that were analysed consisted of three microarrays which included
GSE16404 (Jeffs et al., 2009) that used the MWG human 20K platform and GSE7127 (Johansson
et al., 2007) and GSE4843 (Hoek et al., 2006), which both used the Affymetrix U133 Plus 2
platform (table 4.1). There were two RNA-seq datasets which consisted of GSE61544 (Müller
et al., 2014) and GSE80829 (Tsoi et al., 2018). The MWG human 20K platform contains
two probes for CD274 (ID 13267 and 13266). Further investigation into the DNA binding
sequence of the probes revealed that these two probes have the same oligonucleotide sequence
(ID: obshum40K:A#37607) suggesting that they are technical replicates for the same genomic
sequence. In contrast, Affymetrix platforms are organised into probesets (a set of probes that
target a specific region in a single gene) where an averaged value represents a probeset signal.
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Multiple probesets can be identified for a gene. The Affymetrix U133 Plus 2 platform contains
two probesets (223834_at and 227458_at) for CD274 with each probeset comprising 11 probes
(figure 4.1). The MWG human 20K probe binds to the third exon of the longestCD274 transcript
whereas both the affymetrix probesets bind to exon 7. Hence MWG and Affymetrix platforms
measure different transcripts of CD274 and the two affymetrix probesets measures the same
CD274 transcript. Interestingly, the two MWG probes for CD274 showed poor correlation
(figure 4.2). The poor correlation of probes 13266 and 13267 suggests that the MWG human
20K CD274 probes do not accurately measure the CD274 expression levels. Whether the 13266
probe or the 13267 probe is giving a more accurate read is unclear. Thus, the probes were
analysed separately and only those samples that consistently had high CD274 expression with
both probes were selected for further analysis. In contrast, the two affymetrix probesets were
significantly correlated in both GSE71727 (Johansson et al., 2007) and GSE4843 (Hoek et al.,
2006) datasets (figure 4.2).
Table 4.1: information of melanoma cell lines in each of the external gene expression datasets
Study GSE Platform Number Normalisation
Jeff et al GSE16404 Microarray: Ocimum Biosolutions Human 40k OciChip, 25 Lowess
Johansson et al GSE7127 Microarray: Affymetrix U133 Plus 2 63 RMA
Hoek et al GSE4843 Microarray: Affymetrix U133 Plus 2 45 MAS5.0
Muller et al GSE61544 RNAseq: Illumina HiSeq 2000 13 TMM
Tsoi et al GSE80829 RNAseq: Illumina HiSeq 2000 54 FPKM + quantile
total - - 200 -
4.2.2 CD274 expression is distinctively higher in a small subset of melanoma
cell lines
To identify melanoma cells with strong CD274 expression, first the distribution of CD274
expression was assessed for each of the 5 datasets. Positive skewing in the distribution was
observed in 4 of the 5 datasets (figure 4.3). In particular, there were few samples with a
relatively high CD274 expression (defined as outside 1.5 times the interquartile range above the
upper quartile) within four of the five dataset. This included NZM9, NZM40 and NZM58 from
GSE16404 (Jeffs et al., 2009); COLO239F, MM127 and MM595 from GSE71727 (Johansson
et al., 2007); Ma-Mel_66b from GSE4843 (Hoek et al., 2006); M296 from GSE80829 (Tsoi
et al., 2018). There were no obvious outliers with high CD274 expression in GSE61544 (Müller
et al., 2014) however SKMEL_147 and WM1366 were the top 2 samples with the highest
CD274 expression.
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Figure 4.1: The genomic location of the CD274 gene (PD-L1) probesets from the Affymetrix platform (U133 Plus 2) and
the probes from the OGF MWG human 20K platform. Three sections are shown: 1) the chrosome where the CD274 gene
resides (the red line shows the location), 2) the five different CD274 transcripts from ENSEMBL, 3) the probe locations. The
Affymetrix platform (U133 Plus 2) contains 2 probesets (223834_at and 227458_at) with each containing 11 probes. Both
probesets bind to exon 7 of the longest CD274 transcript. The OGF MWG human 20K platform contains 2 probes (ID is
13266 and 13266) with both having the same oligonucleotide sequence and platform ID (obshum40KA37607). These probes
bind to exon 3 of the longest CD274 transcript.
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Figure 4.2: The 2 probes from the MWG human 20K platform were poorly correlated in the GSE16404 dataset (Jeffs et
al.) (Pearson correlation coefficient=0.17, pvalue=0.35). In contrast the 2 probesets available for Affymetrix U133 Plus 2
platform, were significantly correlated with each other in the 2 datasets available GSE7127 (Johansson et al.) and GSE4843
(Hoek et al.).
4.2.3 Selection of PD-L1CON and inducible samples
Using the 5 external gene expression datasets, we were able to obtain three samples (COLO239F,
MM127 and MM595) with higher CD274 expression available in GSE7127 (Johansson et al.,
2007). These cell lines were kindly provided by professor Glen Boyle from the QIMR Berghofer
Medical Research Institute. NZM9 and NZM40 from GSE16404 had higher CD274 expression
and had been already analysed previously in our lab (as described in chapter 3 of this thesis).
NZM58, the other NZM cell line with higher CD274 expression, was kindly provided by Mr
Wayne Joseph from Auckland University however it failed to grow in cell culture and thus was
not included in our analysis. Melanoma cell lines with higher CD274 expression (section 4.2.2)
from the other lab groups (from GSE7127, GSE4843, GSE80829 and GSE61544) were not able
to be acquired.
Therefore, for a total of 23 melanoma cell lines, PD-L1 protein expression and mRNA expression
was assessed using flow cytometry and RNA-sequencing. This included 3 samples (COLO239F,
MM127 and MM595) from GSE7127 (Johansson et al., 2007), the 12 samples that were
previously analysed (in chapter 3 of this thesis), and in addition 8 melanoma cell lines that
were available in our lab. A significant positive correlation was observed between PD-L1
protein and mRNA expression (cor=0.83, pvalue=7.3e-7). In order to select the PD-L1CON
and PD-L1IND group from these 23 melanoma samples, hierarchical clustering was performed
using only the PD-L1 protein and PD-L1 mRNA expression abundance. Hierarchical clustering
(using elucidean distance and complete linkage agglomeration method) showed three main
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Figure 4.3: The distribution of CD274 expression in the five external gene expression datasets containg a total of 200 melanoma
cell line. Figures A, B and C represent the three microarray datasets. Figures D and E represent the two RNA-seq datasets. For
each figure, the top plot shows the density of the CD274 expression and the bottom plot is a boxplot showing the expression
value for every individual points. All datasets apart from GSE80829 (Tsoi et al.) demonstrated a positively skewed dataset
due to samples with higher CD274 expression. The boxplots from each figure shows the samples that were labelled as outliers
(as defined as outside 1.5 times the interquartile range above the upper quartile) due to higher CD274 expression.
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default “total within-cluster variation” method) confirmed that the same samples group into
three clusters (see section 2.10 for codes). These three clusters were grouped according to
low, intermediate and high levels of PD-L1 protein and mRNA expression (figure 4.4B and
C). The intermediate group was excluded from further analysis in chapter five and six of this
thesis. The seven samples with higher PD-L1 expression were labelled as PD-L1CON. NZM11
was the only cell line where there was an discordance between the PD-L1 mRNA and protein
expression where there was a high mRNA expression but low protein expression (figure 4.4C).
For the ten samples with low PD-L1 expression, the ability of IFN-y to induce PD-L1 expression
was assessed. This is required given that there is a subset of melanoma tumors and cell lines
that cannot be induced for PD-L1 using cytokine signalling, which make up a different PD-L1
subgroup altogether (Kaplan et al., 1998; Dunn et al., 2005; Shin et al., 2017; Zaretsky et al.,
2016). PD-L1 expression was upregulated in all ten melanoma cell lines upon IFN-γ stimulation
and this group of cell lines were labelled as PD-L1IND (figure 4.5). Therefore, I obtained a total
of seven samples in the PD-L1CON group and ten samples in the PD-L1IND group. There was
an even distribution of oncogenic BRAF and NRAS mutations with 7 BRAF, 2 NRAS mutants
and 1 wild-type in the constitutive group and 4 BRAF, 2 NRAS mutants and 1 wild-type in the












































































































































































−5.0 −2.5 0.0 2.5 5.0 7.5


















Figure 4.4: (A) Hierarchical clustering with the PD-L1 protein and mRNA expressions, showed that the samples can be
separated into three main clusters. (B-C) These samples were separated according to the levels of PD-L1 protein and mRNA
expression. This included low (blue), intermediate (grey) and high PD-L1 expression groups (red). The intermediate (grey)
group was removed from downstream analysis in chapter 5 and 6 of this thesis. The PD-L1 mRNA and protein expression was
significantly correlated (Pearson correlation value = 0.83, pvalue = 7.3e-07). NZM11 exhibited high levels of PD-L1 protein

































































































Figure 4.5: PD-L1 protein levels for each of the PD-L1 IND cell lines before (control) and after interferon-y treatment. Flow
cytometry was used to measure PD-L1 protein levels. Y-axis represents the Median Fluorescence Intensity (MFI) normalised
(by subtraction) to the isotype control. All 10 melanoma cell lines in the inducible group were responsive to interferon-y to
stimulate PD-L1 expression. This experiment was not repeated (n=1)
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Here the main aim was to strengthen our constitutive (high PD-L1 expression) and inducible (low
PD-L1 expression) sample groups for downstream transcriptomic analysis. I first investigated
PD-L1 mRNA expression in 200 melanoma cell lines from 5 external databases in order to acquire
additional samples with PD-L1CON expression. To our knowledge, the present study is the first to
analyse CD274 mRNA expression in melanoma cell lines at such a large scale. I found that there
were 8 out of 200 samples (4%) with higher CD274 expression (as defined as outside 1.5 times the
interquartile range above the upper quartile). This small proportion of higher PD-L1 expression
without immune cytokine induction is consistent with others that have reported melanoma tumors
with PD-L1CON expression to be between 1% (Teng et al., 2015) and 17% (Audrito et al., 2017).
One limitation of using melanoma cell lines for further analysis of PD-L1CON expression is
that cell lines may not necessarily reflect tumor tissue from patients. Therefore, for future
investigation, differential analysis of tumor tissue with PD-L1CON expression and PD-L1IND
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expression is warranted. For this purpose, ideally obtaining tissue with high PD-L1 expression
with low immune infiltrates confirmed by immunohistochemistry will be required to obtain the
PD-L1CON group. Whereas for the PD-L1IND group, high PD-L1 expression with high immune
infiltrates will be required.
The group with intermediate PD-L1 expression level was not selected for further analysis as it
was planned to include this group later in my PhD project. However due to time constraints,
analysis into this group was not included in my PhD thesis and investigation into this group is
warranted. Many interesting questions can be asked about this intermediate group. For instance,
1) what proportion of melanoma tissues have an intermediate PD-L1 expression levels? 2) does
the intermediate group have a different transcriptomic and epigenetic profile compared to the low
and high PD-L1 expression group? 3) is the intermediate group a transition from the low to high
PD-L1 expression group?
For NZM11, the PD-L1 protein level was much higher than the mRNA expression. This
strongly suggested that PD-L1 expression for NZM11 is regulated post-transcriptionally. Indeed
there have been a growing number of studies where post-transcriptional mechanisms have
been identified that upregulate PD-L1 expression. This includes deubiquitination via COP9
signalosome 5 (CSN5) (Lim et al., 2016) or SPOP (Zhang et al., 2018a) of the PD-L1 protein to
enhance PD-L1 stability. CMTM6 was also shown to block lysosome-mediated degradation of
PD-L1 to increase its protein abundance without altering the transcript level (Mezzadra et al.,
2017). Furthermore, an epidermal growth factor (EGF) mediated increase in N-glycosylation of
PD-L1 and its protein stabilisation has also been reported (Li et al., 2016).
Overall, I was able to acquire three melanoma cell lines that exhibited substantially higherCD274
expression from GSE7127 and subsequently I confirmed high PD-L1 protein levels. Altogether
I obtained 7 melanoma cell lines with highly elevated PD-L1 protein and mRNA expression
(labelled as PD-L1CON group) and 10 melanoma cell lines with relatively lower PD-L1 protein
and mRNA expression (labelled as PD-L1IND group). Given this new group of samples to the
ones presented in chapter 3, RRBS has now been performed on the rest of samples however data
analysis is yet to be done. Moreover one limitation from the IFN-γ experiment was that this
was performed only once and therefore this requires technical replicates. In addition, antibody
specificity was not validated. Altogether, following these experiments, I was able to go forward
to analyse the RNA-seq data from these samples (in chapter 5 of this thesis) and gain insight on




PD-L1CON cells have a re-programmed
transcriptomic profile that is associated
with dedifferentiation, an active innate
immune pathway and reduced oxidative
phosphorylation
5.1 Background
The functional role of PD-L1 as a suppressor of cytotoxic lymphocyte activity upon extrinsic
cytokine stimulation is well-established in melanoma (Sun et al., 2018). However recently there
has been increasing evidence that PD-L1 not only inhibits the immune attack but is also associated
with invasiveness which arises from transcriptome reprogramming that is intrinsic to the cancer
cell (Audrito et al., 2017; Song et al., 2017). Moreover, PD-L1 expression has been shown
to increase upon the development of acquired and adaptive resistance to targeted inhibitors of
the MAPK pathway in melanoma (Audrito et al., 2017; Song et al., 2017). Development of
drug resistance often results from changes in the molecular landscape that consequently leads
to a more aggressive cancer with heightened metastatic potential and cross-resistance to other
drugs (Erdmann et al., 2019). Altogether, this suggested that melanoma cells with an intrinsic
upregulation of PD-L1 have a distinct cancerous phenotype associated with elevated invasiveness
and treatment resistance.
In the previous chapter of this thesis (chapter 4) I refined the two sample groups of constitutive
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and PD-L1IND expression by obtaining melanoma cell lines with stronger PD-L1 expression.
Furthermore the number of samples were increased to 10 samples (in inducible group) versus
7 samples (in constitutive group) which involved analysing external gene expression datasets
together with flow cytometry analysis. In this chapter, to gained insight on the phenotype
of melanomas with PD-L1CON expression, the transcriptomic landscape was assessed using
RNA-seq. Overall, I found constitutive cell lines were associated with a distinct expression
profile that involved 1) dedifferentiation, 2) an active innate immune pathway and 3) reduced
oxidative phosphorylation. Moreover, I found long non-coding RNAs were highly correlated
with these biological processes in an external dataset and in TCGA data which suggested that
lncRNA could be playing a role in regulating these biological processes.
5.2 Results
5.2.1 Quality control: FASTQC
For every sample (total n = 17: PD-L1IND n = 10, PD-L1CON n = 7), RNA was extracted and
RNA-seq was performed. For the four NZM cell lines, For six of the NZM melanoma cell
lines, Dr Jyoti Motwani cultured the cell lines, extracted the RNA and submitted it for RNA-seq.
For eight melanoma cell lines, Dr Euan Rodger cultured the cell lines, extracted the RNA
and submitted it for RNA-seq. To assess the read quality, the adaptor trimmed FASTQ files
were assessed using fastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The
duplicated reads in a file ranged from 55.17 to 73.14 percent with a mean of 65.6 percent (table
5.1). A high percentage of duplicated reads in RNA-seq can result from a small number of genes
that are highly expressed in a sample. The GC content ranged from 48 to 50 percent with a mean
of 48.9 percent. The sequence length ranged from 20 to 125 basepairs in 28 (out of 34) of the
FASTQ files, and 20 to 150 basepairs for 6 (out of 34) of the FASTQ files.
FastQC performs a range of tests to evaluate 11 different modules which includes 1) adaptor
content, 2) Bastic statistics, 3) overrepresented sequences, 4) per base N content, 5) per base
sequence content, 6) per base sequence quality, 7) per sequence GC content, 8) per sequence
quality scores, 9) per tile sequence quality, 10) sequence duplication levels and 10) sequence
length distribution. FastQC was run on all 17 sample where for each sample there is a read1 and
read2 FASTQ file (n = 34). For every module, a read file is flagged with either pass (“PASS”),
a warning (“WARN”) or fail (“FAIL”). Out of the 11 modules, all 34 FASTQ files passed 7
modules which included adaptor content, basic statistics, per base N content, per base sequence
quality, per sequence GC content, per sequence quality score and per tile sequence quality (table
5.2). For all 34 files, there was a warning for the sequence length distribution module and for 3
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files, a warning was given for having overrepresented sequences. All 34 files, failed for sequence
duplication levels and 21 files, failed for per base sequence content. The warnings and fails needs
to be carefully assessed as the specific set of assumptions that are made for each module is not
in the context of the RNA-seq data.
For the sequence length distribution module, fastQC gives a warning if all sequences are not
the same length. Given that the length of fragments vary during RNA-seq library prepartion,
it is expected not all sequences are the same length with RNA-seq (University, 2020). For all
samples, the sequence distribution were predominantly 125 basepairs in length and there was
a smaller proportion for lower sequence lengths. An example of this is shown for the WM115
read1 FASTQ file (figure 5.1).
For 3 sample files (MM127_R2, MM595_R2, COLO239F_R2), an overrepresented sequence
warning was issued. This module issues a warning if the sequences (at least 20 bp) are found to
represent more than 0.1% of the total number of sequences (Andrews, 2018). The overpresented
sequence in all three was “GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG”,
where the stats were: MM127_R2 (59127 counts or 0.123 percent), MM595_R2 (63654 counts
and 0.132 percent), and COLO239F_R2 (73188 counts or 0.161 percent).
All 34 files, failed for the “sequence duplication levels” module. This module gives a fail error
if more than 50% of the total reads are made up of non-unique sequences (Andrews, 2018).
There are two possible reasons for failure: 1) a technical error as a result of PCR artefacts from
bias introduced by PCR amplification cycles or 2) biological where highly abundant transcripts
generate the exact same sequence reads. Although for whole genome DNA sequencing data, it is
expected that all reads will be unique, (unless sequencing was performed at a very deep level), in
RNA-seq data, duplicate reads will frequently result from those transcripts with high abundance
(University, 2020).
21 out of the 34 files failed for the “per base sequence content” module. Although the proportion
for each of the 4 bases are expected to remain constant with whole genome DNA sequencing data,
for most RNA sequencing data, a technical bias can be observed where there is a non-uniform
distribution of the 4 bases for the first 15 nucleotides. This occurs due to the hexamer primers
that are used during RNA-seq library prepartion (University, 2020). For all failed samples, the
first 15 bases showed non-uniform composition whereas afterwards, the distribution remained
constant (an example is shown with WM115, figure 5.1).
Overall, all 34 FASTQ files (17 samples) showed high quality reads. The failed modules
showcased some of the expected outcomes from RNA-seq files where the assumption made by
FASTQC does not hold.
85
Table 5.1: FastQC sample stats.
sample pct.dup pct.gc tot.seq seq.length group
WM115_R1 67.99 49 60271919 20-125 inducible
WM115_R2 66.81 49 60271919 20-125 inducible
WM2664_R1 67.70 48 61905666 20-125 inducible
WM2664_R2 66.44 49 61905666 20-125 inducible
CM138_R1 67.06 49 57850956 20-125 inducible
CM138_R2 66.31 49 57850956 20-125 inducible
CM150.post_R1 67.12 48 61311163 20-125 inducible
CM150.post_R2 66.25 49 61311163 20-125 inducible
CM145.pre_R1 67.20 49 57080723 20-125 inducible
CM145.pre_R2 66.12 49 57080723 20-125 inducible
CM145.post_R1 64.53 49 53706075 20-125 inducible
CM145.post_R2 63.24 49 53706075 20-125 inducible
NZM12_R1 69.45 49 45348878 20-125 inducible
NZM12_R2 66.40 49 45348878 20-125 inducible
NZM15_R1 67.81 49 43346772 20-125 inducible
NZM15_R2 65.80 50 43346772 20-125 inducible
NZM22_R1 70.78 49 40398470 20-125 inducible
NZM22_R2 68.43 49 40398470 20-125 inducible
NZM42_R1 70.02 49 44233092 20-125 inducible
NZM42_R2 67.95 49 44233092 20-125 inducible
CM143.pre_R1 67.39 49 57528646 20-125 constitutive
CM143.pre_R2 65.84 49 57528646 20-125 constitutive
CM143.post_R1 73.14 49 56979365 20-125 constitutive
CM143.post_R2 66.73 49 56979365 20-125 constitutive
NZM9_R1 66.70 49 40119495 20-125 constitutive
NZM9_R2 61.84 49 40119495 20-125 constitutive
NZM40_R1 64.34 49 40463855 20-125 constitutive
NZM40_R2 61.29 49 40463855 20-125 constitutive
MM127_R1 62.81 49 48096030 20-150 constitutive
MM127_R2 62.07 49 48096030 20-150 constitutive
MM595_R1 61.20 48 48161265 20-150 constitutive
MM595_R2 59.29 48 48161265 20-150 constitutive
COLO239F_R1 59.26 49 45390219 20-150 constitutive
COLO239F_R2 55.17 49 45390219 20-150 constitutive
Note:
Abbreviations
1 pct.dup: percentage of duplication
2 pct.gc: percentage of GC content
3 tot.seq: total sequenced reads
4 seq.length: sequence length
5 group: PD-L1 group
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Table 5.2: FASTQC result summary.
module nb_samples nb_fail nb_pass nb_warn
Adapter Content 34 0 34 0
Basic Statistics 34 0 34 0
Overrepresented sequences 34 0 31 3
Per base N content 34 0 34 0
Per base sequence content 34 21 0 13
Per base sequence quality 34 0 34 0
Per sequence GC content 34 0 34 0
Per sequence quality scores 34 0 34 0
Per tile sequence quality 34 0 34 0
Sequence Duplication Levels 34 34 0 0
Sequence Length Distribution 34 0 0 34
Note:
Abbreviations
1 nb_pass: number passed
2 nb_fail: number failed
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Figure 5.1: FastQC results for WM115 read1 FASTQ file. (A) Quality scores for reads are shown across all bases at each
position. There are three background colors where green means very good quality, orange means reasonable quality, and red
means poor quality. (B) The percentage for four nucleotides for each position in the reads. (C) the number of quality scores
in the WM115 read1 FASTQ file. (D) The distribution of a range of sequence length that were detected. (E) Distribution
of GC content over all reads. (F) The degree of duplication for every sequence. The blue line shows the distribution of the
duplicated reads for the total number of reads. The red line shows the distribution for the deduplicated sequences.
5.2.2 Quality control: raw counts
To assess the quality of the counts from each sample, the raw counts were explored for any
abnormal data. Here the raw counts refer to the counts after the filtration step where the genes with
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low counts were removed (lower than 6 counts in at least 7 samples) and before the normalisation
or batch correction step.
A series of diagnostic plots using the raw gene count were assessed. First, the total count for all
samples was assessed. The total counts ranged from 35,630,156 to 56,944,416 counts where the
mean of total counts was 48,151,769 and 43,784,481 for the PD-L1IND and PD-L1CON samples
respectively (figure 5.2A). The distribution of the log2 transformed counts were similar across all
samples (figure 5.2B). Moreover the interquartile range and median of each sample were uniform
across all samples (figure 5.2C).
Next, a pairwise correlation was performed where each sample was correlated with all other
samples using Pearson correlation. This showed two main clusters where PD-L1CON cell lines
and the PD-L1IND cell lines clustered within its group (figure 5.3A). Moreover, when using the top
500 genes with the highest variance, the PD-L1CON cell lines and the PD-L1IND cell lines clustered
into two separate groups (figure 5.3B). Finally the variability in the dataset was examined via
eigenvectors (using the top 500 genes with highest variance). This recapitulated the correlation
analysis where a clear separation between the PD-L1IND and PD-L1CON group could be observed
(figure 5.4).
Overall, there were no abnormal distribution of counts across all the samples. Moreover even
before normalisation or batch correction, a strong signal was observed to clearly separate between








































































































































































Figure 5.2: Exploratory data analysis of the filtered raw counts (before normalisation and batch correction) of the PD-L1 IND
and PDL1 CON melanoma cell lines. (A) The total counts for each of the 17 samples (10 PDL1 IND and 7 PDL1 CON
samples using Kallisto pseudoalignment. (B) The density of counts (log2 transformed) of the PDL1 IND (blue) and PDL1







































































































































































Figure 5.3: (A) Pairwise correlation heatmap. Pearson correlation was performed between each sample using all genes
(protein-coding and lncRNA genes that remained after filtering out genes with low counts). Hierarchical clustering was used.
PDL1 IND cell lines are shown in blue and the PDL1 CON cell lines are shown in red. The 4 different batches are also
shown.(B) The top 500 genes with the highest variance were selected and hierarchical clustering was performd. All values are
in z-score. PDL1 IND cell lines are shown in blue and the PDL1 CON cell lines are shown in red. The 4 different batches are







































Figure 5.4: Eigenvector was generated using the top 500 genes with the highest variance. The PDL1 IND cell lines are shown
in blue and PDL1 CON cell lines are shown in red. The four batches are shown by different shapes.
5.2.3 PD-L1CONmelanoma cell lines have a distinct gene expression as shown
by unsupervised clustering
To gain a better understanding of the molecular mechanisms underlying melanoma cells
with PD-L1CON expression, transcriptomes were assessed using RNA-sequencing. The samples
consisted of 10 melanoma cell lines that have low PD-L1 expression but where PD-L1 expression
could be induced upon IFN-y signalling (referred to as the inducible group) and 7 cell lines
with high PD-L1 expression (the constitutive group). PCA plots showed that there were 2 main
clusters according to PD-L1 expression (figure 5.5 A) as depicted by principal component 1
(PC1) which accounted for 21 percent of the variance. Hierarchical clustering also showed 2
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main clusters according to the constitutive and inducible groups (figure 5.5 B). K-means also
clustered the samples according to these 2 groups. Overall, PD-L1CON cell lines were clearly
distinct from PD-L1IND cell lines with respect to their protein-coding gene expression profiles.
Differential expression analysis resulted in 462 upregulated and 298 downregulated genes in
the PD-L1CON cell lines compared to inducible cell lines. As expected, CD274 expression
was significantly higher in the PD-L1CON group (FDR p-value = 0.001, log2 fold-change =
7.1)(figure 5.5C and D). PDCD1LG2, which encodes the PD-L2 protein, is located in near
proximity to CD274 and it is frequently expressed together with CD274. PDCD1LG2 was also
significantly upregulated in the constitutive group (FDR pvalue = 0.03, log2FC = 5.0).
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Figure 5.5: (A) PCA plot showing PD-L1 CON (red) and PD-L1 IND (blue) cell lines using the top 500 genes with the
highest variance. The four different RNA-seq batches are shown using shapes. PC1 captures 22% of the variance whereas
PC2 captures 11%. Batch correction was performed using the removeBatchEffect function in the edgeR package (see section
2.11). (B) hierarchical clustering using the top 500 genes with the highest variance. (C) Volcano plot showing the 462 genes
and 298 genes were significantly up and downregulated respectively. The top 10 significantly differentially expressed genes (six
upregulated and four downregulated) are shown as well as CD274 (PD-L1) and PDCD1LG2 (PD-L2). The x-axis represent log2
fold change and the y-axis represents the FDR adjusted pvalue. (D) The gene expression of CD274 (PD-L1) and PDCD1LG2
(PD-L2) between the PD-L1 CON (red) and PD-L1 IND (blue) melanoma cell lines.
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5.2.4 PD-L1CON melanoma cell lines have an increased expression of genes
involved in 1) the active innate immune pathway, and decreased
expression of genes associated with 2) differentiation and 3) oxidative
phosphorylation
In order to find what biological processes were altered in the PD-L1CON cell lines, Gene
Set Enrichment Analysis (GSEA) was performed using the rank-based CAMERA test
(Wu and Smyth, 2012). Gene sets were derived from the Molecular Signature Database
(MSigDatabase)(Liberzon et al., 2011). Moreover, given that we had previously found an
enrichment of genes involved in viral mimicry pathways in a smaller set of PD-L1CON cell
lines ((Chatterjee et al., 2018b), and chapter 3 of this thesis), genes involved in this pathway
were self-curated from published articles (Chiappinelli et al., 2015; Roulois et al., 2015) and
were included in the gene-set lists. The genes in the viral mimicry pathway included 12 genes
which play roles ranging from pattern recognition receptors that detect dsRNA and dsDNA
(DDX58, DDX41, IFIH1), to activation of mitochondrial antiviral-signalling proteins (MAVS),
and transcription factors (IRF7, IRF1) and the activation of interferons (IFI27, IFI44,IFI44L,
IFI16).
Out of the 10,731 genesets that were investigated, there were 404 gene sets that were differentially
expressed. This included 308 genesets that were significantly enriched for upregulation and
96 genesets that were significantly enriched for downregulation in the PD-L1CON cell lines.
Genes involved in interferon (IFN) or tumor necrosis factor (TNF) signalling had the highest
statistical significance (FDR adjusted p-value = 5.68xe-10)(figure 5.6). Genes involved in
the viral mimicry pathway were also positively enriched in the PD-L1CON cell lines (FDR
adjusted p-value = 3.63xe-4)(figure 5.6 and 5.7). Moreover, a list of 9 pattern recognition
receptors, including MDA5 and DDX58 (RIG-1), that detect dsRNA to trigger an interferon and
inflammatory pathway were upregulated in the PD-L1CON cell lines (figure 5.7) as well as MAV
which functions to trigger the anti-viral signalling cascade. The downregulated genes were
enriched for melanocyte differentiation suggesting that a de-differentiation had occurred (FDR
adjusted p-value = 1.75xe-6). Recently, Tsoi and colleagues revealed that melanomas can reside
in a differentiation trajectory of 4 progressive stepwise steps (Tsoi et al., 2018). These 4 steps
encompassed 1) undifferentiated, 2) neural crest-like, 3) transitory, 4) melanocytic. PD-L1CON
cell lines were clearly enriched for genes in the undifferentiated state (figure 5.8). The inducible
cell lines were further clustered into 2 groups, with one group following more of a neural crest-like
gene signature and the other a melanocytic state. Another interesting observation in the GSEA
analysis was the significant downregulation of oxidative phosphorylation genes in the PD-L1CON
samples (FDR pvalue=5.0xe-9). Oxidative phosphorylation was not significantly downregulated
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at the individual gene level, however it was as a geneset (figure 5.7). Indeed out of the 75
genes and 125 genes in the REACTOME_RESPIRATORY_ELECTRON_TRANSPORT and
KEGG_OXIDATIVE_PHOSPHORYLATION genesets, only 3 genes for each geneset (4.0%
and 2.4%, respectively) were found to be significantly downregulated in the PD-L1CON samples.
In contrast, out of the 38 and 14 genes in the GO_DEVELOPMENTAL_PIGMENTATION
and GO_MELANOCYTE_DIFFERENTIATION genesets, 5 genes (13%) and 14 (28%) genes
were found to be significantly downregulated in the PD-L1CON samples. Moreover out of
the 31 genes in the MOSERLE_IFNA_RESPONSE geneset, 14 (45%) were found to be
significantly upregulated. This suggests that for oxidative phosphorylation, the downregulation
of this pathway is predominantly at the geneset level (figure 5.7). Therefore, out of the 404
genesets that were differentially expressed, the top 3 biological processes that were altered in
the PD-L1CON samples included an upregulation of the innate immune response pathway genes,
and downregulation of differentiation and oxidative phosphorylation genes.
To further explore this finding that PD-L1CON expression is accompanied by these 3 biological
processes, I looked into 4 external gene expression datasets containing a total of 175 melanoma
cell lines. A single score was generated for the genes involved in differentiation, oxidative
phosphorylation and the viral mimicry pathway using single sample gene set enrichment analysis
(ssGSEA) (Barbie et al., 2009; Hänzelmann et al., 2013). Given that the genes in the viral
mimicry geneset includes genes from interferon and TNF responsive genes as well as dsRNA
sensors which were also significantly upregulated, I selected the viral mimicry geneset as
representative of the innate immune response. Correlations were made between each of the
three biological process scores and CD274 gene expression. It is important to note that CD274
expression level is being used as a “surrogate” for the identification of cell lines with PD-L1CON
expression and thus, the results need to be interpreted with this consideration. This consideration
is needed because PD-L1 expression can arise from both inducible (extrinsic) and constitutive
(intrinsic) mechanisms in the tumor as shown in figure 1.2. In 3 out of the 4 external gene
expression datasets, CD274 expression was positively and negatively significantly correlated
with the viral mimicry genes and differentiation genes respectively (figure 5.9). However
oxidative phosphorylation genes were not significantly correlated with CD274 expression in
these external gene expression datasets. In order to check the significance of the correlation
observed between CD274 and biological pathway scores, I also randomly selected the same
number of genes in each of the 3 pathways (20 genes, 12 genes, and 115 genes in differentiation,
viral mimicry and oxidative phosphorylation scores respectively) and made correlations with
CD274 expression. There was no consistent positive or negative correlation across all 4 datasets
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Figure 5.6: The upregulated genes in the PD-L1 CON samples are enriched for genes involved in the viral interferon (IFN)
and tumor necrosis factor (TNF) signalling and the downregulated genes are enriched for genes involved in differentiation and
oxidative phosphorylation. The top 20 gene sets (top 5% of significantly differentially expressed gene sets) found using the
Gene Set Enrichment Analysis (GSEA) using the camera test are shown. The p-value 10e-6 significance threshold is shown by


































































































































































































































Figure 5.7: Barcodeplots show that genes involved in the viral mimicry pathway and dsRNA detection are upregulated in the
PD-L1 CON samples whereas genes involved in differentiation and oxidative phosphorylation are downregulated. Moreover
downregulation of oxidative phosphorylation or electron transport chain pathway can be seen to occur predominantly at the
geneset level rather than at the individual gene level. This is shown by the overall shift in the genes (represented by vertical
bars) towards the left and not many genes are shifted to the extreme left. The x-axis shows the ranked list of all protein-coding
genes according to log2 fold-change in the PD-L1 CON group (right side) from the PD-L1 IND group (left side). The vertical















































































Figure 5.8: PD-L1 CON melanoma cell lines have an undifferentiated gene expression signature. In contrast, inducible cell lines
have a neural crest-like or a melanocytic gene expression signature. and in addition, 3 states were involved in the transitions
between these 4 main groups
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R = − 0.45 , p = 0.00021
R = 0.13 , p = 0.33
R = − 0.064 , p = 0.62
R = 0.21 , p = 0.1
R = 0.011 , p = 0.93
R = 0.051 , p = 0.69
R = − 0.41 , p = 0.0055
R = 0.52 , p = 0.00024
R = − 0.21 , p = 0.16
R = 0.38 , p = 0.011
R = 0.17 , p = 0.25
R = 0.25 , p = 0.099
R = − 0.73 , p = 0.0044
R = 0.62 , p = 0.024
R = − 0.17 , p = 0.57
R = 0.47 , p = 0.11
R = − 0.36 , p = 0.22
R = 0.2 , p = 0.5
R = − 0.2 , p = 0.14
R = 0.48 , p = 0.00025
R = 0.073 , p = 0.6
R = − 0.066 , p = 0.64
R = − 0.4 , p = 0.0027
R = − 0.11 , p = 0.42
























































Figure 5.9: For each of the four external dataset, correlation was assessed between the CD274 expression with the three
biological score values (includes differentiation, viral mimicry and oxidative phosphorylation) that was generated using ssGSEA.
GSE7127 and GSE4843 are microarray platform based whereas GSE61544 and GSE80829 are from RNA-seq. Moreover, in
order to check the significance of the correlation observed between CD274 and biological pathway scores, I also randomly
selected the same number of genes in each of the 3 pathways (20 genes, 12 genes, and 115 genes in differentiation, viral
mimicry and oxidative phosphorylation scores respectively) and made correlations with CD274 expression.
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5.2.5 Genes involved in PD-L1CON expression are correlated with the innate
immune pathway, differentiation and oxidative phosphorylation in 472
melanoma tumors in the TCGA dataset.
The alteration of these biological processes associated with PD-L1CON expression was also
assessed using the TCGA SKCM dataset which contains 472 melanoma tumour samples. It
is important to note that in most melanoma tissue, CD274 expression is primarily induced by
cytokines secreted from immune cells in the tumor microenvironment, as opposed to an intrinsic
cellular mechanism which is seen with PD-L1CON expression (Taube et al., 2018; Emran et al.,
2019). As demonstrated in figure 1.2, in tumor samples PD-L1CON expression arises from
intrinsic mechanisms such as genetic and/or epigenetic alterations and is identified in the tumor
by diffuse and homogeneous PD-L1 expression. In contrast, PD-L1IND expression in the tumor
arises from stimulation of cytokine which are secreted from tumor infiltrative lymphocytes
or macrophages and is identified in the tumor by observation of PD-L1 expression near
immune cells. It is important to note that in melanoma tissue, CD274 expression is primarily
induced by cytokines secreted from immune cells, as opposed to PD-L1CON expression. Hence,
correlation measures with CD274 will primarily evaluate induced CD274 expression rather
than constitutive CD274 expression. Therefore instead of using CD274 expression, here I used
the significantly differentially expressed genes (from the PD-L1CON vs PD-L1IND analysis) as a
surrogate measure for PD-L1CON expression using the TCGA SKCM RNAseq dataset. A large
proportion of the upregulated PD-L1CON signature genes were positively correlated with CD274
expression and the viral mimicry genes and negatively correlated with differentiation genes
and oxidative phosphorylation genes (figure 5.10). In contrast, the downregulated PD-L1CON
signature genes showed the opposite trend, with a large proportion negatively correlated with
CD274 expression and the viral mimicry genes, and positively correlated with differentiation
and oxidative phosphorylation. Overall, this suggested that PD-L1CON expression is associated










































































































Figure 5.10: PD-L1 CON signature genes were correlated with CD274 expression, differentiation and oxidative phosphorylation
in the TCGA SKCM dataset. (A) A large proportion of the 462 genes that were upregulated in the PD-L1 CON cell lines
vs. inducible samples were positively correlated with CD274 and genes involved in the viral mimicry pathway and negatively
correlated with genes involved in differentiation and oxidative phosphorylation. (B) In contrast, a large proportion of the
298 genes that were downregulated in the constitutive cell lines were negatively correlated with CD274 and the viral mimicry
pathway and positively correlated with differentiation and oxidative phosphorylation.
5.2.6 PD-L1CON is associated with an active innate signature of immune
infiltration
The positive enrichment of immune response genes in the PD-L1CON samples suggested these
samples are in an active innate immune state. I asked if this response resembles melanoma
tumors with strong immune infiltration as this would support the notion that PD-L1CON cells
have an active immune signalling pathway that results in the PD-L1 expression just as seen in
those tumors with immune infiltrates. The TCGA SKCM dataset was used to investigate whether
the PD-L1CON signature genes correlate with immune infiltration in tumors. The CYT-score
(cytotoxic score) is a well established measurement that infers cytotoxic immune activity using
gene expression data derived from tumors (Rooney et al., 2015). A large number of significantly
upregulated genes in the PD-L1CON melanoma cell lines were positively correlated with the
CYT-score whereas the downregulated genes were downregulated with the CYT-score (figure
5.11A-B). Moreover, further investigation into the absolute abundance estimates of the immune
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cell subtypes as quantified using MCPcounter (Becht et al., 2016) showed that the upregulated
PD-L1CON signature genes were also positively correlated with all the immune subpopulations
(figure 5.11C). In contrast many of the downregulated PD-L1CON signature genes were negatively
correlated with the CYT-score as well as all the immune subtype abundance estimates from
MCPcounter (figure 5.11D). In addition, CIBERSORT, another computational method, was used
to evaluate the relative abundance of 22 immune cell types (Newman et al., 2015). Upregulated
PD-L1CON signature genes positively correlated with only four immune cell types (regulatory
Tcells, M1 macrophages, CD8 Tcells and CD4 memory activated cells) out of 22 (figure 5.11E).
This supported that PD-L1CON may use a similar mechanism to PD-L1IND expression given that
CD8 Tcells are well established to induce PD-L1 expression via secretion of IFN-γ (Garcia-Diaz
et al., 2017). Four immune cell types were significantly negative correlated (figure 5.11F).
The downregulated PD-L1CON signature genes were positively correlated with two immune
cell types and negatively with two immune cell types. The difference between correlation
measurements between MCPcounter and CIBERSORT could be due the relative abundance
measurement of CIBERSORT compared to absolute measurement with MCPcounter. Overall,
this supported the idea that the PD-L1CON cell lines, although in the absence of immune cells,
are in an active immune state as if surrounded with immune cells. This supports the idea that
PD-L1CON expression in cancer cells can be independent of immune infiltration as opposed to
PD-L1IND tumors where immune infiltrate derived cytokine secretion is necessary for PD-L1
expression. An absence of immune infiltration has been demonstrated to promote anti-PD1 drug




























































































































































































































































































































































































































































































































































































Figure 5.11: Significantly differentially expressed genes in the PD-L1 CON samples were correlated with abundance of immune
cells in melanoma tumours. (A) A large proportion of the significantly upregulated genes in the PD-L1 CON samples were
positively correlated with the CYTscore which suggested that PD-L1 CON cells have an active immune signalling pathway
similar to those melanoma tumors with immune infiltration. (B) This was supported by positive correlation between the
upregulated PD-L1 genes and absolute abundance of immune subtypes as estimated using MCPcounter. (C) As opposed to
absolute abundance, CiberSort estimates the relative abundance. Compared to MCPcounter, less significant correlation was
found between the upregulated genes and immune subtypes using CiberSort. (D) In contrast, a large number of the genes
downregulated in the PD-L1 CON samples were negatively correlated with the CYTscore and immune subtypes. (E) This was
supported by negative correlation between the downregulated PD-L1 genes and absolute abundance of immune subtypes as
estimated using MCPcounter. (F) Compared to MCPcounter, less significant correlation was found between the upregulated
genes and immune subtypes using CIBERSORT.
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5.2.7 Transcriptome reprogramming due to acquired resistance to MAPK
pathway inhibition is accompanied by PD-L1CON expression,
upregulation of the viral mimicry pathway and downregulation
of differentiation and oxidative phosphorylation
Acquired resistance to BRAF or MEK inhibition in BRAF mutant melanoma has been shown to
occur via two broad mechanisms: MAPK pathway reactivation or MAPK pathway independence
(Song et al., 2017). MAPK pathway reactivation commonly occurs via genetic mutations of
the BRAF gene such as splicing and BRAF mutant amplification (Song et al., 2017). Whereas
MAPK independent resistance have been shown to be related to a transcriptome reprogrammed
state associated with de-differentiation (Song et al., 2017). Song and colleagues treated melanoma
cells with a single BRAF inhibitor (BRAFi) or BRAFi plus MEK inhibitor (MEKi) until acquired
resistance developed (table 5.3)(Song et al., 2017). These were labelled single drug resistant
(SDR) and double drug resistant (DDR) respectively. In the M249, M395 and M397 cell lines,
drug resistance to BRAFi was regulated by the reactivation of the MAPK pathway, whereas in the
M229, M238, SKMel28 melanoma cell lines, the MAPK pathway was not reactivated and hence
independent of the MAPK pathway. In the study, it was found MAPK independent resistance
was accompanied by transcriptomic reprogramming. Interestingly, here I show that this treatment
resistance driven transcriptomic reprogramming included increased expression of CD274 and
also accompanied an increased expression in genes involved in the viral mimicry pathway and
a reduced expression in genes involved in differentiation and oxidative phosphorylation (figure
5.12). Moreover, up and down PD-L1CON signature genes were up and downregulated at the
acquired resistance stages where resistance was driven by MAPK independent mechanisms. In
contrast in the cell lines where the MAPK pathway was reactivated via genomic alterations
(M294, M395 and M397), there was no change in CD274 expression or any of the biological
processes or the PD-L1CON signature genes (figure 5.13). This suggested that upregulation of
CD274 expression is closely linked to an intrinsic transcriptomic reprogramming that results in
treatment resistance to MAPK pathway inhibitors.
Furthermore, Song and colleagues treated 2 melanoma cell lines with MAPK pathway inhibitors
in a time course experiment to investigate the transcriptome at different initial stages before
reaching permanent acquired resistance. This included no drug treatment (parental), 2 days of
drug exposure (BRAFi2D), slow cycling or Drug Tolerant Persisters (DTP), proliferating or Drug
Tolerant Proliferative Persisters (DTPP) and acquired resistance (SDR or DDR). In both cell lines,
in comparison to parental, CD274 expression increased at the transition from DTP to DTPP when
proliferation occurred (figure 5.14). The viral mimicry genes were also concomitantly increased
during this transition showing that it is tightly linked to CD274 expression. This suggested that
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PD-L1CON expressing cells are highly proliferative.







M249 DDR4 BRAF V600E ultra-amplification
M249 DDR5 BRAF V600E amplification + MEK1F129L
M395_SDR1 SDR1 BRAF V600E splicing
M395_SDR2 SDR2 BRAF V600E amplification
M397_SDR SDR BRAF V600E splicing
Note:
Abbreviations
1 SDR: Single Drug Resistant (BRAFi)
2 DDR: Double Drug resistant (BRAFi + MEKi)

























































































Figure 5.12: Transcriptome mediated resistance to MAPK pathway inhibitors is associated with PD-L1 CON expression. From
the baseline (parental) to the resistant cell line (SDR, DDR), the z-score for CD274 expression, the three biological processes
(ViralMimicry_score, Differentiation_score, OxidativePhosphorylation_score) and the up and down differentially expressed
genes (upPDL1Con_score, downPDL1Con_score) are shown. The barchart is the combined levels from the five sample group.
Error bars represent standard error (SE). P values were generated using paired t.test. M229, M238 and SKMEL28 melanoma
cell lines developed acquired resistance to BRAFi (SDR) or BRAFi plus MEKi (DDR) via transcriptome reprogramming which
was independent of MAPK pathway reactivation (Song et al. 2017). Z-score was calculated by subtracting the mean and
























































































Figure 5.13: genetic mutation mediated resistance to MAPK pathway inhibitors is not associated with PD-L1 CON expression.
From the baseline (parental) to the resistant cell line (SDR, DDR), the z-score for CD274 expression, the three biological
processes (ViralMimicry_score, Differentiation_score, OxidativePhosphorylation_score) and the up and down differentially
expressed genes (upPDL1Con_score, downPDL1Con_score) are shown. The barchart is the combined levels from the five
sample group. Error bars represent standard error (SE). P values were generated using paired t.test. M249, M263 and M395
melanoma cell lines developed acquired resistance to BRAFi (SDR) or BRAFi plus MEKi (DDR) via genetic mutations (such
as BRAF V600E amplifications and splicing) which reactivated the MAPK pathway (Song et al. 2017) (table 5.3). Z-score
was calculated by subtracting the mean and dividing by the standard deviation for each of the ssGSEA generated scores and






























Figure 5.14: Two cell lines that acquired resistance to BRAFi via MAPK independent transcriptome reprogramming were
temporally investigated for expression changes at different stages of BRAFi treatment. The stages included 1) 2 days of
BRAFi treatment (BRAFi2D), 2) Drug Tolerant Persisters (DTP) or the slow cycling stage, 3) Drug Tolerant Proliferative
Persisters (DTPP) where proliferation was regained and 4) SDR (single drug resistant), a complete resistant state to BRAFi.
CD274 expression increased during the transition from the DTP stage to the DTPP stage where proliferation increases, along
with an increased viral-mimicry pathway score. The differentiation-score is subsequently reduced during the transition form
the DTPP stage to the SDR stage.
5.2.8 Cell lines with PD-L1CON expression have a transcription factor
expression signature that plays a key role in dedifferentiation,
invasiveness and innate immune response.
The reprogrammed transcriptome of the PD-L1CON samples raised the question of whether
transcription factors (TFs) could be playing a role in the transcriptomic changes of
dedifferentiation and the innate immune response. The differential expression of 1,107 TFs with
known DNA binding motifs, as revealed by Lambert and colleagues (Lambert et al., 2018), were
investigated. There were 25 significantly upregulated TFs (out of 462 significantly upregulated
genes) and 19 significantly downregulated TFs (out of 298 significantly downregulated genes)
in the PD-L1CON cell lines (figure 5.15).
To investigate the role of TFs in differentiation, I looked into the published transcription
signatures that distinguished seven stepwise stages of the melanoma differentiation trajectory
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(Tsoi et al., 2018). These stages range from the undifferentiated state (low end of the stages) to
the differentiated melanocytic state (high end of the stages) (Tsoi et al., 2018). Out of the 27 TFs
that were upregulated in the PD-L1CON samples, four were found in the differentiation trajectory
gene signatures. Three (SOX9, MECOM, CREB3L1) belonged to the undifferentiated gene
state and one (JUN) belonged to the undifferentiated-neural crest-like state. In contrast, out of
the 21 downregulated TFs in the PD-L1CON samples, five were found in these gene signatures.
Four (SOX6, MITF, KLF15 and IRF4) belonged to the transitory-melanocytic state and one
(SOX2) belonged to the neural crest-like state. This suggested that TFs could be playing a role
in driving the dedifferentiated state in the constitutive PDL1 samples. To investigate this further,
I correlated the 27 up and 21 downregulated TFs in the PD-L1CON samples with CD274 in the 4
melanoma cell line external datasets and the TCGA SKCM dataset (figure 5.15A-B). Next, the
TFs were ranked according to the median correlation value with CD274 expression across the 4
datasets. The majority of TFs (25 out of 27) that were upregulated in the PD-L1CON samples had
a positive median correlation value and vice versa, all the downregulated TFs in the PD-L1CON
gorup had a negative median correlation value.
Six TF genes (RXRG, SOX5, SOX6, SOX10, POU3F2 and SOX8) had a median correlation of
lower than -0.4 (figure 5.15B). Out of these six TFs, RXRG and SOX10 were also in the top
ten downregulated TFs in the PD-L1CON samples with a log2 fold change of -10.9 and -10.7
respectively (figure 5.15B, 5.16A, 5.16BC, figure 5.17A-B). Moreover, there were six TF genes
(SOX9, POU2F2, FOSL2, NR3C1, IRF1, and TFE3) that had a median correlation of higher
than 0.4 (figure 5.16A). Out of these six TFs, POU2F2, SOX9, FOSL2 and IRF1 were in the top
ten of most upregulated TFs in the PD-L1CON samples with a log2 fold change of 5.5, 4.6, 2.4,
2.6 respectively (figure 5.16B-E, 5.17D-E).
RXRG and SOX10 had the lowest median correlation (across the 5 external gene expression
datasets) with CD274 expression out of all the differerentially expressed transcription factors.
Whereas POU2F2 and IRF1 had the highest median correlation (across the 5 external gene
expression datasets) with CD274 expression. RXRG is part of the nuclear receptor superfamily
of transcription factors. RXRG has been reported to be specifically expressed in cutaneous
and uveal melanoma cell lines and unexpressed in cancer cell lines derived from eight other
tissue types (Holbeck et al., 2010; Huffman et al., 2015). RXRG has also been implicated in
suppressing metastasis in myeloid lineage (Kiss et al., 2017) and RXRG promoter methylation
has been associated with poorer survival in non-small cell lung cancer patients with non-smoking
characteristics (Lee et al., 2010). POU2F2 has been suggested to play important roles in prostate
tumorigenesis (Dhingra et al., 2017) and has been reported to promote metastasis in gastric cancer
(Wang et al., 2016). An interesting finding was the low SOX10 and high SOX9 expression
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pattern. SOX10 and SOX9 have been found to be antagonistically cross-regulated with loss of
SOX10 resulting in increasing SOX9 levels and vice versa (Shakhova et al., 2015). SOX9 has
been demonstrated to mediate melanoma invasiveness (Cheng et al., 2015; Yang et al., 2019c).
Indeed 2 independent gene expression signatures (Widmer et al., 2012; Jeffs et al., 2009) that can
distinguish invasive and non-invasive cells from gene expression data showed PD-L1CON cell
lines fit an invasive phenotype (figure 5.18).
SOX10 plays a critical role in regulating neural-crest and melanocyte differentiation and in
melanoma pathogenesis. SOX10 is consistently expressed in melanoma tumors (Harris et al.,
2010) and knockdown of SOX10 induces senescence and cell cycle arrest in melanoma cell
lines (Cronin et al., 2013; Shakhova et al., 2015). SOX10 also plays a critical role in treatment
resistance to BRAFi and MEKi. Moreover loss of SOX10 drives dedifferentiation that results in
treatment resistance to targeted inhibitors of the MAPK signalling pathway (Shaffer et al., 2017;
Sun et al., 2014). Upon drug exposure, loss of SOX10 permits activation of receptor tyrosine
kinase (RTK) genes, namely EGFR and PDGFRB, via TGF-beta signalling (Shaffer et al., 2017;
Sun et al., 2014). The expression of EGFR and PDGFRB and TGFB1 were increased in the
constitutive PDL1 samples (FDR pvalue = 0.058, 0.033, 0.08 log2 fold-change = 4.2, 3.6, 1.8,
respectively). Indeed a cluster of RTK genes were upregulated in the PD-L1CON group (figure
5.19). Thus PD-L1CON cell lines displayed an intrinsic gene expression profile that reflects
resistance to targeted therapeutic drugs in melanoma.
IRF1 plays a critical role in the innate immune response by inducing the expression of various
cytokines (Tamura et al., 2008; Ksienzyk et al., 2012). Moreover IRF1 has previously been shown
to bind to the CD274 promoter and constitutively activate PD-L1 expression (Lee et al., 2006).
FOSL2 dimerises with the JUN family of proteins to form the AP-1 transcription factor dimeric
complex. The CD274 promoter has binding sites for AP-1 transcription factors (Wang et al.,
2018; Zerdes et al., 2018) and two AP-1 TFs including c-Jun and JUNB AP- have been reported










































































































































































Figure 5.15: There were 27 and 21 TFs significantly upregulated and downregulated in the PD-L1 CON samples respectively.
Out of the 21 downregulated TFs, SOX10 and RXRG had the lowest mean correlation across the five external gene expression
datasets. (A-B) The correlation of SOX10 and RXRG with CD274 mRNA expression is shown. Out of the 27 downregulated
TFs, POU2F2 and IRF1 had the highest mean correlation across the five external gene expression datasets. (C-D) The


















































































































































































































































































































































































































































































Figure 5.16: (A) The correlation between 48 significantly differentially expressed transcription factor genes and CD274
expression was found in each of the five external datasets. The transcription factor genes are ordered according to the
lowest to highest median across the five datasets. Six TF genes (RXRG, SOX5, SOX6, SOX10, POU3F2 and SOX8) have
a median correlation of lower than -0.4. Six TF genes (SOX9, POU2F2, FOSL2, NR3C1, IRF1, and TFE3) have a median
correlation of higher than 0.4. (B) The differential expression of the RXRG, SOX10, SOX9 and POU2F2 are shown.
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Figure 5.17: Transcription factors that are known to have an essential role in melanocyte differentiation and in innate immune
response are dysregulated in the PD-L1 CON samples. (A-B) The melanocyte lineage TF’s of SOX10 and MITF were
negatively correlated with increase in CD274 expression in melanoma. (C-D) The IRF1 and STAT1 TF’s which mediate the
innate immune response are positively correlated with CD274 gene expression. These relationships were found in 4 gene












































































































































































































































































Figure 5.18: PD-L1 CON melanoma cell lines have a higher expression of invasive gene signatures compared to
PD-L1 IND melanoma cell. (A) Heatmap showing the expression levels of invasive and proliferative genes the PD-L1 CON and
PD-L1 IND cell lines. Hierarchical clustering is shown for the cell lines and genes. (B) Heatmap showing the expression levels
of invasive and non-invasive genes in the PD-L1 CON and PD-L1 IND cell lines. Melanoma invasive gene signatures were
derived from 2 independent studies (Widmer et al. 2012, Jeffs et al. 2007). Values are z-scores (subtraction of mean and
























































































































Figure 5.19: PD-L1 CON samples formed a distinct cluster from inducible samples using receptor tyrosine kinase genes.
Heatmap shows the expression levels of receptor tyrosine kinase (RTK) genes in the PD-L1 CON and PD-L1 IND cell lines.
A group of receptor tyrosine kinase genes were upregulated in the PD-L1 CON cell lines (FDR pvalue < 0.05 are indicated
by * whereas FDR pvalues between 0.05 and 0.2 are indicated by +). Values are z-scores (subtraction of mean and divided
by standard deviation).
5.2.9 No global changes in lncRNA expression occur in the PD-L1CON cell
lines however a large proportion of significantly upregulated lncRNAs
were derived from the intergenic regions
Our previous finding that PD-L1CON samples are globally hypomethylated (chapter3 of this
thesis)(Chatterjee et al., 2018b) prompted me to investigate whether there are global expression
changes in long non-coding RNAs (lncRNAs). Indeed hypomethylation was prominent in
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the intergenic and intronic regions which may lead to increased expression of long-noncoding
RNAs that reside within these genomic regions (Chatterjee et al., 2018b). Reduced methylation
is typically associated with increased transcription (Thurman et al., 2012).
Similar to protein-coding genes, PCA analysis and hierarchical clustering using lncRNAs showed
two main clusters according to the inducible and PD-L1CON expression groups (figure 5.20A-B).
NZM22 clustered separately from the other PD-L1IND cell lines according to PC2 (figure 5.20A).
Also lncRNAs (a total of 14,049 from GENECODE annotations) were not globally upregulated
in expression in the PD-L1CON samples. This was observed with respect to the total number of
lncRNAs that were detected (figure 5.20C) and moreover normalised counts and log2 fold-change
(from inducible to PD-L1CON sample groups) according to the eight lncRNA subtypes (figure
5.21 and figure 5.22A). Furthermore, there was no difference with respect to the proportion of
expressed lncRNA between the constitutive and PD-L1IND groups (figure 5.20D). Differential
expression analysis, found 178 significantly upregulated and 72 downregulated lncRNAs (figure
5.22B). Interestingly, a larger ratio of the upregulated lncRNA were intergenic derived (figure
5.22C-D). 71% of the upregulated lncRNAs were intergenic whereas 50% of the downregulated
lncRNA were intergenic (pvalue=0.001, Fishers exact test). Moreover, 71% of intergenic derived
upregulated lncRNAs was significantly higher compared to three control groups housekeeping
lncRNA (38% intergenic derived, pvalue=0.005), randomly selected lncRNA (54% intergenic
derived, pvalue=5e-4) and total investigated lncRNA (53%, intergenic derived, pvalue=1.5e-06).
The housekeeping lncRNA included the top 800 lncRNAs (10% of all investigated lncRNA) with
the lowest variance. The randomly selected lncRNA included 800 randomly selected lncRNAs.
This suggested that the hypomethylation of the intergenic region could be resulting in a larger
number of differentially upregulated lncRNAs derived from the intergenic region.
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Figure 5.20: There were no changes in the global lncRNA expression in the PD-L1 CON samples compared to the
PD-L1 IND samples. (A) PCA plot showing the variability between the PD-L1 CON and PD-L1 IND samples. The
top 500 lncRNAs with the highest variance were used for this analysis. (B) Hierarchical clustering showing the difference
between PD-L1 CON and PD-L1 IND samples. (C) The total number of expressed lncRNAs in each sample and (D)




























































































































































































































































































































































































































































































































































































































































































Figure 5.21: Constitutive cell lines did not have an increased expression of long non-coding RNA at a global scale according to
lncRNA biotype. Boxplots showing the distribution of lncRNA expression according to the eight different biotypes of lncRNA.
PD-L1 CON melanoma cell lines are shown in red and PD-L1 IND cell lines are shown in blue. Y-axis represents the log2
of the normalised count. For the macro_lncRNA and non_coding biotypes, only 1 lncRNA remained after filtering, and thus




















































































































































Figure 5.22: A larger proportion of upregulated lncRNAs in the PD-L1 CON samples are derived from the intergenic region.
(A) After differential expression analysis, there was no changes in global expression in the PD-L1 CON samples compared to
the inducible group. (B) 178 lncRNAs were upregulated and 72 were downregulated in the PD-L1 CON samples. The top
10 differentially expressed lncRNAs are shown (9 upregulated and 1 downregulated). (C-D) A large proportion upregulated
lncRNA genes were derived from the intergenic region compared to the downregulated lncRNAs and the controls (housekeeping,
randomly selected lncRNA, total investigated). Housekeeping were top 800 (approximately 10% of total lncRNA analysed)
with the lowest variance. Random were 800 lncRNA genes randomly selected. Investigated were the total annotated lncRNAs
in this analysis (13977 lncRNAs).
5.2.10 lncRNAs correlate with CD274 expression and biological processes in
melanoma tumours
There is an increasing number of lncRNAs that regulate the expression of protein-coding
genes which play crucial roles to the cancer phenotype (Bhan et al., 2017). Here I aimed
to explore whether the significantly differentially expressed lncRNAs could be playing a
120
role in CD274 expression or the 3 biological processes (viral mimicry, differentiation and
oxidative phosphorylation). To do this, I took advantage of an external gene expression dataset
(GSE61544)(Müller et al., 2014) which contains 13 melanoma cell lines, and investigated
whether the 178 upregulated and 72 downregulated lncRNAs correlate with CD274 expression
and the scores of viral mimicry, differentiation and oxidative phosphorylation.
A large proportion of the upregulated PD-L1CON lncRNAs were positively correlated with
CD274 expression and the viral mimicry score but negatively correlated with differentiation
and oxidative phosphorylation scores (figure 5.23). In contrast, the opposite effect was seen for
the downregulated PD-L1CON lncRNA genes where there was a large proportion of lncRNAs
negatively correlated with CD274 expression and the viral mimicry score but positively
correlated with the differentiation and oxidative phosphorylation scores. The same correlation
effect was observed between the PD-L1CON lncRNA gene signature and the biological pathways
in the TCGA SKCM dataset (figure 5.24). One important note is that correlation does not mean
causation therefore experimental validation is required. Overall, this suggested that the lncRNA










































































































Figure 5.23: For the upper panel, each bar in the x-axis represents one of the 106 upregulated lncRNA in the
PD-L1 CON samples and its correlation (pearson) with CD274 mRNA expression and the three ssGSEA scores (viral mimicry
genes, differentiation genes and oxidative phosphorylation genes). The external gene expression dataset from GSE61544 (Muller
et al., 2014). which contains 13 melanoma cell lines was used. For the lower panel, each bar in the x-axis represents one of the
71 downregulated lncRNAs in the PD-L1 CON samples and its correlation (pearson) with CD274 mRNA expression and the
three ssGSEA scores (viral mimicry genes, differentiation genes and oxidative phosphorylation genes). A large proportion of the
significantly upregulated lncRNAs were positively regulated with CD274 expression and the viral mimicry genes whereas there
was a predominant negative correlation with differentiation and oxidative phosphorylation genes. In contrast, the opposite










































































































Figure 5.24: For the upper panel, each bar in the x-axis represents one of the 106 upregulated lncRNA in the
PD-L1 CON samples and its correlation (pearson) with CD274 mRNA expression and the three ssGSEA scores (viral
mimicry genes, differentiation genes and oxidative phosphorylation genes). The TCGA SKCM dataset was used which
contains 472 patient tumors. For the lower panel, each bar in the x-axis represents one of the 71 downregulated lncRNA
in the PD-L1 CON samples and its correlation (pearson) with CD274 mRNA expression and the three ssGSEA scores (viral
mimicry genes, differentiation genes and oxidative phosphorylation genes). A large proportion of the upregulated lncRNAs
in the PD-L1 CON samples were positively regulated with CD274 expression and the viral mimicry score whereas negative
correlation was observed with the differentiation and oxidative phosphorylation scores. In contrast, the opposite association
was observed with the downregulated lncRNAs.
5.2.11 Long non-coding RNAs in close genomic proximity to SOX10 and
IRF1 are differentially expressed
To understand whether lncRNAs may explain the reprogrammed transcriptome of the PD-L1CON
cell lines, I investigated all the differentially expressed lncRNAs near a differentially expressed
protein-coding gene (within 100kb of each other). 51 out of the 54 (94.4%) of the protein-coding
gene and lncRNA pairs were altered in expression in the same direction with 33 upregulated and
18 downregulated pairs (figure 5.25). There were 3 pairs with an upregulated protein-coding
gene and downregulated lncRNA.
The correlation between the lncRNA and protein-coding gene for each pair was assessed. All
54 pairs were significantly correlated which included the 51 pairs that were changing expression
in the same direction being positively correlated and the 3 pairs that were changing in different
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directions being negatively correlated (figure 5.27A). Out of the 54 pairs, 2 pairs had a higher
Pearson correlation value of 0.97 (figure 5.27B). This included the protein-coding genes FOXD1
and SOX8. There were 8 lncRNAs out of the 54 lncRNA and protein-coding gene pairs that were
adjacent to a TF. This included SOX10, SOX8, FOXD3, ZNF792, FOSL2, IRF1, FOXD1, and






















































































Figure 5.25: Out of all the significantly differentially expressed lncRNAs in the PD-L1 CON samples, only those that were
located within 100 kilobases of the significantly differentially expressed protein-coding genes were identified. There were 33
pairs where both the lncRNA and protein-coding were upregulated and 18 pairs where both the lncRNA and protein-coding
were downregulated. There were 3 pairs where the protein-coding gene was upregulated and lncRNA was downregulated. The
x-axis represents log2 fold change of the protein−coding genes logFC from every pair and the y-axis represents the log2 fold
change of the lncRNA from every pair. Only the protien-coding gene name is shown for each pair. The distance between the
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Figure 5.26: (A) The correlation between the lncRNA and protein-coding gene in the 54 pairs (figure 5.21) are shown. X-axis
shows the Pearson correlation value between the protein-coding gene and the lncRNA pair (within 100,000 bps of each other).
Y-axis shows the -log10 pvalue. 51 pairs were positively correlated and 3 were negatively correlated. The 0 correlation value
is shown by the blue dashed line and the 0.05 pvalue is shown by the red dashed line. (B) FOXD1 and SOX8 had the highest
correlation value and were the most statistically significant. The correlation with its lncRNA are shown.
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n = 4










































Figure 5.27: Eight differentially expressed lncRNAs were located near a differentially expressed transcription factor. The x-axis
represents log2 fold change of the transcription factor logFC from every pair and the y-axis represents the log2 fold change of
the lncRNA from every pair. The protien-coding gene name is shown in black and the lncRNA gene name is shown in blue for


















































































































































































































































































































































































































































































































































Figure 5.28: The eight pairs with lncRNA and transcription factors that were in the near genomic proximity (100,000bps).
Both the lncRNA and TF gene were upregulated in the PD-L1 CON group compared to the PD-L1 IND group. The distance
between the lncRNA and protein-coding gene for each pair is shown beside each protein-coding name.
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5.2.12 Investigation of differentially expressed lncRNAs that have been
found in previous studies to have functions, in the PD-L1CON samples
Out of the 177 lncRNAs that were upregulated and 71 that were downregulated in the PD-L1CON
samples, I searched through to find lncRNAs that have been previously been found to promote or
suppress cancer initiation or progression. Of the 177 upregulated lncRNAs, 7 were found to have
been functionally studied to have a role in cancer. Out of these 9 upregulated lncRNAs, 7 were
found to promote cancerous properties which included ARLNC1 (Zhang et al., 2018c), LUCAT1
(Sun et al., 2017), HCP5 (Liang et al., 2018), MANCR (Tracy et al., 2018), and EBLN3P (Liu
et al., 2017) (figure 5.29). Two were found to suppress cancerous properties which included
GASAL1 (Gasri-Plotnitsky et al., 2017) and PICART1 (Cao et al., 2017).
Of the 71 downregulated lncRNAs, 2 were found to have been previously functionally studied
(figure 5.30). This includedBANCRwhich was found to be either a tumor suppressor or promoter
depending on the caner type (Liu et al., 2018) and Long-Non-Coding Transcriptional Activator
of MiR34a (lncTAM34a), which was found to positively regulate the expression of miR34a to
reduce numerous tumorigenic phenotypes (Serviss et al., 2018). Furthermore, it was recently
found that SOX10 directly regulates the transcription of the SAMMSON intergenic lncRNA
(Leucci et al., 2016). SAMMSON was found to be expressed in the majority of melanomas
and essential for melanoma survival in part by regulating mitochondrial function (Leucci et al.,
2016; Vendramin et al., 2018). Knockdown of SAMMSON resulted in a defective mitochondria
structure with an aberrant function (Leucci et al., 2016). Given that SOX10 was significantly
downregulated in our PD-L1CON cell lines, I examined the differential expression of SAMMSON.
SAMMSON was downregulated in the PD-L1CON samples however this did not reach statistical











































































































































































































































Figure 5.29: Boxplots for the nine lncRNAs that were found to be significantly upregulated in the PD-L1CON samples compared








































































































Figure 5.30: (A-C) The three lncRNAs that were significantly downregulated in the PD-L1 CON samples and previously




There has been much evidence suggesting that PD-L1CON expressing cells have a distinct
phenotype that is associated with treatment resistance to MAPK pathway inhibitors and cancer
invasiveness (Audrito et al., 2017; Song et al., 2017). Currently there is a lack of understanding of
how PD-L1CON expression is associated with treatment resistance and cancer invasiveness. Thus
I aimed to elucidate the distinct phenotype of the constitutively PD-L1 expressing melanoma
cell lines by evaluating the transcriptome. Here I found that PD-L1CON melanoma cells have a
reprogrammed transcriptome that identifies dedifferentiation, an active innate immune response
and a reduction in oxidative phosphorylation.
5.3.1 PD-L1CON expression is associated with an active innate immune
pathway and increased IRF1 transcription factor expression
The results in this chapter gains further evidence from our previous publication (Chatterjee et al.,
2018b) that cytokine signaling pathways may play an important role in PD-L1CON expression.
We had previously found evidence that DNA methylation could be playing a role in PD-L1
expression in the PD-L1CON cell lines as supported by a marked global demethylated state in the
PD-L1CON cell lines as well as an enriched expression of genes involved in the viral mimicry
pathway (including dsRNA sensors and IFN signaling genes)(Chatterjee et al., 2018b). The
viral mimicry pathway involves the activation of the innate immune response via expressed
dsRNAs arising from the transcription of ERV elements (Roulois et al., 2015; Chiappinelli et al.,
2015). Here, with a strengthened sample group, biological processes involved in the tumor
necrosis factor (TNF) and interferon (IFN) responsive pathways (which are part of the innate
immune response) were the most significantly upregulated processes in the PD-L1CON samples
and reaffirms the role of cytokine signaling pathways in PD-L1CON expression. This was
accompanied by increased expression of dsRNA sensors (including DDX58, DDX41 and IFIH1)
and numerous genes involved in the viral mimicry pathway. To find whether secreted cytokines
are inducing PD-L1CON expression in an autocrine or paracrine fashion, further investigation
is required. Our collaborators (Peter Hersy’s group) found high levels of IFN-γ secretion in
two of the PD-L1CON samples (CM143.pre and CM143.post) but antibody-based blocking IFN
receptors did not reduce PD-L1CON expression levels (Chatterjee et al., 2018b). This suggested
that PD-L1CON expression is not driven by IFN-γ stimulation however only two out of seven
PD-L1CON samples were tested and further investigation into whether the other five PD-L1CON
melanoma cells are indeed not dependent on IFN-γ stimulation for PD-L1 expression is required.
Overall, my results demonstrate the PD-L1CON expression is regulated by a tumor necrosis factor
(TNF) and interferon (IFN) responsive pathways in which is regulated by an innate mechanism
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rather than by cytokine stimulation.
An important finding from this chapter was evidence that supports that transcription factors are
playing strong role in PD-L1CON expression. Four transcription factors, including IRF1, JUN,
JUNB and FOSL2 (FRA2) expression, that have binding sites near the PD-L1 (CD274 gene)
promoter were significantly upregulated PD-L1CON samples in comparison to the PD-L1IND
samples. Particularly, IRF1 and FOSL2 were strongly upregulated in the PD-L1CON samples and
in addition, positively correlated with CD274 expression in 4 external gene expression datasets
(total of 175 melanoma cell lines) as well as in the TCGA SKCM gene expression dataset. IRF1
is involved in the interferon gamma (IFN-γ) regulated JAK1/JAK2-STAT1/STAT2/STAT3-IRF1
axis which leads to IRF1 binding to the PD-L1 gene promoter to increase its transcription
(Garcia-Diaz et al., 2017; Lee et al., 2006). FOSL2 is part of the Fos gene family which
dimerizes with proteins of the JUN family to form the AP-1 transcription factor complex.
The AP-1 transcription factor was shown to bind to an enhancer in intron 1 of the CD274
gene to promote PD-L1 expression in Hodgkins lymphoma (Green et al., 2012). Given that
transcription factors work cooperatively and in synergy to regulate the expression of a particular
gene (Lambert et al., 2018; Reiter et al., 2017), how FOSL2 and IRF1 collaborate to regulate
PD-L1CON expression would be an interesting future experiment. Recently, a super enhancer
(coined PD-L1L2-SE) was identified to regulate the overexpression of the CD274 (PD-L1) and
CD273 (PD-L2) genes (Xu et al., 2019). Our PD-L1CON samples also have increased PD-L2
gene expression levels and thus whether FOSL2 and IRF1 binds to this super enhancer to
upregulate expression would be interesting. PD-L2 expression has also been reported to be
associated with the promotion of tumor metastasis and poor prognosis (Yang et al., 2019a).
By using chromatin immunoprecipitation sequencing (ChIP-seq), the binding of FOSL2 and
IRF1 can be examined in the PD-L1L2-SE. Moreover, lncRNAs AC116366.2 and FLJ31356
were near IRF1 and FOSL2, respectively, were upregulated in the PD-L1CON cell lines. Whether
these lncRNA plays a role in regulating these transcription factors, or it is co-regulated by the
same mechanism is yet unknown.
Moreover, it is yet unclear whether the viral mimicry pathway is directly regulating the PD-L1CON
expression. This warrants further investigation by knocking down individual components of the
viral mimicry pathway and evaluating PD-L1 expression levels. Potential targets include dsRNA
sensors and the mitochondrial antiviral-signaling protein (MAVs) which are upstream of the viral
mimicry pathway. Furthermore, increased lncRNA expression in the PD-L1CON samples and
correlation of the lncRNAs upregulated in the PD-L1CON samples with the viral mimicry pathway
in the SKCM TCGA dataset supports the notion that ERV expression may lead to PD-L1CON
expression. Indeed a large number of intergenic lncRNA genes are enriched with ERV elements
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(Kelley and Rinn, 2012; Kannan et al., 2015). It was reported that 83% of lincRNAs contain
a transposable element (TE) with a particular enrichment of ERV elements (Kelley and Rinn,
2012). Therefore this warrants further investigation into measuring ERV derived dsRNA in the
PD-L1CON samples in order to assess the cause of the highly activated innate immune response.
An important therapeutic question is whether the highly active innate immune response in
PD-L1CON expression makes it more prone to anti-PD1 therapy. Recently, one growing strategy
to improve response rates to anti-PD1 therapy has been to activate the cancer cell innate immune
pathway using DNMT inhibitors (Loo Yau et al., 2019; Jones et al., 2019).
5.3.2 PD-L1CON expression is associated with dedifferentiation
Here we found that PD-L1CON melanoma cells encompass a expression profile that is associated
with dedifferentiation and resistance to MAPK pathway inhibitors. Dedifferenation offers an
explanation for reports from others that PD-L1CON expression increases upon development
of resistance to MAPK pathway inhibitors (Song et al., 2017; Audrito et al., 2017). Using
Song et al. dataset, I demonstrated that overexpression of PD-L1CON and the PD-L1CON gene
expression signature is more closely related to when resistance to MAPK inhibitors develops
from transcriptome reprogramming, rather than genomic mutations (such as secondary BRAF
mutations) which reactivates MAPK pathway.
Here, we furthered this finding by identifying key transcription factors (TFs) that play crucial
roles in differentiation, cell invasion and treatment resistance in the PD-L1CON cell lines.
Numerous TFs that play key roles in melanocyte differentiation including MITF and the
HMG/Sox domain TF family such as SOX2, SOX5, SOX6, SOX8 and SOX10 were identified to
be downregulated in the PD-L1CON cell lines and this was also observed in other cell line datasets
and in patient tumors (TCGA SKCM dataset). Both MITF and SOX10 are master regulators
in the melanocyte lineage and the loss of these TFs has been associated with dedifferentiation
and furthermore intrinsic and acquired resistance to MAPK pathway inhibitors (Konieczkowski
et al., 2014; Müller et al., 2014; Sun et al., 2014; Shaffer et al., 2017). The inverse relationship
between SOX10 and PD-L1 has important therapeutic implications as the loss of SOX10 can
activate a diverse range of receptor tyrosine kinases (RTKs) which in turn activates a wide
range of signalling pathways to drive treatment resistance (Shaffer et al., 2017; Sun et al.,
2014). Important RTKs that are activated upon loss of SOX10 included epidermal growth factor
receptor (EGFR) and platelet-derived growth factor receptor-β (PDGFRB) (Shaffer et al., 2017;
Sun et al., 2014). Both EGFR expression (FDR pvalue = 0.06, log2 fold-change = 4.2, figure
5.19) and PDGFRB expression (FDR pvalue = 0.03, log2 fold-change = 3.6) were increased
in the PD-L1CON samples. A low SOX10 expression have been identified with a transient state
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with slow cycling features (Sun et al., 2014; Shaffer et al., 2017) in which SOX10 expression is
regained following stoppage of drug treatment. However the SOX10 expression in PD-L1CON
cells is stable suggesting that additional modification allows for a more stable or permanent
expression profile.
The loss of SOX10 expression in the PD-L1CON samples was also observed with the significant
upregulation of SOX9, which offers explanation to the transcriptome reprogrammed state of the
PD-L1CON cell lines. SOX9 and SOX10 have been shown to be reciprocally regulated where a
feedback loop augments the low SOX10/high SOX9 gene pattern (Shakhova et al., 2012, 2015).
SOX9 has been recently reported to be upregulated in dedifferentiated melanomas (Tsoi et al.,
2018) and also participates as a critical component for cancer stem cell plasticity (Sharma et al.,
2018). Upon acquiring chemotherapy resistance in squamous cell carcinoma cell lines, cellular
reprogramming occurred with a switch from a SOX2 to SOX9 dependent stem cell state (Sharma
et al., 2018), similar to a switch observed here from SOX10 to SOX9. This switch from SOX2 to
SOX9 was accompanied by chromatin remodelling with increased H3K9 acetylation (a marker
of gene activation) on promoters of EMT-associated genes (Sharma et al., 2018). Indeed SOX9
was also shown to be a pioneer factor that can modulate chromatin dynamics by controlling the
epigenetic activity of super-enhancers (via initiation of H3K27 acetylation) in hair follicle stem
cells (Adam et al., 2015). Moreover SOX9 has been shown to govern the identity of tumor
initiating stem cells in squamous cell carcinoma (Ge et al., 2017) and promote invasiveness
in melanoma (Yang et al., 2019c; Verfaillie et al., 2015), gastric cancer (Zhang et al., 2018b),
and prostate cancer by promoting cell lineage plasticity (Francis et al., 2018). This suggested
that the low SOX10/high SOX9 expression in PD-L1CON cells be a driver of the transcriptome
reprogrammed state. The findings in this thesis, is the first to show that the low SOX10/high
SOX9 signature is associated with PD-L1 expression. Furthermore, the loss of SOX10 expression
may also play a role in PD-L1CON expression via the AP-1 transcription factor. The knockdown
of SOX10 was shown to increase the AP-1 (Shaffer et al., 2017) which can bind to the PD-L1
promoter to induce its transcription (Green et al., 2012; Jiang et al., 2013).
5.3.3 Reduction in oxidative phosphorylation in the PD-L1CON samples
melanoma suggests metabolic reprogramming
Mitochondrial oxidative phosphorylation mediates treatment resistance to MAPK pathway
inhibitors (Roesch et al., 2013). Interestingly, although PD-L1CON samples have a treatment
resistant gene expression profile, oxidative phosphorylation genes were significantly
downregulated in the PD-L1CON cell lines. One plausible explanation for this is that oxidative
phosphorylation is unable to support the rapid cell division that occurs in the PD-L1CON cell
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lines. Indeed oxidative phosphorlyation is primarily associated with a slow cycling phenotype
(Ahn et al., 2017) and therefore a metabolic shift away from oxidative phosphorlyation may
have occured. A potential metabolic programme that PD-L1CON samples may have switch
to is glycolysis. Glycolysis permits rapid cell division by allowing faster production of
ATP and molecular building blocks that can be diverted into various pathways including the
triacylglycerol biosynthesis pathway and pentose phosphate pathway (PPP) for the production
of amino acids, lipids and nucleotides, which are essential for cell division (Hatzivassiliou
et al., 2005; Christofk et al., 2008a,b; Lunt and Vander Heiden, 2011; Jose et al., 2011). Indeed,
proliferating cancer cells commonly exhibit a dramatically increased glycolysis and lactate
production (also known as the Warburg effect), although the mitochondrial functions are kept
intact (thus referred to as aerobic glycolysis) (WARBURG, 1956; Liberti and Locasale, 2016).
Aerobic glycolysis has also been shown to be associated with dedifferentiation in melanoma (Lu
et al., 2015) and breast cancer (Dong et al., 2013) however, a growing number of studies have
found oxidative phosphorylation to be enhanced in cancer stem cells (Snyder et al., 2018). This
contrasting evidence demonstrates the complexity in metabolic reprogramming with cellular
plasticity (Snyder et al., 2018).
It is important to note that the downregulation of oxidative phosphorylation was not to a
substantial degree as shown by the reduced expression at the geneset level without many being
found to be significantly differentially expressed at the individual gene level (figure 5.7). This
indicated that oxidative phosphorylation is still intact however it is used to a lower extent.
Indeed in most mammalian cells and cancer cells, both oxidative phosphorylation and glycolysis
are used but in different ratios depending on the genetic and epigenetic state of the cell and the
microenvironment, such as the availability of oxygen (Zheng, 2012).
Further investigation is required to assess whether PD-L1CON samples heavily rely on glycolysis
and other metabolic pathways such as lipid synthesis and pentose phosphate pathway required
for cell division. To test whether glycolysis has increased, conversion of glucose to lactate (or
uptake of glucose and excretion of lactate) can be measured in the cell culture media (TeSlaa and
Teitell, 2014). These experiments can give insight into the metabolic pathways that PD-L1CON




PD-L1CON expression and DNMT inhibitor
mediated PD-L1 expression share a
common immune gene expression and
transcription factor signature
6.1 Introduction
In chapter 5 of this thesis, I found that PD-LCON melanoma cells have a dedifferentiated gene
expression signature that is associated with an active innate immune response, reduced oxidative
phosphorylation and dedifferentiation. This finding has strong therapeutic implications given that
PD-L1CON cell populations may increase upon acquiring treatment resistance to MAPK pathway
inhibitors (particularly when mediated by transcriptome reprogramming, figure 5.8). Therefore
it is important to gain understanding of the regulation underlying PD-L1CON expression and its
associated biological processes.
There have been growing indications that DNA methylation plays a role in PD-L1 expression.
Reduced DNA methylation of the CD274 promoter was reported to regulate increased expression
of PD-L1 in various cancers including non-small cell lung carcinoma (Asgarova et al., 2018),
acute myeloid leukemia (Goltz et al., 2017b), head and neck squamous cell carcinoma (Goltz
et al., 2017a) and melanoma (Micevic et al., 2019). However, we did not find any evidence
of differential methylation occurring in the core promoter of CD274 in the PD-L1CON samples
(Chatterjee et al., 2018b). Interestingly, we found significant and marked DNA hypomethylation
in the intergenic and intronic region in the PD-L1CON samples as well as a large number of
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upregulated protein coding genes and intergenic lncRNAs. This suggested to us that rather than
the demethylation of the PD-L1 promoter, PD-L1CON expression is associated with a global state
of hypomethylation. In support of a global hypomethyated state playing a role in PD-L1CON
expression, we and others have found that DNMTi treatment mediated global demethylation can
increase PD-L1 expression. Indeed DNMTi treatment resulted in the upregulation of PD-L1
expression in cell lines from different cancer types including melanoma (in chapter 3 of this
thesis)(Chatterjee et al., 2018b), non-small cell carcinoma (Li et al., 2014), breast cancer, colon
cancer and ovarian cancer (Wrangle et al., 2013). A potential mechanism of DNMTi mediated
upregulation of PD-L1 was speculated to be via the innate immune response, given that DNMT
inhibition also upregulates dsRNA endogenous retroviral element (ERV) expression which in
turn activates the innate immune response (known as the viral mimicry pathway).
Therefore DNA hypomethylation is hypothesised to cause PD-L1CON expression and the
reprogrammed transcriptomic state of the PD-L1CON samples. To investigate the role of
DNA methylation in regulating gene expression in PD-L1CON melanoma cells, I assessed the
transcriptome of the PD-L1IND samples following decitabine (DAC) treatment where PD-L1
protein and mRNA expression became increased.
We found that a large proportion of upregulated genes (127 out of 462 or 27.4%) in the PD-L1CON
samples are also upregulated upon DAC treatment in low PD-L1 expressing cells (inducible
group or PD-L1IND). These 127 genes that were associated with PD-L1CON expression and
DNA demethylation were enriched for immune processes and also included eight transcription
factors. Moreover we found five lncRNAs that may potentially play a role in regulating the PD-L1
expression via DNA hypomethylation and in-cis regulation of protein-coding genes. In addition,
we treated the PD-L1CON samples with DAC and found these samples are more resistant to DAC
treatment with respect to protein-coding gene and lncRNA expression changes compared to the
PD-L1IND samples which corroborated our findings of a globally DNA hypomethylated state of
PD-L1CON samples.
6.2 Results
6.2.1 DAC-mediated demethylation induces significant CD274 expression in
the PD-L1IND but not in the PD-L1CON group
In chapter 3 of this thesis, it was found that DAC mediated demethylation was capable of
upregulating PD-L1 protein levels more highly in the PD-L1IND samples compared to the
PD-L1CON samples (figure 3.15). RNA was extracted from these cell lines after DAC treatment
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and RNA-seq was performed. Consistently, RNA-seq analysis showed that PD-L1 mRNA
expression was significantly upregulated in the PD-L1IND group (log2 fold-change of 2.27,
FDR pvalue = 0.027) but not in the PD-L1CON group (log2 fold-change of -0.06, FDR pvalue =
0.98)(figure 6.1). This showed that in the inducible group, DAC mediated demethylation was
able to promote PD-L1 expression whereas in the constitutive samples where there is already
a high expression of PD-L1 expression and a globally hypomethylated state, DNMT inhibition
was unable to further upregulate PD-L1 expression.
6.2.2 PD-L1CON expression and DNA demethylation is associated with an
upregulation of 127 genes and downregulation of 30 genes
PD-L1CON expression was associated with biological processes of an activated innate immune
response and dedifferentiation and reduction in oxidative phosphorylation (in chapter 5 of this
thesis). Here we first aimed to identify the genes that are important for PD-L1CON expression and
also upregulated upon DNA demethylation in the PD-L1IND cell lines.
In order to do this, we first obtained genes that were significantly differentially expressed
following DAC mediated demethylation in the inducible group where PD-L1 mRNA and protein
expression was significantly increased. Upon DAC treatment in the PD-L1IND group, there
were 1078 genes that were significantly upregulated (FDR adjusted pvalue <0.05, logFC = 0,
quasi-likelihood method) and 484 genes that were significantly downregulated. Next, from these
genes we identified those that overlapped with those genes that differentially expressed in the
PD-L1CON samples in comparison to the PD-L1IND samples. This would identify those genes
that are associated with PD-L1CON expression and DNA demethylation. Out of the 462 genes
that were upregulated in the PD-L1CON group in comparison to the PD-L1IND group, 127 (27.4%)
were also upregulated upon DAC treatment in the inducible group (this included CD274)(figure
6.2A). Out of the 298 downregulated genes in the PD-L1CON group in comparison to the
PD-L1IND group, 23 (7.7%) were also downregulated upon DAC treatment in the inducible
group (figure 6.2B).
I investigated the correlation of these 127 up and 23 downregulated genes with CD274 with
respect to the degree of expression changes upon DAC treatment (log2 fold-change from control
to DAC treatment) in the PD-L1IND group. Out of the 127 upregulated genes, G0S2 (r=0.82,
pvalue=0.03), PPP2R5B (r=0.85, pvalue=0.03) and PIP5KL1 (r=0.84, pvalue=0.04) were
significantly positively correlated with CD274 with respect to the log2 fold-change increase
following DAC treatment (figure 6.3). One genes (NENF) out of 23 downregulated genes was
significantly positively correlated with CD274 with respect to the log2 fold-change following








































Figure 6.1: Upon decitabine (DAC) mediated demethylation, CD274 expression was significantly upregulated in the
PD-L1 IND group (log2 fold-change of 2.27, FDR pvalue = 0.027) but not in the PD-L1 CON group (log2 fold-change of
-0.06, FDR pvalue = 0.98).
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Figure 6.2: Genes that are associated with PD-L1 CON expression and DAC mediated upregulation of PD-L1 expression. (A)
Out of 462 genes that were upregulated in the PD-L1 CON versus PD-L1 IND differential gene expression (DGE) analysis,
127 genes were also upregulated upon DAC treatment in the PD-L1 IND group. Given that DAC treatment-mediated DNA
demethylation upregulated PD-L1 expression in the PD-L1 IND group, these 127 genes are associated with increasing PD-L1
expression via DNA hypomethylation. (B) 23 genes were downregulated in the PD-L1 CON versus PD-L1 IND analysis and
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Figure 6.3: For the 127 upregulated and 23 downregulated genes that were associated with PD-L1 expression and DNA
demethylation, the gene expression changes upon DAC treatment (log2 fold-change of DAC treated relative to untreated
control) was correlated with the CD274 expression changes upon DAC treatment within the inducible group (blue). Out of
127 upregulated genes, 3 genes (G0S2, PPP2R5B, PIP5KL1) were significantly correlated with CD274 upon DAC treatment.
Out of 23 downregulated genes, 1 gene (NENF) were significantly correlated with CD274 upon DAC treatment. Pearson
correlation values and corresponding pvalues are shown for the inducible (blue) and constitutive (red) group separately as well
as altogether (black).
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6.2.3 PD-L1CON expression and DNA demethylation is associated with an
upregulation of immune response genes
Gene set enrichment analysis (GSEA) using the 127 upregulated genes revealed that out of
the top 15 biological processes that were enriched (hypergeometric test), five were related to
the immune or cytokine response (figure 6.4A). Indeed 28 out of the 127 (22.0%) upregulated
genes were part of the GO_RESPONSE_TO_CYTOKINE gene set (figure 6.5). To further
investigate the immune related genes that were associated with PD-L1CON expression and DNA
demethylation, we explored the expression of the AIM (Azacytidine IMmune genes) geneset
in our samples. The AIM geneset includes a list of immune genes that were upregulated upon
azacytidine mediated demethylation in cancer cell lines derived from breast, colorectal and
ovarian tissues (Li et al., 2014). The AIM geneset were also able to stratify patients according
to “low” and “high” immune enriched groups in NSCLC and melanoma cancers (Li et al.,
2014). The list of genes are categorised into 6 groups which includes 1) interferon signalling,
2) cytokines/chemokines, 3) antigen processing and presentation, and 4) inflammation, 5)
influenza and 6) cancer testis antigen. The PD-L1CON samples were highly enriched for the
genes in the AIM genesets supporting that immune genes associated with DNA hypomethylation
is upregulated in the PD-L1CON samples (figure 6.6). Altogether, this showed that immune
related genes are upregulated together in both PD-L1CON cells and in global DNA demethylation
mediated upregulation of PD-L1 which supports that an innate immune response is the underlying
mechanism that leads to PD-L1 expression.
6.2.4 8 transcription factors are associated with PD-L1CON expression and
DNA hypomethylation
We previously found that PD-L1CON expression is associated with a reprogrammed transcriptome
which included key transcription factors (TFs) that have important strong implications in
melanoma (figure 5.11 and figure 5.12). Here we investigated the TFs that are differentially
expressed in PD-L1CON expression and DNA demethylation. Out of the 27 transcription factors
that were upregulated in the PD-L1CON samples in comparison to PD-L1IND samples, eight
transcription factors (CREB3L1, FOSL2, GLIS3, IRF1, NFE4, MAFK, POU2F2 and TFE3)
were also upregulated upon DAC treatment in the inducible group (figure 6.7A, 6.9). Out of the
21 TFs that were downregulated in the PD-L1CON samples in comparison to PD-L1IND samples,
one (ZNF771) was found to be downregulated upon DAC treatment in the inducible group
(figure 6.7B, 6.9).


























Figure 6.4: The 127 upregulated genes that were associated with PD-L1 expression and DNA hypomethylation were enriched
for genes associated with immune response. The top 15 genesets (0.015% of the total gene sets that were assessed) which
were enriched in these 127 genes are shown. Out of the top 5 enriched gene sets, 2 were immune related. Gene Ratio is the




















































Figure 6.5: Out of the 127 upregulated genes that were associated with PD-L1 expression and DNA hypomethylation, 28
genes (22.0%) were included in the GO_RESPONSE_TO_CYTOKINE geneset. X-axis shows the rank of the genes according

















































































Figure 6.6: Heatmap showing expression levels and clustering of the PD-L1 CON and PD-L1 IND samples using the AIM
(Azacytidine IMmune genes) genes. The PD-L1 CON samples had an increased expression of the AIM geneset. The AIM
(Azacytidine IMmune genes) includes a list of immune genes that were upregulated upon azacytidine mediated demethylation
in various epithelial cancer lines (Li et al., 2014). Z-scores are shown (mean subtrated and divided by the standard deviation).
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expression change upon DAC treatment (log2 fold-change from control to DAC treatment) in
the inducible group (figure 6.8) were investigated. None of the TFs were significantly correlated
with CD274 expression with respect to log2 fold-change upon DAC treatment. The top three TFs
with the highest correlation were POU2F2 (r = 0.74, pvalue = 0.094), FOSL2 (r = 0.52, pvalue
= 0.29), and IRF1 (r = 0.47, pvalue = 0.34). Although the TFs and the CD274 expression were
both differentially expressed in the same direction after DAC treatment, the correlation of the
expression fold change after DAC treatment was not significant. However, a positive correlation
can be seen for all of the 8 TFs (figure 6.8) and the small sample size (n = 6) partly explains
the small p-value. When both PD-L1IND and PD-L1CON samples were also included (total of 10
samples), CREB3L1, FOSL2 and TFE3 showed the highest correlation withCD274 with respect
to log2 fold-change upon DAC treatment.
6.2.5 PD-L1CON samples are less responsive to DNMTi treatment with
respect to protein-coding gene expression
PD-L1CON expressing cells were found to have a globally hypomethylated state (section 3.2.2).
This suggested that PD-L1CON samples would be more resistant to DNMTi treatment with
respect to changes to the transcriptome. Indeed there was a lower number of differentially
expressed genes in the PD-L1CON group (81 genes and 37 genes that were up and downregulated,
respectively) compared to PD-L1IND samples (1078 genes and 484 genes that were up and
downregulated, respectively)(figure 6.10A-B). The greater change in gene expression upon
DAC treatment in the PD-L1IND group compared to the constitutive group could also be seen
in the PCA analysis (figure 6.10C). Moreover there was a significantly higher increased log2
fold change following DAC treatment in the PD-L1IND group compared to the PD-L1CON group
(figure 6.10D).
The AIM geneset includes a list of genes related to the immune response which were upregulated
upon DNMTi (azacytidine) treatment in cell lines derived from various epithelial cancers (Li et al.,
2014). The AIM geneset was significantly upregulated following DAC treatment in the PD-L1IND
group (FDR pvalue = 1.25e-13), however not in the PD-L1CON group (FDR pvalue = 0.29)(figure
6.11, C-D). Interestingly, many of the genes in the AIM genesets were downregulated upon DAC
treatment in 3 of the 4 PD-L1CON samples (NZM40, CM143.pre and CM143.post)(figure 6.11A).
One reason for this resistance to DAC-mediated increased expression in the PD-L1CON group is
because the expression of genes in the AIM geneset are already highly expressed in the PD-L1CON
samples. NZM9 was the only PD-L1CON sample which had the majority of the AIM genes
upregulated upon DAC treatment (figure 6.11A). This may be explained by NZM9 having lower
expression levels of the AIM geneset compared to the other PD-L1CON samples (figure 6.11B).
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Figure 6.7: (A) There were eight transcription factors that were upregulated in the constitutive versus inducible group analysis
and also upregulated upon DAC treatment in the inducible group. These eight transcription factors are suggested to be
associated with PD-L1 expression and DNA hypomethylation. The eight transcription factors included CREB3L1, FOSL2,
GLIS3, IRF1, NFE4, MAFK, POU2F2 and TFE3. (B) There was one transcription factor (ZNF771) that downregulated in
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Figure 6.8: For the eight transcription factors (TFs) that were associated with PD-L1 expression and DNA hypomethylation, the
gene expression changes upon DAC treatment (log2 fold-change of DAC treated relative to untreated control) was correlated
with CD274 expression changes upon DAC treatment. Pearson correlation values and corresponding pvalues are shown
for the inducible (blue) and constitutive (red) group separately as well as altogether (black). POU2F2 has the highest
statistical significance (pvalue = 0.094) and correlation value for the inducible group however FOSL2, TFE3 and CREB3L1
were had the highest statistical signifiance (pvalue = 0.016, 0.042, 0.0071, respectively) when the all samples were considered









































































































































































































































































































































Figure 6.9: (A-H) For eight transcription factors that were upregulated in the PD-L1 CON samples and also upregulated
upon DAC treatment in the inducible samples, the gene expression changes upon DAC treatment are shown. These eight
transcription factors are associated with PD-L1 CON expression and DNA hypomethylation.
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Similar to the AIM geneset, the viral mimicry geneset includes a list of genes that are part of
the viral mimicry pathway which includes dsRNA sensors, transcription factors and interferon
stimulated genes (Chiappinelli et al., 2015; Roulois et al., 2015). The viral mimicry pathway
involves increased expression of dsRNA molecules derived from ERV elements, activation of
the dsRNA sensors, increased transcription factors the modulate the innate immune response,
and genes involved in the innate immune response. The viral mimicry geneset was significantly
upregulated following DAC treatment in the PD-L1IND group (FDR pvalue = 0.005), however
not in the constitutive group (FDR pvalue = 0.23)(figure 6.12, C-D, figure 6.12B). Investigation
into individual genes and samples upon DAC treatment showed that the NZM22 PD-L1IND cell
line had the lowest upregulation of the viral mimicry genes upon DAC treatment and consistent
with this, NZM22 clustered with the PD-L1CON samples (figure 6.12A).
6.2.6 Identification of 5 lncRNAs and protein-coding gene pairs that are
1) located in the close genomic proximity to each other (100,000bps),
2) associated with PD-L1CON expression, 3) associated with DNA
demethylation.
I previously found that the PD-L1CON samples had 106 upregulated and 71 downregulated
lncRNAs in comparison to the PD-L1IND samples (section 5.2.7). Here I aimed to identify the
lncRNAs that were associated with PD-L1CON expression and DNA demethylation. To do this,
as I did for the protein-coding genes, I identified the lncRNAs that were differentially expressed
in the PD-L1CON samples in comparison to the PD-L1IND samples and also differentially
expressed following DAC treatment in the PD-L1IND samples. Out of the 106 upregulated
lncRNAs in the PD-L1CON group compared to PD-L1IND group, there were 23 lncRNAs (21.7%)
that were also upregulated upon DAC treatment in the inducible samples (figure 6.13A) where
16 were lincRNA and 7 were antisense. Out of the 71 downregulated lncRNAs in the PD-L1CON
group compared to PD-L1IND group, there were 4 lncRNAs (5.6%) that were also downregulated
upon DAC treatment in the inducible samples (figure 6.13B) where 2 were lincRNA and 2 was
antisense.
I investigated the correlation of these 23 up and 4 downregulated lncRNAs with CD274
with respect to the degree of expression change following DAC treatment (log2 fold-change
from control to DAC treatment) in the inducible group. Next I investigated whether the
lncRNAs and protein-coding genes that were associated with PD-L1CON expression and DNA
demethylation were in the near genomic proximity to each other. There were fice lncRNA

































































































Figure 6.10: Constitutive PDL1 samples were more resistant to DAC treatment mediated gene expression changes compared
to the inducible samples. (A-B) There was a higher number of differentially expressed genes upon DAC treatment in the
inducible group compared to the constitutive group. In the inducible group, there were 1122 genes that increased and 586
that decreased upon DAC treatment whereas in the constitutive group there were 227 genes that increased and 171 decreased
upon DAC treatment. The top 10 significantly differentially expressed genes are shown. (C) From untreated (circle) to DAC
treated (triangle), the PCA plot showed larger changes in the inducible group compared to constitutive group upon DAC
treatment. The reduction of PC2 represents the effect of DAC treatment. (D) There was a significantly higher median log2
fold change in the inducible group compared to the constitutive group after decitabine treatment (median log2 fold-change in



















































































































































































































Figure 6.11: The PD-L1 IND samples showed a significant increased expression of the AZA IMmune gene set (AIMs) following
DNMTi treatment whereas there was no significant increase in the constitutive PDL1 samples. The AIM geneset includes a
list of genes related to the immune response which were upregulated upon DNMTi (azacytidine) treatment in cell lines derived
from various epithelial cancers (Li et al., 2014). (A-B) DAC treatment induced genes in the AIM geneset more highly in the
inducible group compared to the constitutive group. (A) In fact many of the AIM genes were reduced in expression upon DAC
treatment in 3 inducible PDL-L1 cell lines (CM143.post, CM143.pre and NZM40). (C-D) GSEA showed the AIM geneset was
significantly upregulated in the inducible group upon DAC treatment (camera test, FDR adjusted pvalue = 1.1e-13) whereas
there was no significant upregulation in the constitutive group upon DAC treatment (camera test, FDR adjusted pvalue =
0.26). The x-axis shows the ranked list of all protein-coding genes according to log2 fold-change that occurred upon DAC
treatment. The vertical bars on the x-axis represent the genes that are included in the AIM geneset. The y-axis shows the
enrichment score. The AIM genes were more enriched in the higher ranking genes in the inducible group after DAC treatment


























































































































































































































Figure 6.12: The PD-L1 IND samples showed a significant increased expression of the viral mimicry geneset following DNMTi
treatment whereas there was no significant increase in the constitutive PDL1 samples. The viral mimicry geneset includes
a list of genes where upon DNMTi (azacytidine) treatment, dsRNA derived from ERV elements upregulated the innate
immune response (Chiappinelli et al., 2015; Roulois et al., 2015). (A-B) DAC treatment induced genes in the viral mimicry
geneset more highly in the inducible group compared to the constitutive group. (A) CM143.post, in the PD-L1 CON group,
showed a downregulation of all viral mimicry genes. NZM22, in the PD-L1 IND group, clustered more closely with the
PD-L1 CON group. (C-D) GSEA showed the viral mimicry geneset was significantly upregulated in the inducible group upon
DAC treatment (camera test, FDR adjusted pvalue = 0.005) whereas there was no significant upregulation in the constitutive
group upon DAC treatment (camera test, FDR adjusted pvalue = 0.23). The x-axis shows the ranked list of all protein-coding
genes according to log2 fold-change that occurred upon DAC treatment. The vertical bars on the x-axis represent the genes
that are included in the viral mimicry geneset. The y-axis shows the enrichment score. The viral mimicry genes were more
enriched in the higher ranking genes in the inducible group after DAC treatment in comparison to the constitutive group after
DAC treatment. 154
other (figure 6.14 and 6.16). The protein coding genes included CSRNP1, FOSL2, NT5E, and
ITGA3 where ITGA3 was included in two pairs as there were two lncRNAs that were near
ITGA3. The AC092053.3 and FLJ31356 lncRNAs were antisense to the CSRNP1 and FOSL2
protein-coding genes respectively. L34079.3 is also a antisense lncRNA that was located
near the protein-coding gene PINLYP however it does not overlap with PINLYP, but with
XRCC1 which was not differentially expressed upon DAC treatment. The remaining lncRNAs
(PICART1, LINC02009, AC002401.4 and AC084082.1) were intergenic derived. I assessed
the correlation of the lncRNA and protein-coding genes within each of the 8 pairs with respect
to the degree of upregulation upon DAC treatment (log2 fold-change increase from control to
DAC treatment)(figure 6.15). There were 3 pairs with significant correlation which included
L34079.3 with PINLYP, PICART1 with ITGA3 and AC092053.3 with CSRNP1.
6.2.7 PD-L1CON samples are less responsive to DNMTi treatment with
respect to lncRNA expression
PD-L1CON expressing cells were less responsive to DNMTi treatment with respect to
protein-coding gene expression (figure 3.15) which could be attributed to the already globally
hypomethylated state in the PD-L1CON samples. Here we investigated whether PD-L1CON
samples were less responsive to DNMTi treatment with respect to expression of lncRNAs.
There was a higher number differentially expressed lncRNAs in the inducible group (263 up
and 56 downregulated lncRNAs) compared to the constitutive group (53 up and 35 down
lncRNAs) upon DAC treatment (figure 6.17A-B). There was a large difference in the number
of upregulated intergenic lncRNAs where in the inducible group there was 167 upregulated
lincRNA in comparison to 35 in the constitutive group (figure 6.17C). Moreover, the PD-L1CON
samples were less responsive to DNMTi treatment at a global scale of lncRNAs (figure 6.18).
There was a significantly higher increase in lncRNAs in the inducible group (median log2FC
= 0.35) compared to the constitutive group (median log2FC = 0.24) following DAC treatment
(wilcox test pvalue = 8.70e-17) (figure 6.18A). Intergenic lncRNA showed the highest statistical
significance (FDR pvalue= 5.10e-22)(figure 6.18B).
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Figure 6.13: (A) 23 lncRNAs were upregulated in the PD-L1 CON vs PD-L1 IND differential gene expression (DGE) analysis
and upregulated upon DAC treatment in the inducible group. Given DAC treatment induced PD-L1 expression via DNA
demethylation, these 37 lncRNAs are associated with high PD-L1 expression and DNA hypomethylation. (B) 4 lncRNAs that
were downregulated in the PD-L1 CON vs PD-L1 IND DGE analysis were also downregulated upon DAC treatment in the
inducible group. These 3 lncRNAs are associated with low PD-L1 expression and DNA hypermethylation.
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Figure 6.14: The lncRNAs and protein-coding genes that were in the close genomic proximity (100,000bps) to each other whilst
also differentially expressed in the constitutive versus inducible analysis and differentially expressed upon DAC treatment in the
inducible samples are shown. There were seven lncRNAs to protein-coding gene pairs. Both the lncRNA and protein-coding
gene were upregulated in the PD-L1 CON samples and also upregulated upon DAC treatment in the inducible samples. This
included 3 antisense and 4 intergenic lncRNAs. logFC (log2 fold change).
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Figure 6.15: There were seven protein-coding gene to lncRNA pairs. These pairs were in the near genomic proximity (criteria
of within 100,000 basepairs) to each other whilst upregulated in the PD-L1 CON group compared to the PD-L1 IND group
and also upregulated upon DAC treatment in the inducible samples. The correlation between the lncRNA and protein-coding
within each pair were assessed with respect to the log2 fold-change following DAC treatment (DAC - control). Three pairs
(A-C) were significantly correlated. The lncRNA subtype and the distance between the protein-coding gene and lncRNA are













































































































































































































































































































































































Figure 6.16: (A-G) There were seven protein-coding gene to lncRNA pairs. These pairs were in the near genomic
proximity (criteria of within 100,000bps) to each other whilst also upregulated in the PD-L1 CON group compared to
the PD-L1 IND group and also upregulated upon DAC treatment in the inducible samples. Distance between the pairs are


































































3 2 1 0
0 2 0 0


























































Figure 6.17: (A,B) There was a higher number of differentially expressed lncRNAs in the inducible group (319 lncRNAs)
compared to the constitutive group (88 lncRNAs) upon DAC treatment. This included 263 upregulated and 56 downregulated
lncRNAs in inducible group compared to 53 upregulated and 35 downregulated lncRNAs in the constitutive group. (D) The
highest differentially expressed lncRNA subtype upon DAC treatment were intergenic lncRNAs (lincRNA) where there were

















7e−21 2.9e−08 1 1 1 1 5.5e−06 0.59























































































Figure 6.18: (A) There was a significantly higher increase in global lncRNAs in the inducible group (median log2FC = 0.35)
compared to the constitutive group (median log2FC = 0.24) upon DAC treatment (wilcox test pvalue = 8.70e-17 ). (B) The
higher increase in lncRNA expression in the inducible group was mainly driven by intergenic lncRNA (lincRNA) with a log2
fold-change of 0.26 in the inducible group and 0.46 in the constitutive group upon DAC treatment (FDR pvalue = 5.10e-22).
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6.3 Discussion
Chapter 5 of this thesis suggested that the innate immune response could be regulating PD-L1CON
expression via transcription factors. Moreover, we previously found that PD-L1CON cell lines are
characterised with a marked global hypomethylation (Chatterjee et al., 2018b). This suggested
that global DNA hypomethylation may play a role in the overexpressed innate immune response
and PD-L1CON expression. To investigate the role of DNA methylation in regulating gene
expression in PD-L1CON melanoma cells, I assessed the transcriptome of the decitabine (DAC)
treated PD-L1IND samples where the DNA was demethylated and both PD-L1 protein and
mRNA expression were upregulated. Out of the 462 upregulated genes in the PD-L1CON cell
lines (compared to PD-L1IND cell lines), 127 (27.4%) were also upregulated upon DNMTi
treatment mediated PD-L1 expression and these 127 genes were significantly enriched for
cytokine and immune response genes. This supported the notion that DNA hypomethylation at
a broad genomic level may play a role in increasing PD-L1 expression via the activated innate
immune response and therefore further investigation is needed. One important limitation is that
the samples used for the control verses DAC treatment made here used only a proportion of the
full PD-L1IND and PD-L1CON melanoma cell lines. This included 6 out of the 10 PD-L1IND and
4 out of the 7 PD-L1CON melanoma cell lines that were used from chapter 4 and 5. Therefore
further DAC treatment and RNA-seq analysis on the remaining samples is required.
An important question is how DNA hypomethylation is stimulating the innate immune response.
DNMTi treatment has been shown to demethylate endogenous retroviral elements (ERV) and
increase bidirectional promoter activity of ERV elements to generate dsRNA structures. In turn,
these dsRNAs can stimulate the innate immune response (Roulois et al., 2015; Chiappinelli
et al., 2015). Transcriptional activity of ERVs is normally repressed by DNA methylation
and histone modifications in somatic cells however cancers can be globally hypomethylated
and have aberrant ERV expression. The global hypomethylated state of PD-L1CON cell lines
warrants investigation into whether the PD-L1CON cell lines have a higher expression of ERV
derived dsRNA. DsRNA can be isolated from ssRNA and DNA by using J2 antibodies that
can specifically bind to dsRNAs that are more than 40 basepairs in length (Schönborn et al.,
1991; Weber et al., 2006). Upon acquiring dsRNA, RT-qPCR or RNA-seq can be used to
specifically measure dsRNA expression levels. Furthermore ERV elements can be expressed
as single-stranded RNAs and may play regulatory roles as reported for lncRNAs. Indeed
a vast proportion of lncRNAs are derived from ERV genomic regions. High throughput
RNA-sequencing can be used with computational tools to measure the abundance of all
annotated ERV transcripts (also referred to as the retrotranscriptome). Moreover, the marked
hypomethylation of PD-L1CON samples was not only observed in ERV regions but in all other
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transposable elements. Computational tools are available that can measure the expression
levels from transposable elements which includes ERVs, LINE-1, SINE, and DNA transposons
(Teissandier et al., 2019). Expression of transposable elements can be investigated from
total RNA using strand-specific RNA-Seq data with new and emerging computational tools
(Teissandier et al., 2019). A challenge for aligning sequence reads to TEs is that TEs have
large amounts of repetitive sequences. A large number of sequencing reads coming from
TEs can map to multiple areas to the same TE or a similar TE family (known as mapping
ambiguity)(Teissandier et al., 2019). Therefore many mapping tools quantify the abundance of
expression from whole subfamilies of TE based on aggregated expression levels arising from
similar TE sequences. These computational tools include salmonTE (Jeong et al., 2018; Guo
et al., 2018), TEtranscripts (Jin et al., 2015), Repenrich2 (Criscione et al., 2014). A limitation for
this methodology is that the origin of the genomic region of the expression is unknown however
important information about the TE transcriptional level for each TE subfamily is still acquired
and can be evaluated for the PD-L1CON cell lines compared to the PD-L1IND cell lines.
Approximately eight percent of the human genome is constituted by ERVs (Lander et al.,
2001). ERVs harbour cis regulatory elements (CRE) such as enhancers (or TF binding sites)
and promoters as these are required for a virus to hijack the host transcriptional machinery to
induce expression of its own viral proteins (Chuong et al., 2016). However the large majority
of ERVs (around 90%) remain in the human genome as solitary Long Terminal Repeats (LTR)
following deletion of internal ERV sequences that happened from recombination between the
5’ and 3’ LTRs (Lander et al., 2001; Alcazer et al., 2020). These LTRs have now evolved
with the human genome to shape a number of transcriptional regulatory networks (Wang et al.,
2007; Chuong et al., 2016). For example, 1) LTRs were demonstrated to have shaped the TP53
transcription factor regulatory network (Wang et al., 2007), 2) LTRs were found to have shaped
the regulatory network of POU5F1, NANOG and CTCF in pluripotent stem cells (Kunarso et al.,
2010) and 3) LTRs were found to act as crucial CREs for the regulatory network during placental
development (Chuong et al., 2013). To further investigate the notion that DNA hypomethylation
plays a role in increasing PD-L1 expression via the activated innate immune response, the role
of ERVs functioning as CRE to initiate an interferon response related transcriptional network
is required. Indeed, not only do ERV elements get expressed as dsRNA to activate an innate
immune response, ERVs were also shown to facilitate the interferon regulatory network as CREs
in three human cell lines (which were myeloid, epithelial and macrophage derived) (Chuong
et al., 2016). These ERVs were enriched for binding of STAT1 and IRF1 following IFN-y
stimulation and nearby immune genes were overexpressed demonstrating the regulatory role
of ERVs. Both STAT1 and IRF1 were upregulated in the PD-L1CON cell lines and IRF1 was
also up upon DNMTi treatment mediated PD-L1 increase. To demonstrate that ERVs can act
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as regulatory elements to rewire the trascriptional program such as observed for PD-L1CON cell
lines, a number of analyses can be performed. This includes ATAC-seq and ChIP-seq (H3K27ac)
to assess whether open chromatin regions in the ERV regions are enriched for TF binding sites,
particularly for TFs that were found to be differentially expressed in the PD-L1CON cell lines.
Moreover for the open chromatin ERV regions, the nearby protein-coding genes can be assessed
to infer regulatory activity. Emerging computational tools now allow one to make inferences
about whether transposable elements may regulate nearby protein-coding genes by pinpointing
the genomic origin of the ERV expression. These tools includes include TEtools (Lerat et al.,
2017), SQuIRE (Yang et al., 2019b), Telescope (Bendall et al., 2019), LIONS (Babaian et al.,
2019), TEcandidates (Valdebenito-Maturana and Riadi, 2018) and TEffectR (Karakülah et al.,
2019). To further investigate interesting ERV candidates, the chromatin interaction within TADs
can be assessed using Chromosome conformation capture-on-chip (4C) or high-throughput
chromatin conformation capture (HiC).
Eight TFs (including CREB3L1, FOSL2, GLIS3, IRF1, NFE4, MAFK, POU2F2 and TFE3)
were found to be upregulated in the PD-L1CON samples and also upregulated upon DNA
demethylation mediated PD-L1 expression. These eight TFs may regulate PD-L1CON expression
or the transcriptome reprogrammed state of the PD-L1CON cell lines via DNA hypomethylation.
For instance, IRF1 and FOSL2 have been found to bind to the CD274 promoter to increase
PD-L1 expression level. IRF1 has been shown to bind to the CD274 gene promoter to upregulate
PD-L1 expression in the context of both IFN-γ induced and constitutive PD-L1 expression
(Garcia-Diaz et al., 2017; Lee et al., 2006). In colorectal and ovarian cancer cells, IRF7 and IRF3
were found to be key regulators in activating the interferon pathway as part of the downstream
component of the viral mimicry pathway following DNMT inhibitor treatment (Roulois et al.,
2015; Chiappinelli et al., 2015). FOSL2 dimerises with the JUN family of proteins to form the
AP-1 transcription factor dimeric complex. The CD274 promoter has binding sites for AP-1
transcription factors (Wang et al., 2018; Zerdes et al., 2018). Moreover, a number of these
eight TFs have important regulatory roles in reprogramming the cellular phenotype or cancer
progression. CREB3L1 (also referred to as OASIS) is synthesised as an inactive precursor which
is membrane bound on the endoplasmic reticulum (Honma et al., 1999; Omori et al., 2002).
CREB3L1 was found to be activated as part of the innate antiviral response in human hepatoma
cells to inhibit virus replication and cell proliferation (Denard et al., 2011, 2012). The viruses that
were tested included a diverse range of DNA and RNA viruses including hepatitis C. CREB3L1
was reported to stimulate the expression of numerous genes which encode for inhibitors of the
cell cycle (Denard et al., 2011). The role of CREB3L1 in cancer has demonstrated controversial
results. In glioma (Vellanki et al., 2013) and breast cancer cells (Mellor et al., 2013), CREB3L1
was shown to be a suppressor of cell invasion and metastasis. In contrast, a more recent study
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found that CREB3L1 acts as an important activator of metastasis in the mesenchymal subtype of
triple-negative breast cancers in which there is a stimulated PERK kinase pathway signaling and
the EMT process (Feng et al., 2017). CREB3L1 was reported to promote the transcription of a
set of genes related to cancer-specific PERK kinase signaling (Feng et al., 2017). In melanoma,
the function of CREB3L1 is currently unknown and its role in the PD-L1CON cell lines requires
further investigation. CREB3L1 is activated via protein cleavage (Murakami et al., 2006) which
then migrates to the nucleus to promote transcription. CREB3L1, along with POU2F2, were
found to be novel transcription factors that may play a role in regulating prostate tumorigenesis
(Dhingra et al., 2017). GLIS3 was shown to be important for inducing the reprogramming of
human adipose-derived stromal cells into induced pluripotent stem cells (iPSCs) (Lee et al.,
2017). GLIS3 was also shown to be crucial for spermatogenesis (Kang et al., 2016). Moreover
the GLIS3 gene is mapped to chromosome 9p24.2, which is nearby the CD274 gene (9p24.1).
MAFK was found to promote metastasis for triple-negative breast cancer cells by inducing EMT
(Okita et al., 2017).
In conclusion, here I further investigated whether DNA methylation at the global genomic level
plays a role in regulating PD-L1 expression and/or its transcriptome reprogrammed sate. This
was done by examining the differentially expressed genes following DAC mediated PD-L1
upregulation and then identifying only those genes in the PD-L1CON samples that are putatively
methylation regulated. This demonstrated that the innate immune and cytokine response related
genes were associated with DNA demethylation and PD-L1 overexpression. Moreover, eight
TFs were identified to be associated with DNA demethylation and PD-L1 overexpression.
Further study is warranted to determine the exact mechanism that underlies the reduced DNA
methylation levels that causes PD-L1CON overexpression and its transcriptome reprogrammed
state. In particular, investigating the role of ERVs as dsRNAs or a ERV derived regulatory




Discussion and future work
Antibody based drugs that block the PD-1/PD-L1 axis and MAPK pathway inhibitors have
demonstrated unprecedented success for melanoma therapy. However a limitation for both
these treatment regimens is that only a faction of patients have long lasting benefits (Sun et al.,
2018; Flaherty et al., 2010; Chapman et al., 2011). Therefore a major goal in many research
studies has been to identify biomarkers that can predict treatment response or new drug targets
that can be inhibited in order to improve therapy. Whether PD-L1 expression is induced by
extrinsic signals or constitutively expressed via intrinsic mechanisms have different treatment
implications (Cottrell and Taube, 2018; Sun et al., 2018; Zerdes et al., 2018; Shi, 2018). For
instance, PD-L1 induced via cytokine stimulation is predictive of a better prognosis and a
favorable response to anti-PD1 therapy due to the pre-existence of anti-tumor immune activity
in the tumor. However there are many unanswered questions about PD-L1CON expression.
For example PD-L1CON expression has been associated with resistance to chemotherapy in
acute myeloid leukemia (Wang et al., 2015b) and MAPK pathway inhibitors in melanoma
(Audrito et al., 2017; Song et al., 2017). This suggest that melanoma cells that become resistant
to targeted inhibitors can escape the immune response by intrinsically upregulating PD-L1
expression levels. However how PD-L1 expression is regulated via intrinsic mechanisms in
melanoma, particularly following drug resistance, remained unclear. For instance, oncogenic
mutations (including BRAF and NRAS mutants) have not been found to regulate PD-L1
expression and moreover there are contradicting results on whether signaling pathways that
are critical to melanoma biology (including the MAPK pathway, the PI3K pathway and the
JAK/STAT pathway) contribute to PD-L1CON expression (Jiang et al., 2013; Audrito et al., 2017;
Gowrishankar et al., 2015). We on the other hand, previously found PD-L1CON cell lines have
marked global hypomethylation suggesting that DNA methylation may play a role in PD-L1CON
expression (Chatterjee et al., 2018b). In this thesis, PD-L1CON cell lines were shown to have
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a reprogrammed transcriptomic profile inclusive of dedifferentiation, active innate immune
response, and reduced oxidative phosphorylation. Moreover, transcription factors that play key
roles in melanocyte differentiation and the innate immune response were downregulated and
upregulated, respectively.
The results from this thesis demonstrates that the transcriptome of PD-L1CON cell lines represent
a stable treatment resistant phenotype. Numerous studies have shown that long periods (months)
of BRAFi treatment until permanent and acquired resistance develops, induces dedifferentiation
with a loss of SOX10 and activates multiple signaling pathways, which are all part of the
PD-L1CON expression profile (Shaffer et al., 2017; Song et al., 2017; Ravindran Menon et al.,
2015). Furthermore, it was shown in this thesis (see section 5.2.7) that PD-L1CON expression
signatures are enhanced upon development of acquired resistance to MAPK pathway inhibitors
when regulated by transcriptome reprogramming rather than oncogenic driver mutations.
However, experimental validation of whether PD-L1CON cell lines are more resistant to MAPK
pathway inhibitors compared to PD-L1IND cell lines was not performed and therefore further
work on this is warranted.
PD-L1CON cells may arise via an adaptive mechanism to BRAFi or a PD-L1CON subpopulation
may pre-exist in the tumor microenvironment as reported by other studies. Evidence supporting
an adaptive mechanism was shown by Shaffer and colleagues who identified a transient rare
subpopulation of cells in a melanoma cell line that presented resistance markers (Shaffer et al.,
2017). This rare subpopulation of cells had a similar transcriptomic profile as the PD-L1CON
cell that was found in this thesis with an increased expression of EGFR, AXL, PDGFRB, and
JUN. Upon 1 week treatment with BRAF inhibitor, there was a loss of SOX10. However
discontinuation of treatment (termed “drug holiday”) resulted in reverting back to the origninal
or pre-treatment state (Shaffer et al., 2017). A longer period (several months) of treatment
with BRAFi was required to “burn in” a stable resistance phenotype resulting in stronger
activation of alternative signaling pathways receptor tyrosine kinases (AXL, PDGFR, EGFR)
compared to the rare pre-resistant cells subpopulation (Shaffer et al., 2017). The loss of SOX10
and overexpression of various receptor tyrosine kinases of PD-L1CON cells demonstrates that
a permanent or “burning in” of the rewired transcriptome has occured following a stress
response. However out of the total seven PD-L1CON cell lines, only one (CM143.post) had
been treated with a BRAF inhibitor. Cellular stress other than drug treatment (such as hypoxia
and nutrient/glucose starvation) has been shown to reprogramme the transcriptome simmilar to
BRAF inhibitors (Ravindran Menon et al., 2015) although only glucose starvation resulted in
loss of SOX10. Therefore for the other six PD-L1CON melanoma cell lines, hostile conditions
in the tumour environment could have contributed to the rewiring of the transcriptome before
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being generated into a cell line. This also suggests that a subpopulation of PD-L1CON cells may
pre-exist before drug treatment as a result of non-drug stress responses in the tumor. Indeed the
low-SOX10 dedifferentiated state has been shown to represent a small subpopulation of cells in
the heterogenous melanoma population (Sun et al., 2014). Others have reported that PD-L1CON
expressing tumors represent around 1 to 20% of pre-treatment melanomas (Taube et al., 2012;
Teng et al., 2015; Audrito et al., 2017; Emran et al., 2019). To assess whether PD-L1CON cells
are present as a small subpopulation inside a tumor, immunohistochemistry can be performed by
staining for CD8 lymphocyte markers and PD-L1. Other methods include analysing melanoma
single cell RNA-seq datasets to identify cells with PD-L1CON expression signatures. Such
datasets include GSE72056 (Tirosh et al., 2016) and GSE120575 (Sade-Feldman et al., 2018).
Therefore, overall PD-L1CON cells may arise by either from non-drug related environmental
stress (before treatment) or upon drug related stress (during treatment).
Combined usage of anti-PD1 drugs with MAPK pathway inhibitors may allow clinicians to
target the PD-L1CON cells that develop concurrent upon MAPK pathway inhibitor resistance.
However given that here mainly cell lines were used for analysis, it would be important to
assess how frequently PD-L1CON increases upon development of acquired resistance using
patient tumors. The PD-L1CON expression signature (the differentially expressed genes) could
be used infer changes to the PD-L1CON cell population from a RNA-seq dataset derived from
patient tumours following BRAF inhibitor treatment. Various transcriptomic datasets derived
from patient melanomas that have developed resistance to BRAF inhibitors are available which
includes GSE65185 (Hugo et al., 2015), GSE50509 (Rizos et al., 2014), GSE50535 (Sun et al.,
2014) and GSE61992 (Long et al., 2014). However a limitation to this approach is the level
of false positives that can be detected from PD-L1 expression induced by cytokines which are
secreted by tumor infiltrative lymphocytes. Indeed there is a large overlap of innate immune
genes between the upregulated genes in the PD-L1CON cell lines and following PD-L1 increase
after IFN-γ induction. Therefore, to get more of an accurate analysis, immunohistochemistry
staining for PD-L1 and for markers of CD8 lymphocyte in the resistant tumors will be valuable.
In addition to a treatment resistant transcriptomic profile, PD-L1CON samples also have an
expression profile that fits the invasive phenotype from the phenotype switching model of
melanoma. Indeed, the invasive phenotype and the treatment resistant expression profile do have
large overlaps with respect to the genes that regulate these processes such as dedifferentiation
and loss of MITF. This is consistent with reports that development of resistance also provides
more aggressive cancer properties such as higher tumorigenic properties and metastatic potential
(Ravindran Menon et al., 2015).
Moreover, whether there is a change in the number of PD-L1CON cells after development of
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treatment resistance to anti-PD1 or anti-PDL1 therapy can be investigated. Transcriptomic
datasets derived from patient melanomas following resistance to anti-PD1 and anti-CTLA4
therapy are available which includes GSE78220 (Hugo et al., 2016), GSE91061 (Riaz et al.,
2017) and GSE115821 (Auslander et al., 2018). To investigate whether changes in PD-L1CON
expressing cells can be observed in tumors, the differentially expressed genes can be analysed
with ssGSEA in order to obtain a PD-L1CON geneset enrichment score for individual samples.
Alternatively, one-class logistic regression (OCLR) (Sokolov et al., 2016) can be used which is a
novel machine learning algorithm that was developed to identify specific cell subpopulations in a
tumor with heterogeneous populations of cells. It has previously been used to identify stem-cell
like cancer subpopulations from TCGA RNA-seq and 450K methylation datasets (Malta et al.,
2018).
Numerous lncRNAs were found to be differentially expressed within 100 kilobases of
protein-coding genes. Given that some of these lncRNAs were in the near genomic proximity of
crucial transcription factors, whether these lncRNAs could play a role in the PD-L1 expression or
its rewired transcriptome can be investigated. There are various processes that a lncRNA locus
can regulate a nearby protein-coding gene: 1) lncRNA can have sequence specific functions to
recruit regulatory factors and regulate the expression of the nearby gene, 2) there is no lncRNA
sequence specificity but the act of the lncRNA transcription promotes the expression of nearby
genes, 3) the lncRNA transcript is independent to the regulation of the nearby gene and it is a by
product of the DNA sequence that is functioning as a regulatory element (Kopp and Mendell,
2018). Experimental validation to determine whether a lncRNA has a regulatory role on the
neighbouring genes include CRISPR interference (CRISPRi) screens (Liu et al., 2017) to inhibit
the lncRNA expression. Subsequently, expression changes of the neighbouring genes can be
examined using qRT-PCR.
The global hypomethylation in the PD-L1CON cell lines supports the notion that epigenetic
changes are playing a role in the PD-L1 expression and its rewired transcriptome. DNA
methylation is an important regulator of transcription by repressing transcription factor binding
at cis regulatory elements (CRE). Reduced DNA methylation levels have been shown to be
strongly correlated with increased chromatin accessibility suggestive of a direct and causal
relationship (Thurman et al., 2012). Active regulatory regions have also been shown to be
bound by transcription factors and also frequently have low DNA methylation levels (Ziller
et al., 2013; Stadler et al., 2011). Indeed many transcription factors recognise DNA motifs
containing CpG dinucleotides and for some transcription factors, such as NRF1, cannot bind to
its consensus motif or create accessible chromatin when the binding site is methylated (Domcke
et al., 2015). However reduced methylation has also been associated with repressive chromatin
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with repressive histone modification marks of H3K27me3 and H3K9me3 (Hon et al., 2012).
Therefore in order to identify CRE that are active via DNA hypomethylation in the PD-L1CON
cell lines, it will be important to identify open chromatin using ATAC-seq. Moreover, reduced
levels of DNA methylation can also occur as a consequence of binding of pioneer transcription
factors (Barnett et al., 2020). Studies have shown transcription factor binding to methylated
CRE can increase chromatn accessibility and concomitant loss of DNA methylation (Barnett
et al., 2020; Mayran et al., 2018; Donaghey et al., 2018). Thus partly the global hypomethylated
state of PD-L1CON cells may be regulating the rewired transcriptomic profile and partly the
transcription factor changes could be resulting in a reduced methylated state.
7.1 Conclusion
Although PD-L1CON expression has been reported to be infrequent in melanoma, numerous
studies have found increased levels of PD-L1CON expression upon acquired resistance to targeted
inhibitors in melanoma cell lines. However the underlying mechanism that regulates PD-L1CON
expression in melanoma is as yet unclear due to discrepancies across studies. Moreover
how PD-L1 expression is associated with resistance to targeted inhibitors is unclear. Here, it
was found that PD-L1CON expressing cells have a reprogrammed transcriptome inclusive of
dedifferentiation, an active innate immune response and reduced oxidative phosphorylation.
Moreover, the PD-L1CON expression signatures also increased upon development of acquired
treatment resistance to MAPK inhibitors when mediated by transcriptome reprogramming.
Finally, the innate immune response was associated with demethylation and increased
PD-L1CON expression supporting the idea of DNA hypomethylation playing a role in the





Figure 8.1: Permission was granted by the author to reproduce a figure from their publication (Taube et al., 2018)(figure 1.2
of this thesis)
Table 8.1: list of kits and products used in methods
Product Company Catalog_number
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 4368814
Fixable viability stain 450 BD horizon 562247
PD-L1 antibody Biolegend 329706
isotype control antibody Biolegend 400314
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RPMI 1640 Medium Gibco 11875093
DMEM medium Gibco 11995065
αMEM medium Gibco 12561056
Trypsin-EDTA Gibco 25200072
penicillin-streptomycin Gibco 15140122
Nano End Repair Mix 2 Illumina 20015965
A-Tailing Mix Mix Illumina 20015965
TruSeq DNA Single Indexes Set A Illumina 20015960
TruSeq PCR Primer Cocktail Illumina 20015965
dsDNA HS Assay Invitrogen Q32851
Fetal bovine serum Moregate Biotech
IFN-gamma prospec CYT-206
RNeasy Mini Kit Qiagen 74106
RNase-Free DNase Set Qiagen 79254
QIAshredder Qiagen 79656
QIAquick PCR Purification Kit Qiagen 28106
MinElute PCR Purification Kit Qiagen 28006
QIAquick Gel Extraction Kit Qiagen 28706
LightCycler 480 Multiwell Plate 96-well plate Roche 04729692001
Insulin-transferrin-sodium Sigma-Aldrich 11074547001
DMSO Sigma-Aldrich D8418
5-Aza-2′-deoxycytidine (decitabine) Sigma-Aldrich A3656-5MG
L-Ascorbic acid (vitamin C) Sigma-Aldrich 95209
SYBR Premix Ex TaKaRa RR420W
EZ DNA Methylation Kit Zymo D5001
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